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Abstract
The aim of this thesis was to investigate the role o f chemokines and their 
receptors in human pancreatic adenocarcinoma and to explore whether chemokine 
receptors and their ligands are involved in tumor dissemination. The repertoire o f 
chemokine receptors expressed in 11 pancreatic adenocarcinoma cell lines tested 
included CXCR4 and CX3CR1. Their significance was therefore further investigated.
Expression of CXCR4 was higher in lines derived from metastases. The 
chemokine CXCL12 induced chemotaxis in CXCR4-positive cell lines, which was 
inhibited by an anti-CXCR4 specific antibody and by the antagonist AMD3100. Trans- 
endothelial migration, Matrigel invasion and activation of matrix metalloproteases were 
also enhanced by CXCL12. Proliferation was stimulated by CXCL12 in CXCR4- 
positive cell lines and partially inhibited by the inhibitor AMD3100, indicating an 
autocrine loop. The addition of exogenous CXCL12 inhibited apoptosis induced by 
serum starvation. These data demonstrate that autocrine or paracrine loops centred on 
the CXCR4/CXCL12 axis promote pancreatic cancer cell migration, matrix degradation 
and invasion, proliferation and survival.
The function of the chemokine receptor CX3CR1 was investigated in the context 
o f the peculiar propensity o f pancreatic cancer to disseminate and grow along nerve 
fibers, as its chemokine ligand Fractalkine/Neurotactin/CX3CLl is expressed by 
neuronal structures. CX3CR1-positive tumour cells migrated in a dose-dependent 
manner to CX3CL1 and this effect was blocked by specific anti-CX3CRl antibodies. 
CX3CR1 -positive tumour cells adhered to endothelial and neuronal cells stimulated 
with TNFa/IFNy, known to induce Fractalkine expression. Neuronal derived 
Fractalkine elicited migration of CX3CR1-positive pancreatic tumour cells. The 
CX3CL1 chemokine was detected in vivo in surgical sections of pancreatic cancer nerve
metastasis. These results suggest that the CX3CR1/Fractalkine axis could be involved in 
the dissemination of pancreatic tumour cells via nerve structures.
In conclusion, the data presented here support the hypothesis that a selected set 
o f chemokine receptors are expressed in carcinoma of the pancreas and are involved in 
tumour cell migration and invasion. For CXCR4, promotion o f cell survival and 
proliferation was observed. For CX3CR1, a role in perineural tropism is suggested.
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Pancreatic Adenocarcinoma
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1.1 Pancreatic cancer
Generalities
Human pancreatic cancer is a neoplasia primarily of ductal origin, which represents a 
major oncological challenge in the 21st century. It ranks as the fourth most frequent type 
of solid tumor in men (exceeded by lung, colorectal and prostate cancer) and the fifth 
cause of cancer death in women (exceeded by breast, colorectal, lung and ovarian- 
uterine cancer). The reasons for this high mortality rate are strictly correlated to the 
limited knowledge about the biology of this tumor. Despite advances in surgical as well 
as non-surgical treatment efforts, it remains a tumor with poor prognosis and a 5-year 
survival rate of 3-8% (1, 2).
Pancreatic cancer often presents clinically, with non-specific signs and symptoms, 
therefore difficult to diagnose. Known risk  factors for pancreatic cancer are cigarette 
smoking, age (over 80% of the cases develop between 60 and 80), chronic inflammation 
(see Paragraph  1.2), diabetes and diet; not surprisingly, it is not associated to 
consistent environmental or occupational risk factors, as the pancreas is protected from 
direct contact with the environment and does not play a significant role in detoxification 
o f xenobiotics (as in the liver) nor does it filter and concentrate toxins (as in the urinary 
system) (3).
According to the TNM system, the staging of pancreatic cancer (Stage 0 to Stage IVB) 
is determined by 3 factors: T (location and size of the tumor, ranging from TX to T4), N 
(evidence of metastases in lymph nodes close to the cancer, NX to N l) and M (evidence 
of distant metastases, MX to M l).
Specifically, there are 5 stages of tum or size in the current TNM classification:
TX: primary tumor cannot be assessed;
TO: no evidence of primary tumor;
Tis: (carcinoma in situ) is very early stage pancreatic cancer;
T l: tumor size in the pancreas is 2cm or less in any direction;
T2: tumor size is more than 2cm across in any direction;
T3: the cancer has started to grow in surrounding tissues around the pancreas, in 
the duodenum or the bile duct
T4: the cancer has grown further in the stomach, spleen, large bowel or nearby 
large blood vessels.
While the classification based on lymph node involvement is:
NX: regional lymph nodes cannot be assessed;
NO: no lymph nodes containing cancer
N l: there are cancer cells in a single lymph node (Nla) or more (N ib)
And finally, according to metastasis:
MX: distant metastasis cannot be assessed;
MO: the cancer has not spread into distant organs, such as the liver or lungs 
M l: cancer has spread to other organs 
Table 1.1 summarizes the characteristics of pancreatic cancer stages in this system.
Stage Tumor Lymph nodes M etastasis
Stage 0 Tis NO MO
Stage I Tl NO MO
T2 NO MO
Stage II T3 NO MO
T3 NO MO
Stage III Tl N l MO
T2 N l MO
T3 N l MO
Stage IV T4 Any N MO
Stage V Any T Any N M l
Table 1.1 Stage grouping for primary tumors of the exocrine pancreas.
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Therapeutic treatments
Depending upon the type and stage, pancreatic cancer may be treated with 
different therapeutic approaches. As reported by the American Cancer Society, surgery 
may be necessary to remove the tumor (a section or entire pancreas and/or the small 
intestine). The type of surgery depends on the stage of the cancer, the location and size 
of the tumor, and the person’s health. Types of surgery for pancreatic cancer include the 
Whipple procedure (if the tumor is located at the head of the pancreas (the widest 
part); the head of the pancreas, part of the small intestine, bile duct, and stomach, and 
other tissues will be removed), the distal pancreatectomy (if the tumor is located in the 
body and tail o f the pancreas, both of these sections o f the pancreas will be removed, 
along with the spleen), the total pancreatectomy (the entire pancreas, part o f the small 
intestine and stomach, the common bile duct, the spleen, the gallbladder, and some 
lymph nodes will be removed). Generally, surgery can be pursued only if  the cancer is 
localized; when cancer is found in distant lymph nodes and has spread too far to be 
cured, palliative surgery might be done to prevent or relieve symptoms if  the cancer. 
For example, palliative surgery can be used to relieve blockage o f the bile duct (which 
is cause of jaundice, pain and problems with digestion) (4). For those patients with 
adenocarcinoma of the pancreas who are not candidates for surgery or who have a 
recurrence of the cancer after surgical resection, chemiotherapy is often prescribed as a 
standard therapy. 5-Fluorouracil and Gemcitabine have been for used many years as 
chemotherapy; recently, it has been reported that Raltitrexed-Oxaliplatin regimen may 
constitute a treatment opportunity in gemcitabine-resistant metastatic pancreatic cancer
Pancreatic cancer biology
The pancreas consists of two separate functional units -exocrine and endocrine 
pancreas- that regulate the major physiological processes of digestion and glucose 
metabolism. The exocrine pancreas is formed by acinar and duct cells (Fig 1.1). The 
acinar cells represent the bulk of the pancreatic tissue and produce digestive enzymes; 
they are organized into grape-like clusters, forming the termini of the branching duct 
system. The ducts add mucus and bicarbonate to the mixture and form a network of 
increasing size that empty in the duodenum. The endocrine pancreas consists of four 
specialized cell types that are organized into islets, secreting hormones into the 
bloodstream. The a  and p cells regulate the usage of glucose through the production of 
glucagon and insulin, respectively. Pancreatic polypeptide and somatostatin that are 
produced in the PP and 8-cells modulate the secretory properties of the other pancreatic 
cell types.
Given the number of cell lineages, the pancreas can sustain several different tumor 
types, defined by their histological resemblance to the normal counterpart; all of these 
types show distinct clinical behaviour and genetic profiles (Table 1.2). Pancreatic 
adenocarcinoma -a tumor type with ductal-cell histology- is the most common type of 
cancer of the pancreas, accounting for greater than 85% of pancreatic neoplasms (6).
Acinar oeii
Figure 1.1 Anatomy of the 
exocrine pancreas. Duct cells arc 
organized into a branching network 
ending with clusters of acinar cells.
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Tum or type Frequency H istological features
Adenocarcinoma 85% Ductal morphology
Acinar-cell carcinoma 2% Zymogen granules
Endocrine tumors 2% Hormone production
Serous cystadenoma 2% Ductal morphology, cystic 
growth
Table 1.2. Types of pancreatic neoplasms. Different tumor types are defined by their 
histological resemblance to the normal counterpart
A careful molecular and pathological analysis o f evolving pancreatic 
adenocarcinoma has revealed a distinctive pattern of genetic lesions, i.e. a signature 
molecular profile of this malignancy; it consists of mutations in KRAS, CDKN2A, 
TP53 and SMAD4/DPC4 (7, 8). Ongoing studies are trying to define the contribution of 
such lesions to the biological features and evolution of the disease. Pancreatic 
adenocarcinoma is rarely observed spontaneously or following carcinogen 
administration in the laboratory mouse but genetic engineering has allowed the 
generation of strains that harbour germ line oncogenic lesions that are found in human 
pancreatic adenocarcinoma (6). For instance, transgenic mice expressing activated 
KRAS (9) or c-Myc (10) in the acini develop acinar carcinomas.
Although molecular pathology and genetic studies have provided an outline of 
the cellular perturbations associated with pancreatic adenocarcinoma, some key 
questions need to be answered; in particular what is the cell of origin of pancreatic 
cancer. As mentioned before, pancreatic adenocarcinoma cells strongly resemble 
pancreatic-duct cells, displaying cuboidal shape, ductal antigen expression and growth 
in tubular structures. Indeed, there is general agreement that the pancreatic ductal 
epithelial cell gives rise to this malignancy; recent studies of cell renewal and
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differentiation and various rodent models of pancreatic damage have lead to the 
hypothesis that pancreatic-ductal cells are potential facultative stem cells with the 
capacity to differentiate into both endocrine and exocrine lineages. Such a proliferating 
cell with unlimited replicative potential would be a prime candidate for oncogenic 
mutation and tumorigenesis (6).
Analysis on resected pancreatic tissue from cancer patients have allowed for the 
compilation of a temporal map of the genetic lesions within the ductal epithelium 
occurring during the course o f tumor progression. It has been shown that pancreatic 
adenocarcinoma progresses through a series of advancing morphological stages (now 
designated pancreatic intraepithelial neoplasia, PanIN): first, low cuboidal ductal cells 
become tall columnar due to extensive mucin production. Next, these epithelial cells 
start to show a certain degree of nuclear atypia and an enhanced proliferation rate which 
progressively increases and eventually leads to ductal cell shedding into the lumen of 
the ducts which facilitates tumor metastasis (6, 11). These morphological alterations 
correlate with increasing genetic abnormalities, among which activating KRas 
mutations are the earliest and more conserved (Fig 1.2).
Recently, the concept o f pancreatic adenocarcinoma originating from the ductal 
epithelial cells has been questioned; there is evidence (the expression of non-ductal 
lineage marker, including endocrine factors and pancreatic enzymes in pancreatic tumor 
cells) that transdifferentiation of other pancreatic cell types, such as acinar cells, might 
serve as an alternative route to pancreatic adenocarcinoma (6, 11).
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Fig 1.2. Genetic progression model of pancreatic adenocarcinoma. Pancreatic 
adenocarcinoma progresses through a series of morphological stages, each corresponding to 
distinct genetic lesions. {Adapted from Bardeesy et al (6))
1.2 Pancreatic Cancer and inflammation
Microenvironmental cellular interactions seem to be important in the
pathogenesis of pancreatic adenocarcinoma; notably, these tumors show an extensive
proliferation of stromal fibroblasts and deposition of extracellular-matrix components
(desmoplasia) that seem to promote growth and invasiveness (Fig 1.3). The molecular
basis of this phenotype is not resolved, nor it is clear whether the response is part of the
tumorigenic programme or whether it represents a form of host defence against the
tumor. This is in line with the general concept that interactions between tumor cells and
surrounding stroma play a critical role in tumor growth (12-15). Under normal
circumstances, the interaction between normal epithelium and normal stroma helps to
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maintain tissue integrity. However, in cancerous tissue, the interaction between cancer 
cells and surrounding stroma combined with cellular signals such as transforming 
growth factor p (TGFP), results in the formation of abnormal stroma, disruption of 
tissue integrity, and hence invasion and ultimately metastasis. In particular, tumor cells 
are thought to programme an oncogenic stroma that, in turn, contributes to their 
sustaining, through paracrine signalling, angiogenesis and protection from immune 
attack. The importance of tumor-stromal interactions in the aggressive behaviour o f 
pancreatic cancer is supported by experimental evidence that the invasive potential o f 
pancreatic cancer cells can be greatly enhanced by coculture with stromal fibroblasts 
(16). Moreover, this concept is supported by the observation that the less aggressive 
mucinous type of pancreatic carcinoma is associated with very little stromal reaction 
around the tumor (17).
Inflammatory cell mediators
Two cell components of the stroma can have a major role in the carcinogenic 
process: fibroblasts, and leukocytes. Fibroblasts, responsible for the synthesis, 
deposition and remodelling of much of the extracellular matrix (ECM), are recognized 
as a source of growth factors that influence the growth of carcinoma cells; most o f these 
factors are predominantly stimulators of proliferation and can play a role in promoting 
the carcinogenic process (e.g. FGF (fibroblast growth factor), IGF (insulin-like growth 
factor), EGF (epithelial growth factor), HGF (hepatocyte growth factor)). Indeed, 
several studies have shown that fibroblasts, upon modulation by cancer-derived factors 
and given the appropriate environment, can differentiate in myofibroblasts, which can in 
turn produce pro-invasive signals (13).
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Fig 1.3. A cancerous duct. The
arrow indicates the carcinoma 
(Haematoxylin and Eosin x 
100).
The second important player in the stroma-cancer cell crosstalk is represented by 
the inflammatory component, i.e. leukocytes. In fact, although it has long been known 
that cancer frequently arises in areas of chronic inflammation, only in the last few years 
has a functional relationship between inflammation and cancer been established (18); 
examples include colon carcinoma, associated with inflammatory bowel disease (19) 
and stomach cancer, following Helicobacter pylori infection (20). Inflammatory cells 
influence cancer initiation and promotion by secreting cytokines, growth factors and 
chemokines, which stimulate proliferation of epithelia and generate reactive oxygen 
species that can cause DNA damage (18). Among different leukocyte cell types, 
macrophages are the most abundant and an important component of the stroma of 
neoplastic tissues. Several lines of evidence demonstrate that tumor-associated 
macrophages (TAM) can have dual functions in their interactions with neoplastic cells 
and are a key component of inflammatory circuits which promote tumor growth and 
progression (18, 21).
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Chronic pancreatitis and pancreatic cancer
Given the link between inflammation and cancer (18, 21), it seems reasonable to 
investigate whether a connection between chronic pancreatitis and the development of 
pancreatic adenocarcinoma does exist. Chronic pancreatitis, the most prevalent 
disorder of the exocrine pancreas, is an inflammatory disease associated with a gradual 
damage of the organ (11). In patients with hereditary pancreatitis (a hereditary form of 
the disease, accounting for <1% of all forms of pancreatitis and caused by a mutation o f 
the trypsinogen gene on chromosome 7), the risk of developing pancreatic cancer is 53 
times the risk in unaffected individuals; moreover, epidemiological data suggest an 
increased risk of pancreatic cancer in patients with sporadic chronic pancreatitis that 
correlates with the duration of inflammation (22). However, despite the deleterious 
effect of chronic inflammation on tissue integrity, only a small percentage o f pancreatic 
cancers are due to chronic pancreatitis.
The pathophysiology of pancreatitis involves the aberrant release o f proteolytic 
enzymes that cause acinar cell injury and a subsequent inflammatory response which in 
most cases is associated with gradual resolution. In chronic pancreatitis, the acinar 
injury is believed to recur, causing persistent infiltration of inflammatory cells, 
eventually leading to atrophy and fibrosis. Chronic inflammation occurring 
simultaneously with cell proliferation would be an ideal landscape for malignancy to 
develop.
Cytokines: new molecular mediators in pancreatic adenocarcinoma
Also for pancreatic adenocarcinoma, the inflammatory mechanisms responsible 
for the development of the neoplasia rely on the release of several cytokines, 
transcription factors and inflammatory enzymes. Indeed, a number of cytokines are
found increased in pancreatic cancer (e.g. TNFa, IL -ip , IL-6, IL-8, CCL2) (22-27).
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Each cytokine can evoke a cascade o f events in inflammatory cells, including the 
synthesis and release of other cytokines and growth factors and affect the host response 
to tumor cells. Moreover, some cytokines can provide positive signals for pancreatic 
cancer cell growth, including EGF, IGF, IL -la , which originate in peri-tumoral 
inflammatory cells, but may also be produced by the pancreatic cancer itself, thus 
exerting an autocrine action (28, 29). TNFa has been proposed to increase survival of 
pancreatic cancer cells (30). In addition, a peculiar aspect of pancreatic cancer cells is 
their loss of responsiveness to growth inhibitory cytokines, including TGFP (28). This 
growth factor deserves attention, as it plays a dual role in cancer microenvironment; in 
fact, while promoting tumor growth through stromal and angiogenesis support and 
impairing immune surveillance, TGFp can also act as a growth inhibitor o f most 
epithelial cells. However, mutations in the TGFp signalling pathway downstream of the 
receptor may impair TGFp mediated growth inhibition, while retaining other pathway 
components, including the ones favouring tumor invasion and metastasis (14, 31). Thus, 
loss of responsiveness to TGFp as observed in pancreatic cancer, is associated 
to acquisition of a tumoral phenotype (28).
As for other carcinomas, also for pancreatic cancer a connection between 
inflammation and cancer progression is the transcription factor NFkB, which regulates 
the transcription of several inflammatory genes as well as cell cycle. Not surprisingly, 
NFkB is found constitutively activated in a high percentage o f pancreatic 
adenocarcinomas, inhibiting apoptosis in these cells and cytokines, such as TNFa, may 
favour development and growth of malignant cells through NFkB activation (30). Also 
IL-8 expression is induced in vitro through NFkB activation; this chemokine, 
constitutively expressed at high levels in pancreatic cancer cells, produces an autocrine 
growth stimulatory effect in certain cell lines (32) and inhibition of its activity in
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transplanted pancreatic tumor cells leads to suppression of tumor growth and metastasis 
in nude mice (33).
Although leukocytes are the main source of inflammatory mediators, still also 
pancreatic tumour cells can produce a number of cytokines and growth factors. In vitro 
established pancreatic cancer cell lines represent a valuable tool for the characterization 
of inflammatory mediators. The first part of results of my thesis will be focused on the 
characterization of pancreatic cancer cell lines, with attention to the release of 
inflammatory mediators (See Chapter 4).
1.3 Invasion and metastasis in pancreatic cancer
The devastating evolution of pancreatic cancer is not only due to the high 
proliferating potential of pancreatic cancer cells, but also to the ability of these cells to 
metastasize even when the primary tumor spread is limited. Metastasis is the main cause 
o f treatment failure and death for pancreatic cancer patients. This is due to the difficulty 
of removing metastasis through conventional surgery; indeed, often in pancreatic 
adenocarcinoma metastases involve vital organs, (including liver, celiac plexus, some 
lymph nodes, depending on their location and large blood vessels, such as the portal 
vein), therefore excluding surgery as a treatment option. From these considerations it is 
evident that controlling metastasis is a major goal to improve the life expectancy of 
pancreatic cancer patients.
Recently, microarray expression profiling of metastatic cells and in vivo video 
microscopy are providing new advancement in the characterization o f metastasis (34- 
36). However, despite its importance in the aggressiveness of pancreatic cancer, how 
metastatic progression develops is still unknown and very little knowledge is available 
about the molecular mechanisms regulating this process.
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A multistep process
The metastatic process consists of a series o f steps all o f which must be 
successfully completed to give rise to a metastatic tumor. As a primary tumor grows, it 
needs to develop a blood supply -the angiogenesis process- that can support its 
metabolic needs and can also provide tumor cells an escape route to leave the primary 
mass and enter the circulation (process known as intravasation). The cells need to 
survive in the circulation until they can arrest in a new organ; here they might 
extravasate from the circulation into the surrounding tissue. Once in the new site, cells 
must initiate and maintain growth to form pre-angiogenic micrometastases; this growth 
must be sustained by the development of new blood vessels in order for a macroscopic 
tumor to form (37). The same steps are supposed to take place in pancreatic cancer 
metastasis formation.
The capability o f sustained angiogenesis is a feature of cancer which dictates 
malignancy. The formation of new blood vessels is permissive for local and systemic 
expansion of the tumor mass and can be induced by multiple molecules, released by 
both cancer and stromal cells. Numerous factors controlling the formation o f tumor 
vascularisation have been found overexpressed in pancreatic cancer, including vascular 
endothelial growth factor (VEGF), IL-8 and members o f the TGF and FGF family, as 
already said. Tumor cells produce and secrete these molecules, which bind receptors 
expressed on endothelial cells, thus guiding the process of new vessel formation. In 
particular, as far as VEGF is concerned, pancreatic cancer cells express also the cognate 
receptors VEGFR-I and VEGFR-II and the ligand/receptor system consisting o f VEGF 
and VEGF-RII has been proposed to be of biologic significance in the pathogenesis o f 
pancreatic cancer growth (38, 39).
Sooner or later during the development of pancreatic cancer, some pioneer cells 
detach from the primary mass and move out, invade adjacent tissues and circulate to
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distant organs, where they may form new colonies. Migration and invasion of cancer 
cells into surrounding stroma are likely to be prevented by cell-cell and cell-matrix 
interactions, thus disruption of these adhesive connections leads to increase motility of 
tumor cells, which detach from the primary lesion. Therefore, adhesion molecules on 
the cell surface play an important role in tumor cell migration and regulate the potential 
for epithelial cells to metastasize, being adhesion molecule interactions also able to 
convey regulatory signals to the cell (40). Several classes of proteins are participating 
when cells exhibit an invasive or metastatic phenotype, including cell-cell adhesion 
molecules (CAMs), cadherins and integrins. E-cadherin function is lost in a majority 
of pancreatic tumors (41); generally, the presence of E-cadherin is considered as an 
important suppressor of invasion and metastasis and its functional elimination may 
represent a key step in the acquisition of this phenotype. ICAM-1 and VCAM-1 
expression has been found increased in pancreatic cancer samples in comparison with 
normal tissues; they likely contribute to cancer cell migration and spread to distant 
organs (42). Finally, changes in integrin expression are also evident in invasive and 
metastatic pancreatic cancer cells (43).
The role of Lymphangiogenesis in cance metastasis
Like in normal tissues, both vascular and lymphatic vessels are present in malignant 
tissues. Lymphoangiogenesis, namely the proliferation of new lymphatic vessels, is an 
important initial step in tumour metastasis. Tumour cells spread via the lymphatic 
system to regional lymph nodes and finally into larger lymphatic vessels, wich re-enter 
into the blood vascular system; therefore, similarly to angiogenesis, 
lymphoangiogenesis provides new vessels that malignant cells can use to escape the 
confines of the primary tumour (44). For several years, the study of lymphatic vessels 
has been difficult, most likely due to a lack o f appropriate molecular markers that could
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be used to discriminate between lymphatics and blood vessels. The discovery of 
lymphatic vessel cell-surface markers, such as VEGFR3, podoplanin, LYVE-1 and 
CD34 has allowed the purification and study of these vessels (45). 
Lymphoangiogenesis is controlled in part by members of the vascular endothelial 
growth factor (VEGF) family, mostly VEGF-C and VEGF-D and their cognate 
receptors on lymphatic endothelium, VEGFR-3 (44). In addition to the two VEGF 
family members, fibroblast growth factor 2 (FGF2), platelet derived growth factor B 
and hepatocyte growth factor (HGF) stimulate lymphatic vessel growth (45). Growth 
factor stimulation of lymphatic vessels enhances lymphatic metastasis. Several studies 
have found positive correlations between VEGF-C and VEGF-D expression and 
vascular invasion, lymphatic vessel and lymph node involvement and distant metastasis; 
VEGF-C expression in tumour cells may be induced by growth factors or 
proinflammatory cytokines, and some may be derived by inflammatory cells in tumours. 
Lymphatic vessels in pancreatic cancer have not been studied well, however, 
lymphoangiogenesis appears important in metastasis of pancreatic cancer (40). 
Morphological studies clearly indicate alterations of lymphatic vessels in the periphery 
o f the tumours, which can be due to overexpression of VEGF-C, as excess o f VEGF-C 
causes lymphatics to enarge. VEGF-C expression has been associated with increased 
lymphatic vessel invasion and lymph node metastasis, but not with decreased patient 
survival in pancreatic cancer (46).
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The role of extracellular proteases
The second class of players in transforming pancreatic cancer into an invasive 
and metastatic phenotype are extracellular proteases; in the 1970s it was first 
recognized that tumor-derived proteases, e.g. plasminogen activators and 
metalloproteinases, play an important role in the cleavage of basement membranes and 
extracellular matrix molecules and thus assist in the processes of invasion and 
metastasis of cancer cells (47). Later, it became accepted that also non-tumoral stromal 
cells may contribute to this process (48). Proteases can also play a role in the early 
phases of tumor development through their ability to proteolitically activate several 
molecules, releasing them from the matrix; examples include VEGF and TGFp (49-53).
The MMP family can be broadly subdivided into five groups: collagenases, 
stromelysins, elastases, membrane-type (MT) MMPs and the gelatinases. Although the 
classification system was developed on the basis of substrate specificity, it is now 
recognized that there is some overlap between some members of the family (e.g. MMP- 
2 can cleave fibrillar collagen similar to the collagenases) (Table 1.3). The multigene 
family of metal containing proteases shares several common characteristics: (a) each 
degrade at least one component of the basement membrane; (b) their catalytic activity 
depends on the presence of zinc ions at the catalytic active site; (c) they are inhibited by 
metal chelators and tissue inhibitors known as tissue inhibitors of metalloproteinases 
(TIMPs); and (d) they are secreted as zymogens and require activation extracellularly, 
usually accompanied by loss o f a 10-kDa amino-terminal domain (54-56). The 
collagenases catalyze degradation of fibrillar forms of collagen (i.e. type I, II, I I I ). The 
stromelysins have relatively broad substrate specificity, catalyzing degradation o f many 
different substrates in the ECM, including proteoglycans (core protein), laminin, 
fibronectin. The group of m em brane-type M M Ps possess a transmembrane domain 
and catalyze activation of progelatinase A and degrade a variety of ECM substrates. The
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cytokine-induced Gelatinase B (MMP-9) and the constitutively expressed Gelatinase 
A (MMP-2) are also known as type IV collagenases and degrade gelatin (denatured 
collagen) and type IV, V, VII, IX, X collagen. Type IV collagen is particularly abundant 
in basement membranes, which are the membranes separating organ parenchyma from 
the underlying stroma. Four endogenous specific inhibitors of MMPs (tissue inhibitor of 
metalloproteases, TEMP) have also been described: TIMP-1 to TIMP-4; they inhibit 
protease activity by forming high-affinity complexes with the active MMPs.
Given the important role played by MMPs in cancer progression, there has been 
great interest in the development of MMP inhibitors (MMPIs) (57-59); as 
metalloproteases are also involved in the migration of endothelial cells during 
angiogenesis, MMPIs can affect metastasis both by acting directly on tumor cell 
invasion, but also by inhibiting angiogenesis.
Preclinical studies testing the efficacy of MMP suppression in tumor models 
were very exciting and synthetic metalloproteinase inhibitors (MPIs) rapidly developed; 
however, the results o f some of these trials have been disappointing and the clinical 
development o f MPIs had to overcome unforeseen problems (60). Batimastat (BB-94), a 
broad spectrum inhibitor, became the first MMPI to be tested in humans (61); it was 
then replaced by Marimastat (BB-2516), another peptido-mimetic MMPI orally 
available (62-64). Despite some limitations, Marimastat has proved to be as effective as 
conventional therapy (gemcitabine) in treatment o f pancreatic carcinoma patients (65).
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MMP ECM  substrate
MMP-1 (Interstitial Collagcnase) 
MMP-8 (Neutrophil Collagcnase) 
MMP-13 (Collagenase-3)
MMP-18
Fibrillar collagens
MMP-3 (Stromelysin-1) 
MMP-10 (Stromelysin) 
MMP-11 (Stromelysin-3) 
MMP-7 (Matrilysin)
Laminin, fibronectin, non-fibrillar collagens
Metalloelastase Elastin
MMP-14 (MT1-MMP)
MMP-15 (MT2-MMP) 
MMP-16 (MT3-MMP) 
MMP-17 (MT4-MMP)
Gelatinase A, fibrillar collagens, 
proteoglycans, ECM glycoproteins
Gelatinase A
Gelatinase A
MMP-2 (Gelatinase A) 
MMP-9 (Gelatinase B)
Type I, IV, V and fibrillar collagens, gelatin 
Type IV, V collagen, gelatin
MMP-19 Gelatin
Table 1.3 The Matrix Metalloprotease Family. The original classification system was 
developed on the basis of substrate specificity.
Regulation of the MMPs occurs at three levels: alteration of gene expression  
(one of the most potent family of inducers are phorbol esters, such as PMA, as well as 
inflammatory cytokines, IL1, IL-8, TNFa), activation of zymogens (by agents such as 
trypsin 2, cathepsins, elastase) and inhibition of tissue inhibitors of metalloproteases. 
Alteration of all three levels of control have been associated with tumor cell 
progression. There is often a balancing effect within the corresponding physiological 
inhibitors of MMPs, to create the environment necessary for either physiological or 
pathological processes.
The main function of MMPs is degradation of the extracellular matrix, a 
mechanism required for many physiologic functions, including angiogenesis, wound 
healing, bone resorption and mammary involution, as well for pathological conditions, 
including cancer. Indeed, in either case the rate-limiting step is the breakdown of
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connective tissue barriers. The difference between them is that physiological invasion is 
regulated, whereas tumorigenic invasion appears to escape any limiting control. 
Correlating with this observation, MMPs are invariably upregulated in the stromal 
compartment o f invasive epithelia; for instance, MMP-2 expression is increased in 
several tumors and strongly correlates with nodal status and tumor stage (66, 67). 
MMP9 derived from hematopoietic cells o f host origin, has been shown to contribute to 
skin carcinogenesis (68). In addition, MMP9 has complex effects beyond matrix 
degradation, including promotion of angiogenesis and release o f growth factors (69, 
70). Several studies in pancreatic cancer indicate that proteases are upregulated (in 
particular MMP-2 and MMP-9), protease inhibitors are downregulated (TIMP1 is 
reduced in tumors with lymph node metastasis) and inactive zymogen forms of 
proteases are converted into active enzymes (71). Moreover, the plasminogen 
activator/plasmin system has been implicated in tumor invasion and metastasis; tissue 
type plasminogen activator (t-PA) and urokinase type plasminigen activator (u-PA) and 
their respective receptors, annexin II and u-PAR, have been demonstrated to contribute 
to the invasive behaviour o f pancreatic cancer (72)). There is also evidence that certain 
pancreatic cancer cells induce uPA expression in stromal cells, which then bind to the 
urokinase receptor (uPAR) expressed on the cancer cells (73). This likely enables 
cancer cells to migrate through tissue barriers.
Organ selective spreading
In common with many other cancers, pancreatic adenocarcinoma also displays 
preferential organ metastatization; locoregional lymph nodes, liver, especially with 
tumors in the tail and the body of the pancreas, the celiac plexus (a network o f many 
nerves grouped around the aorta, causing back pain when pressed upon by a growing 
tumor), superior mesenteric vessels, closely associated to the pancreas and portal
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vein. The location of the metastases determines whether the cancer can be surgically 
removed or not, therefore having an important impact on the outcome of the disease.
One of the principal causes of metastasis in pancreatic adenocarcinoma is the 
high frequency of local recurrence; indeed, although surgery has been shown to be an 
effective therapeutic approach, the tendency to recurrence usually leads to the death of 
the patient within 1 or 2 years after surgery. It has been proposed that pancreatic cancer 
may have a multifocal origin and that tumors left in the remaining pancreas after a 
Whipple operation may be the source of local recurrence, but this hypothesis has not 
found support, because total pancreatectomy does not change the outcome (74). 
Microscopic tumor metastases already existing in the liver at the time of surgery are a 
possible source of recurrent disease, but it is unlikely that they are the explanation for 
tumor recurrence in the retroperitoneum (75).
A possible source of recurrence may be represented by neural invasion. Detailed 
pathohistologic studies of a large series of resected pancreatic ductal adenocarcinoma 
have shown that one of the most persistent characteristics is perineural invasion (76- 
78). Although perineural invasion also occurs in other types of cancer, this phenomenon 
is most consistently observed in pancreatic cancer. This seems to be due to anatomical 
reasons; indeed, the pancreas hosts a large amount of neural tissue, including ganglia, 
and it is in close proximity to abundant neural plexi and ganglia in the retroperitoneum. 
This observation is highlighted in the hamster pancreatic cancer model, where 
perineural invasion can be found in virtually all cases (79, 80).
Fig 1.4 Pancreatic cancer perineural invasion.
Hematoxylin Eosin staining of a surgical section of 
pancreatic cancer adenocarcinoma with tumour 
cells infiltrating an intrapancrcatic nerve 
(magnification xlOO). N indicates the nerve.
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Pour et al support the idea that all pancreatic cancers show perineural invasion if 
several sections have been scrutinized histologically. This observation and other 
existing data strongly suggest that tumor cells residing in the celiac and superior 
mesenteric ganglia indeed represent the main source of pancreatic cancer recurrence 
(74).
Novel concepts on metastasis: proposed role for chemokines and their 
receptors
For many years, researchers have tried to give an explanation for the 
phenomenon of organ-specific metastasis. In particular, the observation that many types 
of cancer display organ-specific pattern of metastasis but these organs sometimes do not 
correspond to those found in the drainage site has prompted to hypothesize the existence 
of organ-specific attractant molecules. These mediators would be responsible for tumor 
cell chemoattraction, stimulating the migrating tumor cells to invade the walls o f blood 
vessels and finally enter the organs.
Chemokines, small cytokines endowed with chemotactic activity, through the 
interaction with specific receptors, have been found to perfectly fit with this theory; 
indeed, recent studies have shown that tumor cells express patterns of chemokine 
receptors that match chemokines specifically expressed in organs to which these cancers 
commonly metastasize (81-83).
In this thesis I have investigated the expression of chemokine receptors in 
human pancreatic adenocarcinoma to test the hypothesis that chemokine receptors could 
play a role in pancreatic cancer dissemination.
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Chapter 2 
Chemokines and their Receptors
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2.1 The chemokine family
Structure and nomenclature
Chemokines are chemotactic cytokines that activate specific receptors expressed 
on cellular membranes. Chemokine reeptors sense a chemical gradient and mobilize 
cells in the gradient direction. The principal targets o f chemokines are bone marrow- 
derived cells and, as motility is an essential part of their function, chemokines play 
pivotal roles in coordinating leukocyte navigation. However, chemokines are not only 
simple chemotactic factors. These proteins can regulate several cellular activities, 
including maintainance of homeostasis, angiogenesis/angiostasis, cellular differentiation 
and activation, wound healing, tumor growth and metastasis, lymphocyte homing and 
development o f lymphoid tissue, and regulation of the immune response. All cell types, 
including structure cells, have the potential to actively participate in chemokine 
production.
The chemokine family (Table 2.1) comprises about 50 members; most are low 
molecular weight molecules (8-10 kDa), all consisting of roughly 70-130 amino acids, 
with four conserved cysteines (84-88). Two main subfamilies, CXC (a) and CC (p) 
chemokines are distinguished, according to the position of the first two cysteines, which 
are separated by one amino acid (CXC) or adjacent (CC). The cysteines form two 
disulfide bonds which confer to the chemokines their characteristic three-dimensional 
folding, with a flexible N-terminal loop connected to the more structured core o f the 
molecule (3 p-sheets) and a terminal a-helix. The CXC chemokine family can be 
further subdivided according to the presence or absence o f a conserved tripeptide m otif 
glutamic acid-leucine-arginine (ELR) at the N-terminus of the protein, before the CXC 
domain; this motif is not simply structural but seems to be linked to function, giving 
specificity for neutrophil chemotaxis and angiogenesis. Two variants of the chemokine
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structure paradigm have been described: Lymphotactin-a (XCL1) and lymphotactin-p 
(XCL2), the two members of the C (y) family, have two instead of the ususal four 
conserved cysteines and Fractalkine (CX3CL1), also called Neurotactin, has three 
amino acids between the first two cysteines, giving rise to the one-member CX3C (8) 
subfamily. A systematic nomenclature for chemokines became necessary as more and 
more new molecules were found. This classification relies on the principle established 
for their receptors, defined as CXC, CC, XC and CX3C followed by R and a number; 
thus chemokines are defined by the same structure-related acronyms followed by L (for 
ligand) and the number of their gene (designated long ago as SCY -small secreted 
cytokines- and numbered chronologically) (87, 89).
There are also differences in the genomic organisation o f the chemokine 
families. Many of the genes for the CXC chemokines, which act on neutrophils are 
located on chromosome 4, while a majority of the genes for the CC chemokines, which 
act on monocytes are clustered on chromosome 17 (89). These genes may have arisen 
by duplication and divergence from primordial chemokine genes but remained in 
clusters, supporting the idea that their functions are to some extent related. The 
remaining chemokines are in new chromosomal locations away from these two main 
clusters. These genes are more conserved between species and have highly specific 
functions, suggesting that they are older in evolutionary terms (89).
Like cytokines, chemokines are secreted proteins; only two of them, CXCL16 
and CX3CL1 are synthetized with a typical transmembrane sequence, which anchores 
them to the cell membrane, and the chemokine domain suspended by a mucin-like stalk.
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Chemokine Ligands Other Names Chemokine Receptors
CXC Subfamily
CXCL1 GROa/MGSA-a CXCR2>CXCR1
CXCL2 GROp/MGSA-p CXCR2
CXCL3 GROy/MGSA-y CXCR2
CXCL4 PF4 CXCR3B
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2 CXCR2
CXCL8 IL-8 CXCR1, CXCR2
CXCL9 Mig CXCR3A
CXCL10 IP-10 CXCR3A
CXCL11 I-TAC CXCR3A
CXCL12 SDF1 a/p CXCR4/ CXCR7
CXCL13 BCA-1 CXCR5
CXCL14 BRAK/bolekine Unknown
CXCL15 Murine lungkine Unknown
CXCL16 Bonzo ligand CXCR6
C Subfamily
XCL1 Lymphotactin/SCM-1 aJATAC XCR1
XCL2 SCM-ip XCR1
CX3C Subfamily
CX3CL1 Fractalkine CX3CR1
CC Subfamily
CCL1 1-309 CCR8
CCL2 MCP-1/MCAF/TDCF CCR2
CCL3 M IP-la/LD78a CCR1, CCR5
CCL4 MIP-ip CCR5, CCR8
CCL5 RANTES CCR1, CCR3, CCR5
CCL6 CIO CCR1
CCL7 MCP-3 CCR1, CCR2, CCR3, CCR5
CCL8 MCP-2 CCR1, CCR2, CCR3, CCR5
CCL9/10 MIP-ly CCR1
CCL11 Eotaxin CCR3
CCL12 Murine MCP-5 CCR5
CCL13 MCP-4 CCR1, CCR2, CCR3
CCL14 HCC-1 CCR1, CCR5
CCL15 HCC-2/Lkn-1 /MIP-18 CCR1, CCR3
CCL16 HCC-4/LEC/LCC-1 CCR1
CCL17 TARC CCR4, CCR8
CCL18 DC-CKl/PARC/AMAC-1 Unknown
CCL19 MIP-3 p/ELC/exodus-3 CCR7
CCL20 MIP-3 a/L ARC/exodus-1 CCR6
CCL21 6Ckine/SLC/exodus-2 CCR7
CCL22 MDC/STCP-1 CCR4
CCL23 MPIF-1/CKP8-1 CCR1
CCL24 Eotaxin-2/MPIF-2 CCR3
CCL25 TECK CCR9
CCL26 Eotaxin-3 CCR3
CCL27 CTACK/ILC CCR10
CCL28 MEC CCR10
Table 2.1. The chemokine family (<adapted from Allavena et al Crit Cancer Treatment Review
2005)
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Functional classification
Beside structure, chemokines can also be grouped according to their function; in
fact, they can be produced by leukocytes and tissue cells either constitutively or after 
induction, thus a former classification grouped chemokines into the functional 
subfamilies termed “inflammatory” and “homeostatic”. Thus, homeostatic chemokines 
usually guide the trafficking of leukocytes under steady state conditions, during immune 
surveillance of healthy peripheral tissues and control the architecture of secondary 
lymphoid organs; by contrast, inflam m atory chemokines are produced and control the 
recruitment of effector leukocytes under conditions of inflammation, immune reactions, 
tissue injury and tumors. In particular, tumors are characterized by the constitutive 
expression of inducible chemokines (90); examples include CCL2 production in breast 
and pancreatic cancer, melanoma, sarcomas and lung tumors (91)(Fig. 2.1).
CCL1
CCL2
CCL3L1
CCL5 CCL7
CCL14 CCL3CCL 15
CCL 16 CCL4
CCL 17CXCL12 CCL8CCL 19
CXCL13CCL 18 CCL I CCL 13
CCL2 CCL20
CCL23
CCL24CCL21 CCL22 CCL28
CXCL1
CCL26XCL1 XCL2CCL25
CXCL3CXCL2
CXCL5CCL27
CXCL7CXCL8CX3CL1 CXCL9 CXCL10
CXCL11
NeoplasiaNormal traffic k
InducibleC onstitutive
Infection
Inflammation
Immunity
Fig. 2.1 Chemokine functional classification. Tumors are characterized by the constitutive 
expression of inducible chemokines (adapted from (90)).
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Many chemokines have broad target cell selectivity. In particular, expression of 
inducible chemokines can be elicited by almost any stimulus that alters cellular 
homeostasis; they can be thought o f as vertebrate cellular “SOS response” that recruits 
leukocytes to areas of tissue injury. Recent findings, however, indicate that several 
chemokines cannot be assigned unambiguously to either one of the two functional 
categories and therefore are referred to as “dual function” chemokines (92). Dual 
function chemokines participate in immune defense functions (i.e. are upregulated under 
inflammatory conditions, examples include the interferon-inducible chemokines 
CXCL9, CXCL10, CXCL11) and also target non-effector leukocytes, including 
precursors and resting mature leukocytes, at sites of leukocyte development and 
immune surveillance (for instance CCL1, CCL25, CXCL16) (92). Many dual function 
chemokines are highly selective for lymphocytes and have a role in T-cell development 
in the thymus, as well as in T-cell recruitment to inflammatory sites. Remarkably, dual­
function and homeostatic chemokines usually bind to a single receptor, expressed 
mainly on lymphoid cells, in contrast to inflammatory chemokines, which bind to 
multiple receptors (see below).
Chemokine and receptor specificity
Chemokines exert their biological activity on leukocytes by binding to seven 
transmembrane domain, G-protein coupled receptors (see below). The principal target 
of chemokines are leukocytes and these small proteins tightly regulate their traffick, 
such as during their recruitment into sites of inflammation or positioning in secondary 
lymphoid organs (87, 89). In general, different chemokine classes tend to exhibit 
different ranges of leukocyte specificity; schematically, CXC-ELR+ chemokines (ELR 
is a highly conserved amino acid motif: Glu-Leu-Arg) are the major chemoattractants 
for neutrophils, whereas CXC-ELR- chemokines attract lymphocytes and monocytes
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but have little or no action on neutrophils. Chemokines belonging to the CC family act 
primarily on monocytes, but they can also attract lymphocytes, NK cells, basophils and 
eosinophils. CX3C and C chemokines act on lymphoid cells (T cells and NK cells) and 
Fractalkine is also active on monocytes. Despite this specificity, redundancy in the 
action on target cells is an intriguing feature of chemokines: no chemokine is uniquely 
active on one leukocyte population and usually a given leukocyte population has 
receptors for and responds to different chemokines. This confers robustness to the 
system, as variations in the amount or quality of any chemokine or receptor would have 
bearable consequences for basal trafficking of leukocytes (85, 93, 94). Moreover, the 
interaction o f chemokines with their receptors is characterized by considerable 
promiscuity. Most ligands interact with more than one receptor and most known 
receptors have been reported to interact with multiple ligands; only CXCR4, CXCR5, 
CXCR6, CCR6, CCR9 and CX3CR1 bind to only one chemokine. Probably all cell 
types can produce chemokines under appropriate conditions and usually, a cell produces 
many chemokines concomitantly in response to the same stimulus (polyspeirism) Once 
again, this receptor promiscuity and polyspeirism contribute to the robustness o f the 
chemokine network, essential features which act to retain the chemokine system 
function, even if genetic or epigenetic alterations affecting individual components 
occur.
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Chemokine Receptors
Structure and nomenclature
Chemokines induce cell migration and activation by binding to specific G- 
protein-coupled cell surface receptors on target cells. Ten CC (CCR1-10), seven CXC 
(CXCR1-7, the last is a very recent acquisition), one CX3C (CX3CR1) and one XCR 
(CXR1) receptors have been identified (86, 89). Receptor expression is a crucial 
determinant o f the spectrum of action o f chemokines. The profile o f chemokine- 
receptor expression on an individual cell is determined by its lineage, stage of 
differentiation and microenvironmental factors, such as chemokine concentration, the 
presence of inflammatory cytokines, low oxygen tension (hypoxia). Indeed, some 
receptors are restricted to certain cells (e.g. CXCR1 is predominantly restricted to 
neutrophils), whereas others are more widely expressed (e.g. CCR2 is expressed on 
monocytes, T cells, natural killer cells, dendritic cells, and basophils). Moreover, 
chemokine receptors can be constitutively expressed on some cells, whereas inducible 
in others (e.g CCR1 and CCR2 are constitutively expressed on monocytes, but are 
expressed on lymphocytes only after IL-2 stimulation); again, the expression of some 
chemokine receptors can be restricted to a cell state of activation and differentiation 
(e.g. CXCR3 is expressed on activated Thl T lymphocytes, whereas CCR3 is 
preferentially expressed on Th2 lymphocytes) (95). Although initially studied on 
leukocytes, some chemokine receptors are also expressed in nonhematopoietic cells, 
including neurons, astrocytes, epithelial and endothelial cells. These observations 
suggest that the chemokine system has other roles in addition to leukocyte chemotaxis.
As already pointed out for chemokines, the remarkable feature o f the chemokine 
receptor family is their promiscuity as far as ligand binding is concerned; however, 
although relatively few receptors bind only one ligand, CC receptors bind only CC
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chemokines and CXC receptors bind only CXC chemokines. This ligand-receptor 
restriction may be related to structural differences between CC and CXC chemokines, 
which have similar primary, secondary and tertiary structures but different quaternary 
structures (96).
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Fig. 2.2. Chemokine Receptor family. Ligand specificity is represented, with many receptors 
binding more than one single ligand.
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Chemokine receptor signaling
The first studies on chemokine signaling showed that functional responses were
prevented by pre-treatment of the cells with Bordetella pertussis toxin, indicating that 
the receptor was coupled to GTP-binding proteins of the Gi type (97), which eventually 
turned out to be the rule for all the chemokine receptors. Although the details o f the 
chemokine signalling pathways appear to vary slightly depending on the cellular 
context, the general rule is that, on chemokine binding, the G protein activated by GTP 
dissociates in a  and By subunits, the latter activating two major signal transduction 
enzymes PLC (both the isoenzymes (32 and (33 (98) and PI3Ky. PLC cleaves PIP2 
yielding to two second-messengers: IP3, (which induces the release o f calcium ions 
from intracellular stores, leading to a transient rise of the free calcium concentrations) 
and DAG (which activates several isoforms of PKC). While the rise in the concentration 
of intracellular calcium has been widely used to test the responsiveness of chemokine 
receptors to different chemokines, activation of PKC isoenzymes is stimulated by 
almost any surface receptor and therefore is not special for chemokine-induced signal 
transduction. However, PKC activation by chemokines contributes to receptor 
phosphorylation which leads to desensitization and inhibition o f functional responses 
(99) (see later). In myeloid cells, migration is not dependent on PLC(3 activity, but 
requires activation of PI3Ky (100, 101); PI3Ky rapidly generates PIP3 and initiates the 
activation of another kinase, PKB (102). In a chemotaxing cell, signaling components 
responsible for the formation of cell polarity, directional sensing and F-actin 
polymerization, such as PI3K, PIP3, the small GTPase Rac, PKB, translocate to the 
leading edge of the cell, where they contribute to local actin polymerization, whereas 
the mediators of actomyosin contraction are recruited to the trailing edge (103)(Fig. 
2.3). Another important player is Cdc42, a small GTPase, which is recruited to the 
leading edge, where it has the essential role to exclude from the leading edge a
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phosphatase, PTEN, negative regulator of PI3Ky. Without Cdc42, cells exhibit a 
random walk, rather than directed migration (104-106). Thus, upon chemokine 
stimulation, PI3K localizes anteriorly, whereas PTEN localizes posteriorly and this 
spatial and temporal regulation determines the polarity of the migrating cell (107).
Chemokine Receptor
G a { protein
MAPK
pathway
PTEN
Cdc42
RacGTP
Cell polarity 
Gradient sensing F-actin polymerization Myosin Assembly
Leading edge
Fig 2.3. Signaling through chemokine receptors. Different signalling components localize 
either in the leading edge or in the trailing edge, determining cell movement (adapted from 
Tanaka et al, ( 108)).
There is increasing evidence that chemokine receptors can also activate several 
intracellular effectors downstream of G coupling, including the low molecular weight 
protein Ras and Rho and the mitogen-activated protein (MAP) kinase pathway (109,
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Trailing edge 
] Direction o f Cell movement
110). Recently it has been suggested that, like cytokine receptors, chemokine receptors 
are also able to signal through the JAK-STAT pathway (111, 112). Upon ligand 
binding, the receptor dimerizes and catalyses the phosphorilation of the JAK kinases 
which in turn phosphorylate the receptor itself; this event brings to STAT molecule 
recruitment, dimerization and translocation to the nucleus where it triggers the 
expression of cytokine dependent genes.
Chemokine receptor signalling is transient, and the rapid termination of receptor 
activity is achieved by three mechanisms: receptor inactivation, desensitization and 
internalization. Receptor inactivation is mediated by the intrinsic GTPase activity of 
the G a subunit, which hydrolyzes GTP and reunite with Gpy to return to the initial 
conformation of inactive heterotrimers. Desensitization is caused by receptor 
phosphorilation, through G-protein-coupled receptor kinases, among which PKC and 
finally internalization is caused by p-arrestin or adaptin-2 mediated receptor 
sequestration and internalization, through clathrin-coated pits or caveolae. The speed of 
response recovery is determined by the fate of internalised receptors, either lysosomal 
degradation or dephosphorylation and cell surface recycling; the pathway leading to 
either degradation or recycling following receptor internalization are determined by the 
guardians of all vesicular machinery, Rab GTPases (113) and by the rate o f de novo 
chemokine receptor synthesis.
CXCR4 is a unique receptor in this regard, as it does not share with the other 
chemokine receptors the common feature of rapid inactivation; indeed, it possesses the 
remarkable property o f being able to induce prolonged signalling (114). Stimulation of 
prolonged signalling of Akt/PKB and ERK2 is likely to contribute to this phenomenon 
(115). Recently, Tilton et al have raised various possibilities to explain this fact, the 
most likely being that CXCR4 remaining at the surface is not desensitised (as is usual 
with chemokine receptors) but can continue to transduce a signal in response to
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CXCL12, despite receptor internalisation. Receptor recycling could also contribute to 
this effect (115).
Signal transduction downstream chemokine receptors is much more complicated 
than the one above described; indeed, a given receptor will activate signalling pathways 
influenced by those from other receptor systems.
Beside the conventional signalling receptors, other chemokine binding molecules with 
high structural similarity to chemokine receptors have been described, namely the Duffy 
antigen receptor for chemokines (DARC) (116), D6 (117, 118) and CCX-CKR (119). 
These receptors do not elicit migration or conventional cellular responses, but still retain 
the capability to bind chemokines with high affinity. They are also referred to as “silent 
receptors” and have been suggested to favour transfer of chemokines across endothelial 
barriers and/or to act as decoy receptors which dampen inflammatory reactions (120).
2.3 In vivo biology of Chemokines and Receptors
The eponymous function of chemokines and their receptors is to mobilize cells 
in a gradient direction. This biological function is particularly important in leukocyte 
recruitment at sites of inflammation, although it is now well known that many different 
cells express chemokine receptors and are therefore able to respond to chemotactic 
stimuli. The process of recruitment o f circulating leukocytes at sites of inflammation 
begins with the chemokine and chemokine receptor interaction, which eventually 
culminates in the final cell movement.
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Multistep model of leukocyte extravasation
Binding to endothelium occurs through complex interactions of adhesion 
molecules and chemokines, exposed on endothelial cells and their receptors, expressed 
by the moving cell. Leukocytes tether to vessel walls using selectins, molecules that are 
specialized for adhesion under shear stress; these molecules have been demonstrated to 
be expressed also by other cell types, therefore presumably involved in the binding to 
the endothelium of different types of cells. This process, also referred to as rolling, is 
the first weak stop signal for circulating cells. Then a second class o f adhesion 
molecules, integrins, is responsible for firm adhesion; they are structurally designed for 
rapid conformational changes regulating their affinity and leading to firm arrest of cells 
on the vessel wall and then transendothelial migration. Chemokines, bound to 
glycosoaminoglycans on the surface of endothelium, are thought to provide the signals 
that convert the low-affinity, selectin-mediated interaction into the high-affinity, 
integrin -mediated interaction that leads to extravasation o f leukocytes.
Blocking of leukocyte adhesion to endothelium by pertussis toxin, a G-protein- 
signalling inhibitor, confirms this hypothesis (121).
Role of chemokines in physiologic processes
Chemokine biological function is particularly important in leukocyte 
recruitment at sites of inflammation and therefore, the primary role o f chemokines in 
guiding leukocyte migration bears the important consequence that blocking chemokines 
or their receptors profoundly affects all those inflammatory responses requiring 
leukocyte recruitment.
The trafficking of Dendritic cells (DC) and lymphocytes through secondary
lymphoid organs is finely regulated by chemokine receptors. DC can take up antigens in
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peripheral tissues and migrate to draining lymph nodes where they present antigen to 
naive T cells, triggering the T cells to proliferate and differentiate. These activated T 
cells can then migrate to the inflamed tissues to perform their effector functions. The 
movement o f T cells and DC between lymph nodes and the periphery may be controlled 
by differential chemokine receptor expression (122). Circulating monocytes and 
immature DC can express receptors for chemoattractants such as fMLP (representative 
of bacterial proteins) and C5a (generated in the complement cascade) as well as 
chemokine receptors including CXCR4, CCR1, 2, 3, 4, 5 and 6 (123, 124). Using these 
receptors, immature DC can migrate towards sites where there is a high concentration of 
inflammatory chemokines such as CCL2, CCL3 and CCL5. Immature DC can also 
respond to constitutively expressed chemokines such as CXCL12, and this may be 
important for localising DC in tissues under normal conditions. At sites of 
inflammation, immature DC are activated by inflammatory cytokines such as TNF- 
a  and IL-1 (125), which results in DC maturation. This causes a switch in their 
chemokine receptor expression. Maturing DC lose their responsiveness to CCL3, 4, 5, 7 
and 20 (126, 127), but concomitantly upregulate CCR7 and gain responsiveness to 
CCL 19 and CCL21 which are expressed in T cell rich areas of secondary lymphoid 
organs including lymph nodes, spleen and tonsils.
Naive T cells can express CXCR4 and CCR7, which may account for their 
localisation in secondary lymphoid organs. Upon interaction with antigen-presenting 
DC, naive T cells are activated and alter their chemokine receptor profile. Activated T 
cells can express CXCR3, CXCR4, CCR1, 2, 3, 4, 5, 6, 7 and 8 (128, 129). Activated T 
cells can polarise to T helper 1 (Thl, expressing IFN-y and IL- 12) and T helper 2 (Th2, 
expressing IL-4) subsets, which differ in their cytokine production and function during 
an immune response and also express different chemokine receptors. CCR5 and
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CXCR3 are preferentially expressed on Thl cells, while Th2 cells preferentially express 
CCR3, CCR4 and CCR8 (128, 129), although this differential chemokine receptor 
expression is not clear-cut. Finally, naive B cells can express CXCR5 and CCR7 (130) 
which direct them to the follicles of secondary lymphoid organs, where the ligands 
CXCL13, CCL 19 and CCL21 are expressed. Upon maturation to plasma cells, B cells 
downregulate CXCR5 (131) and CCR7 (132), but have increased sensitivity to 
CXCL12 (through CXCR4) which regulates plasma cell positioning in the spleen and 
lodgement in the bone marrow.
Various indications in the literature suggest that chemokines have a role in the 
development of different biological responses that goes beyond cell recruitment. 
Chemokines have been shown to play a direct role also in definition of the cytokine 
milieu during both inflammatory and immune responses as well as in important 
mechanisms such as hematopoiesis. Thus, chemokines not only support differential 
leukocyte recruitment, but also directly affect target cell functions. Chip-based gene 
expression profile analysis in chemokine-activated monocytes revealed that CC 
chemokines induce specific transcriptional programs in target cells, demonstrating that 
chemokine effects on target cells include induction of transcriptional events (133).
Chemokines not only attract T cells, but they may also have roles in regulating T 
cell biology, influencing Thl/Th2 polarisation (134). CCL2 can suppress Thl 
responses and cause an increase in IL-4 (Th2 cytokine) production by activated and 
memory T cells in vitro (134, 135). CCL2 addition to macrophages in vitro can also 
decrease IL-12 (Thl cytokine) expression (136). CCL2 may therefore promote Th2 
polarisation both directly and indirectly by increasing IL-4 and decreasing IL-12 
production, respectively. In contrast, addition of CCL3 to in vitro cultures o f activated T
47
cells promoted the development o f IFNy-producing cells (135) and hence Thl 
differentiation. Similarly, CCL3, 4 and 5 production by monocyte-derived DC can 
promote the development of IFNy-producing cells (137). However, experiments in mice 
deficient in the chemokines CCL2 and CCL3 and the chemokine receptors CCR1 and 
CCR2 have been less conclusive, and in some instances given opposite results, 
depending on the experimental protocols used (138-141).
More work is required to further elucidate the role of chemokines in the 
differentiation o f T cells, and also the contribution of chemokines produced by T cells 
themselves. This may have implications for the use o f chemokine receptor antagonists 
in the treatment of inflammatory disease.
Chemokines play also an important role in hematopoiesis. Stem cells and 
progenitor cells (HPC) in the bone marrow are subjected to the influence o f a variety o f 
different cytokines, resulting in either stimulation or inhibition of proliferation (142). 
Chemokine receptor expression by HPC may regulate the homing o f these cells within 
the bone marrow during differentiation and maturation, and their mobilisation into the 
circulation. In particular, haematopoietic progenitor cells express CXCR4 and can 
migrate in response to CXCL12 (143); therefore, this chemokine/receptor pair plays an 
important role in the balance between retention and mobilization of progenitor cells in 
the bone marrow and this function is accomplished through a mechanism o f receptor 
desensitization and downregulation, with CXCL12 being constitutively produced in 
high amounts in bone marrow. Moreover, they can also be important for the retention of 
HPC in the bone marrow, during B lymphopoiesis; retaining B cell precursors in the 
bone marrow would enable their regulated differentiation into mature B cells (144). 
Beside hematopoiesis, CXCR4 and CXCL12 are important in development and 
embryogenesis, as clearly demonstrated by knockout mice (145, 146). Both CXCR4 and 
CXCL12 deficient mice die in utero, pointing out their role in development and
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embryogenesis; this may also explain why CXCL12 is such a highly conserved 
chemokine. These mice have severely reduced numbers of B cell progenitors and 
myeloid progenitor cells, suggesting that the CXCL12/CXCR4 pair is responsible for B 
cell lymphopoiesis and bone marrow myelopoiesis. Surprisingly, T lymphopoiesis is 
unaffected in these mice. They also have severe heart defects, including defective 
cardiac ventricular septum formation and a disorganised cerebellum. Evidence have 
been collected that mice deficient in either CXCR4 or CXCL12 have defective 
formation of the large blood vessels supplying the GI tract, possibly due to defective 
regulation of vascular branching and/or remodelling processes in endothelial cells (145).
Chemokine in vivo functions are not limited to immunity and inflammation; given their 
broad spectrum activities, it not surprising that they play a role in several types of 
human pathologies, including asthma, cardiovascular diseases, transplantation, 
neuroinflammation, HIV-associated diseases and neoplasia (147). Here I give a general 
overview of the role of chemokines in some important pathologies.
Chemokines in Pathology
A sthm a is a chronic disease o f the small airways where chronic inflammation 
leads to reversible airway obstruction. The leukocyte infiltrate characterizing allergen 
response consists of eosinophils, mononuclear cells (particularly Th2 cells), basophils 
and mast cells. Among different chemokine receptors expressed on the leukocytes 
associated with asthma, CCR3 seems to play a prominent role (148), since it is the 
receptor for CCL 11 (eotaxin); this chemokine was first described due to its ability to 
attract eosinophils which are closely correlated with lung dysfunction clinically (149). 
Indeed, protein and mRNA expression of CCR3 are elevated in the bronchial mucosa 
and skin of patients with asthma (150), where it is expressed on eosinophils, basophils,
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mast cells and airway epithelial cells (151).
Multiple sclerosis (MS) is a demyelinating autoimmune disease mediated by 
CD4+ T cells specific for one or more autoantigens in the central nervous system, which 
produce a variety of destructive inflammatory mediators. Beside auto-reactive T 
lymphocytes, MS lesions contain a variety of cell types, including 
monocytes/macrophages and T cells which are subsequently recruited, activated 
microglia and activated cerebrovascular endothelium (152). During active MS attacks 
there are significantly increased levels of CXCL9, CXCL10, and CCL5 in cerebrospinal 
fluid (153) and CCL2, CCL7 and CCL8 have been found immunohistochemically in 
MS lesions (154). Various chemokine receptors are also expressed in MS lesions: CCR2 
and CCR5 are found on macrophages, microglia and T cells, and CCR3 is also found on 
reactive astrocytes (155). MS patients heterozygous or homozygous for the CCR5A32 
allele (which encodes a non-functional form o f CCR5) have delayed disease onset of 
approximately 3 years compared with affected siblings (156), suggesting that CCR5 
may be a target for therapy. CXCR3 is expressed by more than 90 % of CD3+ T cells in 
cerebrospinal fluid, and >99 % of T cells in perivascular accumulations in active lesions 
(153). The presence of CXCL9 and CXCL10 in MS lesions may account for the 
recruitment of CXCR3 positive T cells; CXCR3 may also be a target for therapeutic 
intervention in MS (157).
Rheumatoid arthritis is characterized by the presence of a mixed inflammatory 
cell infiltrate into synovium-lined joints, in response to autoantigens. The success of 
anti-TNF-based therapy has indicated the critical role played by this cytokine in 
arthritis, presumably mediated by the induction o f chemokines. Synovial fluid from 
pathological joints contains high levels of CCL2, CCL3, CCL5 and CXCL10 and both
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synovial-lining cells and leukocytes are the source. Leukocytes are also the target, 
expressing CCR2, CCR5, CCR2 and CXCR3 (158, 159).
Accumulating evidence indicates that chemokines play a central role in 
cardiovascular disease and in particular in atherosclerosis (160), a chronic 
inflammatory disease o f the blood vessel wall, characterized by the accumulation of 
mononuclear cells. It is a multifactorial disease, with risk factors such as smoking, 
hypertension, hypercholesterolemia, family history and diabetes; however, there is 
consensus on the origin of atherosclerotic plaques from an inflammatory response to the 
arterial damage, occurring either because of hypercholesterolemia or shear stress. One 
of the chemokines found involved in this pathology is CCL2: indeed, CCL2 and CCR2 
deficient mice have 60-85% less arterial lipid deposition than wild type mice, in 
hypercholesterolemia models and this is consistent with the role o f CCL2 in leukocyte 
recruitment. Recent evidence demonstrate that a broad spectrum CC-chemokine 
blockade reduced atherosclerosis in an Apo-E knockout mice (161, 162).
Another important chemokine in atherosclerosis is CX3CL1, namely 
Fractalkine: this chemokine is produced by endothelial cells after inflammatory 
cytokine stimulation and can mediate leukocyte adhesion and infiltration into the 
vascular wall, as well as NK-cell-mediated endothelium injury. High levels o f mRNA 
for CX3CL1 and other 16ql3-chromosome-linked chemokines have been observed in 
human arteries with advanced atherosclerotic lesions (163). The ability to recruit 
leukocytes and its expression in vascular cells strongly suggest a pivotal role for 
Fractalkine in the pathophysiology of atherosclerosis (164). Moreover, in humans, gene 
polymorphisms at amino acids 249 and 280 o f the Fractalkine receptor have been 
reported (165-167), causing amino acid substitution: valine (V) instead of isoleucine (I) 
in position 249 and methionine (M) instead of threonine (T) in 280. Homozygosity for
51
V249-CX3CR1 has been found to be associated with increased risk for acute coronary 
events in comparison to 1249 heterozigosity (167). The molecular explanation is that the 
V249 variant displays higher binding affinity to the chemokine, corresponding to an 
enhanced ability of monocytes to adhere to the vascular endothelium (168).
As the chemokine system plays an essential role in host defense, it is not 
surprising that chemokines and their receptors may be involved in rejection of 
allogeneic transplants. In particular, after an early non specific release o f inflammatory 
chemokines attracting neutrophils and monocytes, CXCR3 and CCR5 ligands appear, 
several days after the transplants, consisting with their orchestrating the movement of 
cells involved in acute rejection (169). Moreover, it has been demonstrated that 
CX3CL1 expression is enhanced in rejecting cardiac allografts (170); in addition, the 
treatment of organ recipients with polyclonal anti CX3CR1 blocking antibodies 
markedly prolonged survival of MHC-mismatched heart allografts (170).
As far as bone marrow transplant is concerned, CXCR4 and its ligand 
chemokine CXCL12 are very important. As comprehensible given their role in the 
balance between stem cell precursor retention and mobilization in the bone marrow, 
CXCR4/CXCL12 play a role in bone marrow engrafment of CD34+ cells and this may 
have clinical implications with regard to therapeutic stem cell transplantation.
CD4 is the primary cell surface receptor used by human immunodeficiency virus 
(HIV) to penetrate T lymphocytes and macrophages. The chemokine receptors CXCR4 
and CCR5 function as co-receptors which, along with CD4, allow viral envelope fusion 
and entry (171, 172). A range of chemokine receptors have now been shown to have co­
receptor activity in vitro, including CCR1, 2, 3, 4, 5, 8, 9, CXCR2, 4, 5, 6 and CX3CR1
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(173), but so far only CXCR4 and CCR5 have been shown to act as co-receptors in 
vivo, hence X4 tropic and R5 tropic viruses are described. Since chemokine receptors 
act as co-receptors for HIV entry, endogenous chemokine production can regulate HIV 
replication. In 1995, Cocchi et al published that CCL3, CCL4 and CCL5 have CD8+ T- 
cell-derived HIV inhibitory activity (174). Also, individuals homozygous for the A32 
allele of CCR5, who are deficient in cell surface CCR5 expression, can remain 
uninfected despite exposure to HIV (175, 176). These observations suggest that 
chemokines and their receptors which are involved in HIV infection are potential targets 
for the development of new drugs to treat HIV. For example, small molecule 
antagonists of CCR5 and CXCR4, which can block HIV entry, are entering clinical 
trials (177, 178).
2.4 Chemokines in Cancer
Since their discovery, the field of chemokines was strongly connected to cancer 
biology. Indeed, in the early 1980s it had been noted that tumor supernatants contained 
chemo-attractants active on monocytes (179); the Tumor-derived Chemotactic Factor 
isolated in the culture supernatants of tumor cell lines was lately identified as CCL2 
(180). The role of chemokines in tumor biology has dramatically developed in the last 
decade and has expanded from the regulation of leukocyte attraction within the tumor 
mass to the promotion of tumor cell survival, proliferation and dissemination (82, 83, 
181).
As already said, primary tumor growth, invasion and metastasis to distant organs 
are dependent on a highly orchestrated series o f events, including cellular 
transformation, a pro-angiogenic environment, local tumor cell growth, invasion
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through the extracellular matrix (ECM) and vascular basement membrane, entry into the 
circulation and eventually non-random tumor-cell metastasis to distant organs. In 
addition to their role in regulating leukocyte trafficking, chemokines have been shown 
to be involved in each of these events.
Chemokines in the tumor microenvironment
In the tumor microenvironment chemokines are produced both by stromal cells 
(fibroblasts, endothelial cells and infiltrating leukocytes) and by the tumor itself. CCL2 
is probably the CC chemokine most frequently secreted by cancer cells. Human tumors 
shown to express CCL2 in vivo include sarcomas, gliomas, lung tumors, carcinomas of 
the breast, cervix and ovary, melanoma and pancreas (91) Several lines o f evidence, 
including correlation between production and infiltration in murine and human tumors, 
passive immunization and gene modification, indicate that CCL2 plays a pivotal role in 
the recruitment of monocytes in neoplastic tissues, as discussed below (91, 133).
As mentioned above, tumors are generally characterized by the constitutive 
expression of chemokines belonging to the inducible realm. The molecular mechanisms 
accounting for constitutive expression have been defined only for CXCL1 and involve 
NFkB activation. Melanoma cells display high expression of NF-kB-inducing kinase 
(NIK) and this phenotype is responsible for constitutive activation of IkB kinase and 
MAPK signaling cascades, as well as for constitutive activation of NF-kB (182, 183) 
This may represent a general mechanism underlying constitutive expression of 
inflammatory chemokines in tumors.
Role of chemokines in tumor progression.
Beside CCL2, a variety of other chemokines have been detected in neoplastic
tissues as products of tumor cells or stromal elements. These include CCL5, CXCL12,
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CXCL8, CXCL1, CXCL13, CCL17 and CCL22. CCL5 is produced by breast 
carcinoma and melanoma (184, 185). In breast cancer CCL5 expression by tumor cells 
correlates with a more advanced stage of disease, suggesting that CCL5 may be 
involved in breast cancer progression (184, 186). Melanoma is probably the most 
studied cancer type in which CXC chemokines and in particular CXCL1 and related 
molecules (CXCL2, CXCL3, CXCL8 or IL-8) have been demonstrated to play a role in 
tumor progression (187). They do so by direct stimulation of neoplastic growth, 
promotion of inflammation and induction of angiogenesis. CXCL1 was initially 
identified and purified from supernatants of melanoma cell lines and characterized as an 
autocrine growth factor (188, 189). Blocking of CXCL1, or its receptor CXCR2, with 
specific antibodies inhibited the growth of melanoma cells in vitro (189). Conversely, 
the over-expression of CXCL1 (190), CXCL2 or CXCL3 (191) in various melanoma 
cell lines increased their ability to form colonies in soft agar and their tumorigenicity in 
nude mice. A few other studies have proposed a similar role for CXCL8 related 
chemokines in head and neck (192) pancreas (193) and Non-Small-Cell Lung Cancer 
(NSCLC) (194). Autocrine and paracrine expression of CCL20 has been reported in 
pancreatic cancer (195). Finally, CXCL13 is a B cell chemokine and is highly expressed 
in Helicobacter pylori-induced lymphoma (196) and a role for CXCL13 in the 
localization of tumor cells has been suggested.
Chemokines regulate angiogenesis.
Angiogenesis is a key event in tumor growth and progression and chemokines 
have a major impact on the regulation of neovascularization in tumor tissues. As already 
said, the N-terminus of several CXC chemokines contains a highly conserved amino 
acid motif (Glu-Leu-Arg: ELR motif), which immediately preceeds the first cystein 
(197). ELR+ chemokines have potent angiogenic activity. The angiogenic members
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include CXCL1 through CXCL8, with the exception of CXCL4. These chemokines act 
through a common receptor, CXCR2. Although some ELR+ chemokines bind both 
CXCR1 and CXCR2, it is widely accepted that only CXCR2 mediates the angiogenic 
activity and, accordingly, endothelial cells express only CXCR2 (198) Another 
important ligand-receptor pair is CXCL12 and CXCR4. Even if  CXCL12 is a non-ELR 
chemokine, its activity has been implicated in neo-angiogenesis (199, 200).
The importance o f ELR+ chemokines in supporting angiogenesis during the neoplastic 
progression has been established in a variety of tumor cell types, including prostate and 
ovarian carcinoma and NSCLC (201-203). Both in mouse tumor models and in surgical 
specimens obtained from tumor patients, expression of CXCL5 and CXCL8 was 
associated with increased neovascularization and inversely correlated with survival. 
Conversely, depletion o f CXCL5 resulted in attenuation o f tumor growth and 
angiogenesis. The finding of the unique use of CXCR2 receptor, despite the redundancy 
of ELR+ chemokines, provides a good opportunity to target this receptor for therapeutic 
interventions.
On the other hand, another series o f CXC chemokines lacking the ELR m otif 
(non-ELR) are characterized by the ability to block or inhibit angiogenesis. The 
angiostatic members are CXCL4, CXCL9, CXCL10 and CXCL11. The three latter 
chemokines are interferon-inducible and bind the CXCR3 receptor (86, 204). Recent 
observation has demonstrated that CXCR3 exists in two different isoforms: CXCR3A 
and CXCR3B, which differ in their NH2 terminus (205) CXCR3B (205), which is more 
expressed than CXCR3A in endothelial cells, appears to mediate the angiostatic activity 
of IFN-inducible chemokines. In addition, CXCL4 was shown to bind to CXCR3B 
(205). Non-ELR CXC chemokines have been shown to inhibit angiogenesis in several 
tumor models. Over-expression of CXCL9 and CXL10 in tumor cells leads to
56
spontaneous tumor regression in lymphoma cells (206) NSCLC (207) and melanoma 
(208).
Therefore, the balance of ELR+ versus non-ELR chemokines produced in the 
tumor microenvironment may determine the degree of angiogenesis surrounding and 
inside the tumor tissue and the consequent tumor progression.
Chemokines mediate leukocyte recruitment in tumors
The local production o f inflammatory chemokines by tumor and stromal cells 
would be expected to cause the recruitment o f various types o f leukocytes to the tumor 
tissue. Indeed, tumors are composed o f cancer and stromal cells, which sometimes are 
very developed and can even outnumber neoplastic cells. Besides fibroblasts and 
endothelial cells, leukocytes (especially macrophages and T lymphocytes) are the most 
represented cell types. Because these inflammatory cells secrete a variety o f biologically 
active molecules, they are likely to regulate neoplastic processes that affect the growth 
and spread of tumor cells.
CXCL8 and related chemokines act primarily on neutrophils. In spite of 
constitutive production of these ligands by tumor cells, neutrophils are not a major and 
obvious constituent of the leukocyte infiltrate. However, these cells, though present in 
minute numbers, may play a key role in triggering and sustaining the inflammatory 
cascade, for instance by releasing angiogenic molecules (209).
Tumor-Associated M acrophages (TAM) derive from monocytic precursors 
circulating in the blood (210) Experimental evidencesuggests that tumor infiltrating 
macrophages may facilitate tumor growth and progression, as, although they can 
potentially display tumor cytotoxicity, they are believed to have primarily pro-tumor 
functions (Fig 2.4) (21, 210, 211). In breast cancer, tumor cells produce CCL5, and the
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level of expression correlates with the extent of macrophage infiltration and lymph node 
metastasis (184). In a mouse model, the long-term administration of a CCL5 antagonist, 
Met-CCL5, significantly reduces the subcutaneous growth of CCL5-producing 
syngeneic mouse breast cancer cells without affecting their proliferative ability, but 
concurrently inhibits leukocyte infiltration in the tumor (212). In addition to being a 
target for chemokines, TAM are a source o f a selected set o f these mediators (CCL2, 
CCL17, CCL18, CCL22). CCL18 was recently identified as the most abundant 
chemokine in human ovarian ascites fluid (213). When the source o f CCL18 was 
investigated, it was tracked to TAM, with no production by ovarian carcinoma cells. 
CCL18 is a CC chemokine produced constitutively by immature DC and attractant for 
naive T cells, by interacting with an unidentified receptor (87). Attraction o f naive T 
cells in a peripheral microenvironment dominated by M2 macrophages and immature 
DC is likely to induce T cell anergy.
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Fig 2.4. Tumor-derived chemokines actively recruit circulating blood monocytes at the 
tumor site. In the tumor micro-environment monocytes differentiate into Tumor-Associated 
Macrophages (TAM), which have an ambiguous role in their relationship with cancer cells, but 
most frequently have pro-tumoral functions.
Also T lymphocyte recruitment at the tumor site has an important role and 
chemokines are part of amplification and regulation systems of polarized T cell 
responses. Some chemokines may enhance innate and specific host immunity against 
tumors but, on the other hand, other chemokines may contribute to escape from the 
immune system, by recruiting Th2 effectors and regulatory T cells (214, 215). 
Nasopharingeal and ovarian carcinoma express CCL5 and CCL3, ligands of CCR5; 
they have been proposed to regulate T cell infiltration (216, 217); transduction of CCL5
MONOCYTES
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in tumor cells resulted in loss of tumorigenicity due to activation of anti-tumor 
immunity (216). Despite this evidence, in vivo expression of CCL5 is associated with 
advanced disease in breast and cervical cancer (184, 218). Also expression of CXCL9 
has been associated with heavy infiltration of T lymphocytes in human melanoma (219) 
and in mouse tumor models (220, 221). CXCL10 was reported to be an important factor 
for IL-12-mediated anti-tumor response through the recruitment and activation o f CD8 
lymphocytes (222) and NK cells.(223) The chemokine CCL21 recruits dendritic cells 
and lymphocytes (naive T, NK cells and a subset of memory T cells), and displays anti­
neoplastic effects when transduced in tumor cells(224-226) or injected locally (227). 
Similar results were reported for CCL19, which shares with CCL21 the same receptor 
CCR7 (228).
A variety of dendritic cells (DC) subsets are also found in tumor tissues and 
chemokines are involved in their recruitment (229, 230). Although usually rare cells, 
DC have been detected in several tumor types, including lung, prostate, nasopharynx, 
kidney, thyroid, breast, ovary carcinoma and melanoma (231, 232)
Finally, another interesting example o f tumor leukocyte interaction is Hodgkin’s 
lymphoma. Reed-Stemberg cells in Hodgkin’s lymphoma have been shown to express 
CCL22 and CCL17 (233, 234). These chemokines recognize CCR4 which is 
preferentially expressed on Th2 lymphocytes and on T regulatory cells (85, 235). 
Interestingly, in the same tumor, stromal cells produce CCL11, which attracts 
eosinophils and Th2 cells. Therefore, in this human tumor, neoplastic elements and 
stroma use complementary tools to recruit immunocompetent cells associated with 
polarized type II responses, unable to mediate anti-tumor immunity. In the same vein of 
driving into tumors polarized Th2 cells, the oncogenic virus human herpesvirus 8 
(HHV8), involved in the pathogenesis of Kaposi’s sarcoma and hematological 
malignancies, encodes three CC chemokines (vMIPI, II and III) which interact with
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CCR3, CCR4 and CCR8 expressed on Th2 cells and T regulatory cells (235). 
Consistently with these in vitro observations, Kaposi’s sarcoma is infiltrated by CD8+ 
and, to a lesser extent, CD4+ cells with a predominant Th2 phenotype. Therefore, 
HHV8 virus-encoded chemokines represent a strategy to subvert antiviral/antitumor 
immunity by favouring the recruitment o f inefficient cells and cells with suppressive 
activity. In addition to viral chemokines, HHV8 encodes for a chemokine receptor 
homologue, ORF74, also known as KSHV vGPCR, showing similarity with CXCR2 
(236). This receptor triggers a constitutive signal which is further increased by CXCL8 
and CXCL1, providing a good example of a direct role of chemokines and receptors in 
neoplastic transformation. Indeed, over-expression of KSHV vGPCR alone resulted in 
the development of lesions resembling Kaposi’s sarcoma (237).
Chemokines and extracellular proteases
The field of chemokines in tumor biology has dramatically developed in the last 
decade and has expanded from the regulation of leukocyte attraction within the tumor 
mass to the promotion of tumor cell survival, proliferation and mobilization (91).
It has long been known that tumor-derived proteases can cleave the extra­
cellular matrix molecules and lead to the dissolution o f the basement membrane, thus 
facilitating the process of tumor cell invasion. What it has remained unknown until very 
recently is that chemokines are potent inducers of enzymes and receptors which degrade 
the extracellular matrix and favour tumor invasion (49, 238, 239). As I have already 
discussed before, a variety of proteolytic enzymes, in particular the tissue type 
plasminogen activator (t-PA), the urokinase-type plasminogen activator. (u-PA) and the 
large family of matrix-metalloproteinases (MMPs) have been implicated in this 
degradation (68 , 240); indeed, the activity o f these enzymes has been associated with 
more aggressive neoplastic behaviour. Confirming the role o f chemokines in the
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activation of these enzymes, in a gene expression analysis, the chemokine CCL5 
specifically induced gene expression of various MMPs, especially MMP9, along with 
the uPA receptor (133). CXCL8 expression by human melanoma cells induces 
transcriptional activation of expression of the gene encoding MMP2 and augmented 
collagenase activity in these tumor cells, which leads to increase invasiveness (241). In 
prostate cancer, CXCL8 over-expression induces the expression of MMP-9, leading to 
increased tumor cell invasiveness and metastatic potential in nude mice (242).
Not only tumor cells produce proteases. Leukocytes, in particular macrophages, 
are potent producers of proteases and strong evidence demonstrates that chemokines 
activate TAM to release MMPs in the tumor micro-environment. A number of studies 
have highlighted the role of TNF in the regulation o f MMP activity in monocytes and 
chemokines have been demonstrated to activate MMP activity in monocytes through 
TNFa pathway (238).
The role of CCL2 in pancreatic cancer
Several studies have indicated that CCL2 is primarily responsible for the 
recruitment of monocytes at the tumor site. Indeed, CCL2 levels correlated with the 
abundance of TAM in several types of adenocarcinoma, including ovarian, breast and 
pancreas (25, 243-245). Interestingly, CCL2 production has been detected also in TAM, 
indicating the existence o f an amplification loop for their recruitment (244). In 
accordance with the potential dual role of TAM, the gene transfer of CCL2 into tumors 
had contrasting effects. At least three reports indicated reduced tumorigenicity (246- 
248). The results of another study pointed to an opposite effect: the number of 
spontaneous lung metastases was augmented in animals injected with CCL2- 
transfectants compared to those injected with parental cells (249, 250). The impact of
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CCL2 on tumor growth in a nontumorigenic melanoma system revealed a biphasic 
effect. Low-level CCL2 secretion, with "physiological" accumulation of TAM 
promoted tumor formation, while high CCL2 secretion resulted in massive macrophage 
infiltration into the tumor mass and in its destruction (250). Similarly, a high inoculum 
of CCL-2-transfected melanoma cells showed retarded tumor growth, while a small 
inoculum was more tumorigenic (251). These results are consistent with the 
"macrophage balance" hypothesis (21, 211). Moreover work in gene-modified mice has 
shown that CCL2 can orient specific immunity in a Th2 direction; although the exact 
mechanism for this action has not been defined, it may include stimulation o f IL-10 
production in macrophages (141).
In the last couple of years, we have been interested in the role of CCL2 in 
pancreatic adenocarcinoma. As I said above, CCL2 is found in many epithelial cancers; 
we have found that CCL2 is secreted by some pancreatic carcinoma cell lines, while 
these tumor cells never express CCR2, the functional receptor for CCL2 (Fig 2.5). 
Moreover, inflammatory cytokines such as IFNy, IL ip , TNFa synergistically up- 
regulate its expression (data not shown).
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Fig 2.5. CCL2 in pancreatic adenocarcinoma cell lines. mRNA analysis revealed that 6 out of 
14 pancreatic cancer cell lines analyzed express the chemokine CCL2. ELISA assay confirmed 
the result at the protein level. None of the cell lines express the corresponding receptor (from 
Monti et al (25)).
The expression of CCL2 was detected also in supernatant of primary tumors 
(Fig 2.6) as well as in surgical sections of pancreatic cancers (Fig.2.7 (25)).
Fig. 2.6 Expression of CCL2 in 
human pancreatic cancer in vivo.
CCL2 expression was determined at 
the protein level in supernatants of 4 
human pancreatic tumor cell primary 
culture by ELISA.
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400a
PK 48 PK 51 PK 89 PK 91
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Fig. 2.7 Expression of CCL2 in human 
pancreatic cancer in vivo.
Immunoistochemical localization of CCL2 
in human pancreatic cancer cells(left) and 
normal tissues (right). Representative 
examples (x200; x400) of paraffin sections 
stained with antibodies to CCL2 (5D3-F7).
The tumor associated CCL2 is released into the circulation of tumor- bearing patients 
(Fig. 2.8) (25).
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Fig. 2.8 Median levels of serum CCL2 in 
pancreatic diseases. Lane 1, healthy subjects 
(median value=67 pg/ml). Lane 2, patients with 
pancreatic ductal adenocarcinoma (median 
value=105 pg/ml). Lane 3, patients with other 
pancreatic adenocarcinoma (median value=90 
pg/ml). Lane 4, pancreatic benign tumors (median 
value=70 pg/ml). Lane 5, pancreatic inflammatory 
diseases (median value=80 pg/ml).
Serum CCL2 levels are positively correlated with intratumoral macrophage infiltration 
(Table 2.2) (25).
C C L2 serum  
levels M(|) (CD68+)
Low
(57<pg/ml)
24 ± 4%
Normal 46 ± 8%
High
(91>pg/nil)
57 ±  12%
Table 2.2. Correlation between CCL2 serum levels 
and macrophage infiltration. (Low group, n=27; 
Normal group, n= 47; High group, n=76). The amount of 
leukocytes infiltrating the tumor was evaluated as 
immunostained cells at x200 magnification (average of 
10 random fields) by using a Leitz Diaplan microscope.
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Taken together, these data strongly indicate that CCL2 is expressed and secreted in vitro 
and in vivo by pancreatic tumor cells, thus confirming what has been observed also for 
other carcinomas, in particular in ovarian cancer. Tumor derived CCL2 could promote 
the recruitment of leukocytes, in particular monocytes/macrophages, as indicated by the 
correlation between CCL2 levels and CD6 8 -positive cells; therefore this chemokine 
could play a central role in the crosstalk between tumor cells and their 
microenvironment.
2.5 Chemokines and receptors in tumor spread 
and progression
Novel concepts in organ selective metastasis
For many years, the prevailing explanation of the metastatic process was that 
some tumor cells somehow escape from the primary mass, enter lymph or blood 
circulation and stop in small blood vessels, where they would give rise to secondary 
tumors. This mechanical model predicts that the formation of a metastatic lesion 
depends on the number o f tumor cells delivered to an organ. This does not fit with the 
observation that many types o f cancer display an organ-specific pattern o f metastasis 
but these organs sometimes do not correspond to those found in the drainage site. In 
other words, the selective metastasis pattern a particular tumor displays cannot be 
explained simply by blood and lymph flow. Examples are breast cancer preferential 
metastatization to liver, brain and lung, prostate cancer spreading to bone. Pancreatic 
cancer displays a peculiar recurrence along nerve structures.
Some theories have been put forward to explain the phenomenon of organ selective
metastasis. In 1889, an English surgeon, Stephen Paget, on the basis o f his numerous
observations of cancer patients, proposed the seed and soil theory, according to which
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the metastasis pattern is due to the dependence of the seed (the cancer cell) on the soil 
(the secondary organ). This idea was challenged in the 1920s by James Ewing, who 
suggested that circulatory patterns between a primary tumor and specific secondary 
organs were sufficient to account for organ-specific metastasis. These theories are not 
mutually exclusive, and current evidence supports a role for both o f them: both 
mechanical factors (how many cells are delivered to an organs) and seed-soil 
compatibility factors (does the organ preferentially support or suppress the growth of 
the specific cancer-cell type) contribute to the ability of specific types o f cancer to 
spread to various target organs, by acting at different stages of the metastatic process. 
The initial steps are likely to depend on blood-flow patterns, as most circulating cancer 
cells arrest by size restriction; in fact, capillaries are small (typically 3-8 pm in 
diameter) and designed to allow the passage o f red blood cells (7 pm in diameter and 
highly deformable), whereas many cancer cells are quite large (20  pm or more in 
diameter). However, once cells have been seeded to an organ, their subsequent growth 
will depend on the compatibility of the seed with the soil that they encounter in the 
organ, therefore on the molecular interactions between cancer cells and the environment 
of the new organ.
Numerous candidates have been proposed as mediator molecules o f the 
interaction between cancer cells and the organ, in particular organ specific growth 
factors and adhesion molecules. Recently, a chem o-attraction theory (also referred to 
as homing theory) has been proposed, according to which organ-specific attractant 
molecules enter the circulation, stimulating the migrating tumor cells to invade the walls 
o f blood vessels and enter the organs. Chemokines and their receptors have been found 
to perfectly fit with this theory; in fact, recent studies have shown that tumor cells 
express patterns of chemokine receptors that match chemokines specifically expressed 
in organs to which these cancers commonly metastasize. In particular, the concept that a
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particular chemokine-receptor pair may promote organ-specific tumor metastasis was 
first experimentally addressed by Muller et al (81). Therefore, the identification of 
molecular addresses (i.e. chemokines) or adhesion receptors (selectins) on endothelial 
cells in vascular beds of distal organs that specifically trap circulating malignant cells 
supports the active arrest view of the homing theory (252). As chemokines are involved 
in the homing of leukocytes, it seems reasonable to suppose that they contribute to the 
homing of cancer cells to specific secondary sites, thereby promoting organ specific 
metastasis. This theory is strengthened by the observation that chemokine signalling 
results in the transcription of target genes involved not only in cell motility, but also in 
cell invasion, interaction with the extracellular matrix and survival (91, 181).
Tumor cells express chemokine receptors
While the expression of chemokines in human and experimental tumors has been 
the object of intense investigation, the expression of chemokine receptors has been 
pursued to a much lesser extent, until very recently.
Tumor cell motility is a pivotal step in the intricate process leading to the 
formation of metastases, and tumor cells that have increased metastatic potential are 
more motile than non-metastatic tumor cells. Morphological studies of rat sarcoma cells 
have shown that the structure of the actin network relates to the degree o f the 
malignancy, and determines the cell motility (253). Moreover, in MCF-7 breast cancer 
carcinoma cell line, the level o f F-actin showed a significant increase after treatment 
with the CC chemokine M IP -la  and M IP-lp (254).. In the same work, confocal 
microscopy further indicated a redistribution of the cytoskeletal F-actin within 45 min 
after chemokine stimulation with movement of F-actin towards the periphery o f the 
cells in a polarized manner. These data suggest that chemokines can attract tumor cells.
68
Medium conditioned with mouse lung microvessel endothelial cells possesses 
chemotactic activity for a highly lung metastasizing variant o f the RAW117 murine 
large cell lymphoma cell line, but not for the poorly metastatic parental cell or a liver 
metastasizing variant. The chemotactic activity was purified and identified as JE, the 
murine counterpart of CCL2 (255). Another interesting murine tumor model suggested 
the involvement of chemokines in organ selective metastatization: ESb-MP cell line, a 
variant o f the highly metastatic cell line ESb, (derived from a murine T cell lymphoma) 
displayed frequent in vivo metastasization to the kidney, while the parental cell line 
rarely infiltrate this organ; moreover, it migrated in response to kidney organ 
conditioned media, to which the parental cells did not respond. This raised the 
possibility that a kidney derived chemotactic factor may be involved in the attraction of 
ESb-MP cells in vitro and may account for the kidney specific localization o f ESb-MP 
metastases in vivo. JE/CCL2 and CCL5 chemokines were purified from murine kidney 
derived mesangial cell supernatant as inducers of in vitro migration of ESb-MP variant 
cells but not o f the parental cells (256). Further studies with radiolabeled chemokines 
revealed that cell surface expression of chemokine receptors is necessary but may not be 
sufficient for functional responsiveness. In fact, cells must possess also the proper 
molecular array to transduce a receptor triggered signalling cascade.
Earlier studies already pointed out that tumor cells express functional chemokine 
receptors. Some tumor cell lines migrated in response to CXCL8 and related 
chemokines, and antibodies against CXCR2 were able to inhibit the growth of 
melanoma cells in vitro (189). Other inflammatory chemokines have been tested and 
induced motility of malignant cells o f hematopoietic and epithelial origin (257). CCR4 
is often expressed in adult T-cell leukemias that preferentially invade the skin, where 
one of the CCR4 ligands, CCL17, can be expressed (258). CCR3 is expressed in CD30+ 
cutaneous lymphomas, and its ligand CCL11 is often expressed in the tumor cells and
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tumor-associated skin lesions (259). As far as solid tumors are concerned, the most 
potent chemoattractants for human breast adenocarcinoma cell lines were CCL3, CCL4, 
CCL5 and CCL2. Breast carcinoma cells also express CXCR4, the receptor for 
CXCL12, and this receptor has been recently implicated in the process o f metastasis 
(81). Since then, many other tumors of different lineages have been evaluated and 
shown to express chemotactic receptors (Table 2.2) (83, 91).
Tumor type Chemokine receptor expressed
M ost frequent O ther receptors
Breast CXCR4 CCR7
Ovary CXCR4 CCR9
Prostate CXCR4 CCR9
M elanoma CXCR4 CXCR3, CCR7, CCR10
NSCLC CXCR4 CCR7
Table 2.3.Chemokine receptors expressed by human tumor cells. CXCR4 is the most 
frequently found in different histological types of malignancies {adapted from Balkwill F  (91))
Overall these results support the concept that chemokines could direct tumor cell 
migration in vivo: malignant cells bearing chemokine receptors on their cell surface 
would be endowed with the capability to respond to chemokine gradients and 
selectively migrate to specific organs where the chemokine is present.
In this thesis I have investigated if  chemokines and their receptors are involved in 
human pancreatic adenocarcinoma metastasis and progression.
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Chapter 3 
Materials and Methods
71
3.1 Cells and Tissues
Cell lines
All cell lines were grown in pyrogen-free conditions in a humidified atmosphere 
o f 5% CO2 and 95% air at 37°C. The cells were grown in tissue culture plastic flasks or 
plates (Falcon, Bedford, MA), passaged when confluent by trypsinization 
(trypsin/EDTA, 0.05/0.05 w/v)and seeded at an appropriate density (usually, less than 
5x l04 cells/ml).
Human pancreatic carcinoma cell lines AsPC-1, Capan-1, MiaPaCa-2, Panc-1, 
Hs766T, were purchased from the American Type Culture Collection, (Rockville, MD), 
A8184, PT45, HPAF, CFPAC, PaCa44, T3M4 were kindly provided by Prof. Scarpa 
(Department of Pathology, University of Verona, Verona, Italy). Four cell lines were 
obtained from primary tumors (PT45, PaCa44, MiaPaCa2, Panel), three from ascites 
(AsPC 1, A8184, HPAF) and four from metastasis (T3M4 and Hs766T from lymph 
node metastasis, CFPAC and Capan 1 from liver metastasis,) (26). The cell lines were 
maintained in DMEM (Gibco, Scotland, UK) supplemented with 10% FBS (Hyclone, 
Logan, UT). The immortalized epithelial cell line derived from normal human 
pancreatic ducts HPDE6 , kindly obtained from Dr. Ming-Sound Tsao (University of 
Toronto, Toronto, Ontario, Canada), has been previously shown to maintain the 
phenotypic and genotypic characteristics of normal human pancreatic ducts (260). The 
ovarian cell line OVCAR-3 (derived from primary tumour) was cultured in RPMI 
medium (Gibco, Scotland, UK); the ovarian cancer cell lines OVCAR-4 (derived from a 
primary tumour), SK23, SKN (obtained from SKOV3 p53 transfection (261)), A2780 
(derived from a primary tumour), IA9, SKOW3 (derived from ascites), the breast cancer 
cell lines MCF-7, MDA-MD435 and MDA-MD231 (derived from lung metastasis), and 
the colon cell lines HCT116 (derived from a primary tumour) and SW620 (derived from
lymph node metastasis) were cultured in DMEM 10% FBS. These cell lines were 
already available in the lab.
Prior to their use in functional assays (migration, invasion) or flow cytometry, 
cells were detached without trypsin, to avoid surface receptor cleavage; medium and 
serum were removed and cells washed thoroughly with physiological saline solution 
and left 10 minutes at 37°C in medium 1% FBS.
Neuroblastoma (SKN-BE and SY5Y), and astrocytoma cell lines, already 
available in the lab, were cultured in DMEM 10% FBS; the glioma cell line H4 in 
OptiMEM medium (Gibco), supplemented with 10% FBS. To analyze Fractalkine 
mRNA expression, cell lines were stimulated with TNFa (10 ng/ml), interferon-y (1000 
U/ml) and RNA extracted after 24 hours. For adhesion assays, cell monolayers were 
stimulated with TNFa (10 ng/ml), interferon-y (1000 U/ml) overnight and medium 
replaced before starting with the assay. Finally, to collect supernatants for CX3CL1 
measurement, cells were seeded at 106 cells/ml in six-well plates in DMEM 10% FBS 
and cultured for 18 hours before replacing medium and stimulating them with 
TNFa/IFNy. After overnight incubation, medium was replaced with serum-free medium 
and conditioned supernatants collected after 24 hours.
Primary tumors
Table 3.1 reports the origin of the surgical specimens analyzed and the clinico- 
pathological features o f the corresponding patients. Primary tumors from surgical 
specimens were cut into little pieces with a scalpel and enzymatically digested with 
trypsin (0.125%) for 2 hours at 37°C, as previously described (25); additional 
purification on a density gradient (Ficoll) and by adherence on tissue plastic were
73
performed. Cells were plated on Primaria plates (Falcon, NJ) at a density o f lx l0 6 
cell/ml and maintained in DMEM supplemented with 10% FBS. Tumor cells grew as 
adherent cells with epithelial morphology and were >95% positive for expression of 
cytokeratine 7, as assessed by intracellular staining with a FITC-labeled mouse anti­
human anti-cytokeratin 7 monoclonal antibody (clone CK3-6H5, Miltenyi Biotec, 
USA). After 24-48 h, cells were prepared for RNA extraction, performed with Trizol 
(Life Technologies, Inc.), following the manufacturer’s instructions.
Patient
N° Age Sex
Tumor
site
TNM
Stage
Vessel
invasion
Perineural
invasion
Lymph
node
invasion
Size
(cm) Hystology
PK 93 70 M Head II Yes Yes No 3.2 Adenocarcinoma
PK 96 76 F Head I Yes Yes No 3.6 Adenocarcinoma
PK 97 56 M Tail IH Yes Yes No 4.3 Adenocarcinoma
PK126 63 M Head I No No Yes 2.9 Adenocarcinoma
PK 132 55 F Head II No Yes No 3.5 Adenocarcinoma
PK 136 59 F Head II No No No 2.7 Adenocarcinoma
PK 135 65 M Tail III Yes Yes Yes 4.1 Adenocarcinoma
Table 3.1. Origin of surgical specimens processed to obtain primary tumors.
Clinico-pathological features of patients are listed.
PBMC
PBMC were used as internal control for RNA analysis.
To this aim, they were purified by Ficoll-Hypaque density centrifugation. Briefly, buffy 
coats from healthy donors from the Blood Transfusion Service (Desio Hospital) was 
diluted 1:1 with sterile saline and centrifuged for 10 minutes at 1000 rpm. After 
centrifugation, supernatant containing platelets was thrown away and 0.9% Sodium 
Chloride added till 35 ml. Then, 15 ml of Ficoll-Hypaque (GIBCO, Scotland UK) were 
laid underneath cell suspension using a syringe with a long needle and centrifuged for 
20 minutes at 1750 rpm. The mononuclear cell layer was removed using a sterile 
pasteur, and washed thoroughly by resuspension in sterile saline. PBMC were then used 
for RNA extraction.
74
HUVEC
Human endothelial cells were obtained from umbilical vein (HUVEC) and 
cultured as described previously (262, 263). Briefly, cells were collected from umbilical 
cords, rinsed inside with physiological saline solution. A solution of collagenase 1A 
(SIGMA) was injected into the cord. After a 20 minute incubation at 37°C, the cord was 
rinsed with medium containing 20% FCS and the collected solution centrifuged. Cells 
were routinely used confluent at 2nd-6th passage. Cells were maintained in E l99 medium 
with 2 0 % bovine serum, supplemented with endothelial cell growth supplement (100  
pg/ml; Collaborative Research Inc, Lexington, MA) and heparin (100. jig/ml; Sigma 
Chemical Co, St Louis, MO). The purity of EC cultures was checked by expression of 
von Willebrand factor and found to be greater than 99% positive. HUVEC were used 
both in transmigration and adhesion assays and stimulated with TNFa/IFNy for mRNA 
analysis by Northern Blot.
3.2 Reagents
Where indicated, cell lines were treated with IL -lp (10 ng/ml), TN Fa (10 
ng/ml), interferon-y (500 U/ml), all purchased by Peprotech, for 8 hours. Hypoxia was 
generated by culturing cells for 4 hours in an atmosphere-controlled culture chamber 
(Bellco Glass) containing a gas mixture composed of 94% N2, 5% CO2 and 1% O2. 
Cells were cultured in 6 -well plates in DMEM 10% FBS. Desferrioxamine (0.4 
mmol/L, SIGMA) was used in the same experiment as chemical compound to mimic 
hypoxia.
AMD3100 (Sigma, Fig 3.1) is a byciclam compound (1,4,8,11- 
tetraazacyclotetradecane octahydrochloride)(264); it is currently used as a CXCR4 
chemokine receptor antagonist in HIV patients and for stem cell mobilization from the
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bone marrow in transplanted patients. AMD3100 is extremely specific in its affinity for 
the CXCR4 receptor: this depends at least in part on an electrostatic interaction between 
the basic (positively charged) nitrogens o f the cyclam moieties and the acid (negatively 
charged) carboxylates of the aspartic acid residues located at positions 171, 182, 193 
and 262 of the CXCR4 receptor. AMD3100 does not interact with a variety of 
chemokine receptors other than CXCR4 (265).
^  Structure of the byciclam AMD3100.
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3.3 Methods for analysing mRNA expression
Total RNA extraction from fresh or cultured cells was performed with Trizol 
(Gibco), following manufacturer’s instructions. Three different methods were used to 
evaluate mRNA expression, depending on the sensitivity required by the analysis. 
Fractalkine expression in endothelial cells and neuronal cell lines was analyzed by 
Northern Blot. Chemokine receptors on pancreatic cancer cell lines were previously 
analyzed by RT-PCR with specific primers, followed by semi-quantitative Real-Time 
PCR, used to compare cell lines and get eventual difference between their expression 
levels. Specifically:
Northern Blot
cDNA for CX3CL1 was prepared as previously described (266), and 
subsequently used for probe labelling. 10 pg of total RNA were subjected to
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electrophoresis through a 1 % agarose-formaldehyde gel (1 % agarose [Gibco], 6 % 
formaldehyde, 20 mM MOPS, 0.5 pg/ml ethidium bromide) then blotted by capillary 
transfer onto nylon membrane (Hybond N+, Amersham, UK). After transfer, the 
membrane was heated for 2 hours to 80°C to allow crosslinking. The membrane was 
placed in a suitable hybridisation tube and pre-hybridised for 1-2 hours at 42 °C with 20 
ml of hybridisation buffer (0.2 M sodium phosphate buffer pH 7.2, 100 pg/ml salmon 
sperm, 7 % SDS 45 % formamide). cDNA probes were labelled by random priming 
using the Megaprime DNA labelingsystem (Amersham, Buckinghamshire, UK) 
according to the manufacturer’s instructions. Prior to use, the radiolabelled probe was 
heated to 100 °C for 5 minutes, then quenched on ice for up to 30 min. Probe was then 
added to 20  ml of hybridisation buffer (approximately 1 x 106 cpm/ml o f buffer), which 
was poured on to the membrane in place of the pre-hybridisation buffer. Hybridisation 
was performed overnight at 42 °C. Following hybridisation, membranes were washed 
twice with 2 x SSC, 0.1 % SDS for 5 min at room temperature, twice with 0.1 x SSC,
0.1 % SDS for 15 min at 68 °C and finally once with 2 x SSC for 10 min at room 
temperature. The membrane was then wrapped in Saran wrap and exposed overnight to 
Kodak Biomax MS film with an intensifying screen, at -70  °C.
RT-PCR
cDNA was synthesized by random priming from lp g  of total RNA with GeneAmp
RNA PCR kit (Applied Biosystems), according to the manufacturer’s instructions. The
following primers were used for the subsequent PCR: human CXCR4 (sense: 5 ’ AGC
TGT TGG CTG AAA AGG TGG TCT ATG 3 ’; antisense: 5’ GCG CTT CTG GTG
GCC CTT GGA GTG TG 3’); human P-actin (sense: 5’ AAG ATG ACC CAG ATC
ATG TTT GAG 3’; antisense: 5’ GGA GCA ATG ATC TTG ATC TTC 3’). PCR was
performed with AmpliTaq DNA Polymerase (Applied Biosystems) following the
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manufacturer’s instructions. Cycling conditions: 26 cycles (20 cycles for p-actin) o f 1 
min at 94°C, 1 min at 56°C, 1 min at 72°C. PCR products were resolved by 
electrophoresis on 2 % agarose gels and visualized by ethidium bromide staining.
Real-Time PCR
Real-Time PCR was performed using SYBR Green dye and Gene Amp® 5700 
Sequence Detection System (PE Biosystems, Foster City CA). The sequences o f primer 
pairs specific for each gene (Invitrogen) were designed with Primer Express® Software 
(Applied Biosystems). 2pi of cDNA (obtained from the amplification of 1 pg RNA in a 
total volume of 50 pl)was used as the template; 12.5pl of 2X SYBR Green PCR Master 
Mix (Applied Biosystem) was mixed with template and primers. The total reaction 
volume was 25pl. Cycling conditions were 10 min at 95° C, 40 cycles of 15 s at 95° C 
and 1 min at 60°. Experiments were performed in triplicate for each sample. mRNA was 
normalized to p-actin mRNA by subtracting the cycle threshold (Ct) value o f P-actin 
mRNA from the Ct value of the gene (ACt). Fold difference (2A-AACt) was calculated 
by comparing the ACt with either the ACt of the cell line HPDE6 or with that of 
unstimulated cells.
The sequences o f primer pairs were as follows: human CCR2 (sense: 5 ’ CAT 
CGG TTA TTT TGG CGG AA 3’; antisense: 5’ GGT GAC CGT CCT GGC TTT TAA 
3’); human CCR6 (sense: 5’ TGC CAC GTG CAA GTT GCT TAA 3’; antisense: 5’ 
AGC AGC ATC CCG CAG TTA AAG 3’); human CCR7 (sense: 5’ TGC ATC AGC 
ATT GAC CGC TA 3’; antisense: 5’ TAT CCA GAT GCC CAC ACA GGA 3’); 
human CXCR2 (sense: 5’ CAG TCC TTT GGC TTC ATC GTG 3’; antisense: 5’ GGT 
GAA TCC GTA GCA GAA CAGC 3’); human CXCR4 (sense: 5’ CAA GGC CCT 
CAA GAC CAC AAT 3’; antisense: 5’ CCC AAT GTA GTA AGG CAG CCA A 3’);
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hum an CX3C R I (sense: 5’ TGA TTT GGC TGA GGC CTG TTA T 3’; antisense: 5’ 
GGA CAG GAA CAC AGT CCC AAA G 3’); hum an p-actin (sense: 5’ TCA CCC 
ACA CTG TGC CCA TCT ACG A 3 ’; antisense: CAG CGG AAC CGC TCA TTG 
CCA ATG G 3’).
3.4 Flow Cytometry
Pancreatic cancer cells were removed from flasks non-enzymatically, after three 
washes and a 10 minute incubation at 37°C with physiological saline. Nearly 300000 
cells were then resuspended in ice cold washing buffer (phosphate-buffered saline 
(PBS) containing 1% human serum) and incubated with 10 pg/ml fluorescin-labelled 
mouse anti-human CXCR4 antibody (12G5; R&D Systems, Minneapolis, MN) or 3 
pg/ml PE-labeled mouse anti-human CX3CRI antibody (MBL, Watertown, MA) or 
antibody anti CX3CLI (clone 81506, R&D, Minneapolis, MN, USA) for 30 minutes at 
4°C. Cells were analysed with a FACScalibur flow cytometer.
3.5 ELISA assay
CCL2 was measured with antibodies developed in our laboratory; sensitivity o f 
the test was 4 pg/ml. Commercial kit by R&D were used for all the other cytokines; the 
sensitivity of the assays was as follows: CCL5: 2 pg/ml, CCL22: 1 pg/ml, CXCL8 : 4 
pg/ml, CXCL12: 4 pg/ml, VEGF: 4 pg/ml, HGF: 16 pg/ml, TGFb: 4 pg/ml, IL lb: 2 
pg/ml, IL6 : 1 pg/ml, IL10: 4 pg/ml, TNFa: 2 pg/ml. Cells were plated at the same 
density and medium replaced when 80% confluence was reached; supernatants were 
collected after 24 hours. At least three different experiments were performed and the 
median of the values calculated.
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To measure CX3CL1 in supernatants, neuroblastoma cells were seeded at 106 
cells/ml in six-well Costar plates (Coming, Inc.) and cultured for 18 hours before 
replacing medium and stimulating them with TNFa/IFNy in DMEM without FBS. After 
overnight incubation, medium was replaced with serum-free medium and conditioned 
supernatants collected after 24 hours. The amount o f CX3CL1 released in the 
supernatant after 24 hours was quantified by ELISA with commercial kit (R&D, 
Minneapolis, MN, USA). At least three experiments were performed and the media ± 
SE calculated; p value was calculated with Student t Test analysis.
3.6 Immunohistochemical analysis
Paraffin sections of three pancreatic cancer patients (PKwere deparaffinised in xylene (2 
x 10 min) and taken down through graded alcohols (100%, 90%, 70%, 5 min each). 
Endogenous peroxidase was blocked by adding 100 pi o f 3% H2O2 (in H2O) to each 
section for 30 minutes, in the dark.
Sections were then microwaved in boiling 0.01M sodium citrate pH 6.0 for 10 min to 
retrieve antigen, and rinsed in 400 ml PBS. The slides were laid out in a humidified box 
and excess PBS was blotted from around each section using a tissue.
To each section, 100-200 pi primary antibody at appropriate dilution was added to 
cover the section, specifically, the rabbit polyclonal anti human CX3CR1 antibody was 
diluted 1:350 in PBS, while the goat anti-human anti CX3CL1 Ig 1:50 in PBS. The 
slides were incubated for 1 hour in a humidified box at room temperature.
Sections were washed twice in PBS for 3 min, prior to incubate them with 100-200 pi of 
secondary antibody (EnVision HRP rabbit/mouse, DakoCytomation).
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After washing, the peroxidase substrate 3,5-diaminobenzidine (DAB; Liquid DAB + 
Substrate Chromogen System, DakoCytomation) was prepared, by diluting one drop in 
500 pi o f buffer and incubated for 5 minutes with the slides.
Sections were washed in distilled water and counterstained for 2 seconds in 
Hematoxilin (Mayer, DIAPATH) diluted 1:5 in H20.
The slides were dipped in distilled water and dehydrated through graded alcohols (70%, 
90%, 100%, 2 min each).
3.7 Methods for analysing cell migration
Chemotaxis
Many different assays are available to measure and quantify the process o f in 
vitro cell migration; they basically depend on the principle that chemokine signals 
transmitted through their GPCR cognate receptors provide directional cues and 
stimulate an enhanced rate of cell locomotion. These in vitro assays have been designed 
to reflect the guiding principle and the driving force of leukocyte migration from the 
blood to the tissues and in the extravascular tissues. Mechanistically, this entails the 
ability of chemokines to activate leukocyte integrins and to convert the initial loose, 
rolling interaction of leukocytes with the endothelial cells into firm adhesion and 
spreading.
The method o f chemotaxis is based upon active migration o f test cells through a filter 
with pores of a precise size. The filter is placed in a chamber to create two 
compartments, as originally introduced by Boyden (267). Cells are added to the upper 
compartment, whereas the lower compartment is filled with the chemotactic substance 
(Fig 3.2).
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Fig 3.2 Chemotaxis assay with a modified Boyden chamber.
As a consequence, a chemotactic gradient is created and cells penetrate through the 
pores of the filter to the lower compartment. The number of migrated cells indicates the 
potency of the chemotactic substance. A commercially available commonly used device 
is the 48-well chemotaxis chamber (the so called modified Boyden Chamber, 
Neuroprobe), which allows to test different cells and cheinoattractant in the same assay. 
The microchamber consists of a top and bottom acrylic plate, sealed by a silicon gasket. 
The upper wells, containing cells are separated from the lower wells (containing 
chemoattractant) by a micropore membrane. The filter separating the two chamber 
compartments can vary; depending on the cell type, different filter materials and pore 
sizes should be used. Cellulose ester filters allow to measure the migration distance into 
the filter, whereas polycarbonate membranes are used to determine the number of cells 
migrated through the pores. Usually, PVP (polyvinyl pyrrolidone)-pretreated 
membranes are used, while for cells displaying reduced adhesion, PVP-free membranes 
can be used whose lower surface has been coated with matrix proteins (collagen, 
fibronectin, gelatin). Different size pores are available, ranging from 3 to 13 jam. At the 
end of the assay, whose time can vary depending on cells (lh  to overnight), filters are 
fixed and stained. Usually the final result is calculated from the average counts of at
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least three wells. The chemotactic activity can be expressed either as chemotactic index 
(percentage of the maximal number of cells migrated to the control cheinoattractant 
(e.g. assay medium)) or as net migrated cells (the number o f cells migrated to the 
control medium is subtracted from the number of cells migrated to the 
chemoacctractant). As expected, all the assays used to measure chemotaxis have been 
set up for different leukocyte populations, therefore established protocols are available. 
As cancer cell chemotaxis is a relatively recent acquisition, we have adapted a classical 
protocol to our purposes (Protocol 1). Basically, larger pores and longer migration time 
have been required for cancer cells to get an appreciable migration.
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Protocol 1: Chemotaxis
1. resupend cells in appropriate medium (DMEM, 1% FCS) and dilute to 
700000 cells/ml;
2 . prepare serial dilutions of cheinoattractant in the same medium;
3. add 28-30pl of the cheinoattractant to the lower compartment o f the
microchamber;
4. put the filter (13pm pore for Hs766T, 8pm pore for the other cell lines) on 
the bottom plate and reassemble the microchamber;
5. add 50 pi of the cell suspension to each well (corresponding to 20000-40000 
cells);
6 . incubate chamber at 37°C in a 5% CO2 incubator for the time required 
(Overnight for Hs766T, 8h for the other cell lines)
7. dismount the microchamber unit, wet the non-migrated cell side of the
membrane with PBS and wipe the cells off this filter side;
8 . fix the cells which adhere to the lower surface of the membrane with 70% 
methanol, dry and stain with Diff-Quick;
9. place the membrane on a microscope slide to dry and count cells at 400X 
magnification, in 10 oil immersion fields for each well.
For each cell line, I standardized migration conditions and applied minor modifications. 
In particular, filters were always coated with fibronectin (5 pg/ml, Sigma); pore size 
ranged from 13pm to 8 pm ,depending on the cell line properties. Chemokines used as 
chemoattractants in the lower compartment were purchased from Peprotech, (Rocky 
Hill, NJ). Net migrated cells over control cells were counted in ten microscope high 
power fields (magnification:xl000). At least eight spots were counted for each
84
experimental group; values are the mean ± SE of three different experiments and p 
value calculated by Student T Test. Where indicated, cells were incubated with a 
blocking anti-CXCR4 mAb (12G5, R&D; lOpg/ml), or with AMD3100 (Sigma, 
1 pg/ml) or anti-CX3CRl/CX3CLl mAb (polyclonal, Torrey Pines, Houston, TX and 
clone 81506, R&D, respectively).
Transmigration assay
Human endothelial cells were grown to confluence on polyvinylpyrrolidone (PVP)-free 
polycarbonate filters (12 pm pore) and mounted on Boyden chambers over a second 
filter (Fig. 3.3).
9
Boyden chamber
Filters
Cheinoattractant
Fig 3.3 Transmigration assay with a Boyden chamber. Endothelial cells are grown on the 
filter.
'^Cr-labeled tumour cells were seeded in the upper compartment and coincubated with 
endothelial cells monolayers for 16 hours at 37°C. Nonadherent cells were gently 
washed away and adherent cells were removed with a cotton swab. The radioactivity in 
the double filter and in the lower compartment referred to transmigrated cells. The 
adherent cells were considered to comprise both cells bound to endothelial cells as well 
as those that had transmigrated. Values are the mean ± SE of three different experiments 
and p value calculated by Student T Test.
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Invasion Assay
Cell invasion protocol was a kind gift of Dr. Maura Poli (Mario Negri Institute 
Bergamo, Italy); briefly, it was examined using a 48 well modified Boyden chamber 
and a reconstituted extracellular matrix membrane (Matrigel, Becton Dickinson) (Fig.
filter
Cheinoattractant
Fig 3.4 Invasion assay with a modified Boyden chamber. A Matrigel layer is deposed on top 
of the filter.
Cell invasion chambers were prepared by carefully placing onto a polycarbonate 
PVP-free filter 10 pi of Matrigel (0.5 pg/ml) and incubating at 37°C for 30 minutes to 
allow Matrigel polymerization; then 45 pi of cell suspension was added to each well 
and incubated at 37°C overnight. Migrated cells were evaluated as for the chemotaxis 
experiment.
The activity of selected metalloproteases in pancreatic cancer cell and monocyte 
supernatants was assessed by using a MMP Gelatinase Activity Assay Kit (Chemicon, 
International, Inc.), according to manufacturer’s instructions. Fig 3.5 illustrates the test 
principle. Briefly, the kit utilizes a biotinylated gelatin substrate, which is cleaved by 
active MMP-2 and MMP-9 (gelatinase) enzymes. Remaining biotinylated fragments are
3.4).
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3.8 Gelatinase activity assay
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then added to a biotin-binding 96-well plate and detected with streptavidin-enzyme 
complex. Addition of enzyme substrate results in a colored product, detectable by its 
OD (450 nm). The activity detected in the supernatants can be easily quantified by 
comparison with a MMP-2 positive control, (APMA-activated human MMP2 enzyme). 
This kit provides a quick and sensitive system for evaluating the gelatinase activity in 
cell supernatants and other biological fluids. Moreover, unlike traditional zymography, 
this assay measures MMP activity in solution, which is often different than the apparent 
activity observed on zymographs, where the MMP enzymes are physically separated 
from their natural inhibitors. Pancreatic cancer cell lines were cultured and stimulated 
with CXCL12 100 ng/ml for 24 hours and supernatants collected for the MMP assay. 
Values are the mean ± SE of three different experiments performed. P value was 
calculated by Student T Test.
MMP
MMP
- E
-  B
-  B
G elatinase
C leavage
Activity
Shortens
Biotinylated
Gelatin
M olecules
Enzyme- Streptavidin
-  B
Detection o f  
Rem aining 
Biotin
■ni i m  ■ ■ ■ ■
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Fig 3.5. MMP activity assay. Gelatinase activity in supernatants is measured by assessing their 
capability to cleave a biotin-labeled gelatine substrate.
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3.9 Adhesion assay
Adhesion of tumour cells to neuroblastoma cell monolayers was studied as described 
previously, with minor modifications (263, 268). Neuroblastoma cells were grown to 
confluence in flat-bottomed 6 -well plates. 51Cr-labeled tumour cells (Amersham, UK) 
were coincubated with neuroblastoma monolayers at 37°C for 1 hour in DMEM 1% 
FBS, under slow agitation, to prevent aspecific attachment. At the end, nonadherent 
cells were washed away and adherent cells were solubilized with 1 mL o f 0.1% sodium 
dodecyl sulfate and radioactivity was counted in a gamma counter. Results represent the 
percent of adherent cells ± SE of three replicates/group. P value was calculated by 
Student T test.
3.10 Methods for analysing cell proliferation and 
apoptosis
CFSE dilution assay
Proliferation was measured in vitro using the vital dye 5-(and-6)- 
carboxyfluorescein diacetate succinimidyl ester, mixed isomer (5-(6)-CFDA, SE 
[CFSE], Molecular Probes, Inc., Eugene, OR); this method is currently used to 
investigate lymphocyte proliferation and based on the dilution of the dye incorporated, 
upon serial cell division (269, 270). Briefly, cells were labelled with CFSE (0.5 juM) 
before seeding in 12-wells plates. Stimuli were given after 12 hours o f resting in 
medium without serum. After 3 days, cell division was indicated by decreased CFSE 
fluorescence intensity, as assessed by flow cytometry. At least three different 
experiments were performed and one representative reported.
8 8
Cell Cycle Analysis
For cell cycle analysis, cells were seeded in 12 well plates and let adhere for 12 
hours, after which medium was replaced with DMEM 1% FBS. After 72 hours, they 
were collected, washed once with PBS and fixed with 70% ethanol at -20°C for 24 
hours. Fixed cells were washed three times with PBS and incubated for 1 hour with a 
Propidium Iodide (PI) solution (Sigma Chemical Co.; 20pg/ml) containing RNAase A 
(Sigma Chemical Co.; 0.1 pg/ml). Cells were then subjected to cell cycle analysis for 
determining DNA contents by flow cytometry. Cell debris were excluded on the basis 
o f forward versus side scatter. Doublets and clumps were excluded by gating on a 
bivariate distribution of AUX (PI peak pulse) versus the PI integrated signal. Data from 
10,000 events were collected in the final gated histograms. The cell histogram was 
divided into 3 regions according to cell cycle phase: G0/G1, G2/M and sub-Gl peak (PI 
fluorescence from fractional DNA content of apoptotic cells), which defined the 
proportion of apoptotic cells. At least three different experiments were reported and one 
representative was reported.
Apoptosis Assay
Staining with Annexin V is the method to evaluate earlier apoptotic events, such 
as loss of plasma membrane asymmetry.
The percentage of cells undergoing apoptosis was determined using fluorescein- 
conjugated human annexin-V (Pharmingen, BD Biosciences). Cells were plated in 12- 
well plates and cultured for 18 hours. Then they were incubated for 24 hours under 
apoptosis-inducing conditions (serum deprivation) with or without CXCL12 (100 
ng/ml). Cells were collected and stained at room temperature in the dark for 15 minutes 
in 200 pi buffer containing FITC-annexin-V (5 pi); after incubation they were subjected
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to FACS analysis. Annexin-V+ cells correspond to apoptotic cells. Values are the mean 
± SE of three different experiments performed.
3.11 Stable infection with a CX3CR1-GFP viral 
vector
A viral vector carrying the sequence coding for human CX3CRI fused to the 
sequence for the reporter gene GFP was prepared. A former plasmid vector was 
generated and tested and subsequently inserted into the viral vector.
Plasmid encoding the CX3CR1-GFP fusion protein preparation
Human CX3CRI cDNA (encoding the Ile249-Met280 variant) subcloned in the 
mammalian expression vector pCDNA3 was a kind gift of Philippe Deterre (Pasteur 
Institute, Paris, France). To generate the fusion protein CX3CRI-GFP, the pEGFP-Nl 
vector and CX3CRI cDNA were prepared by digestion with restriction enzymes to 
generate complementary ends. Briefly, a forward primer was appositely designed to be 
specific to the 5’ end of CX3CRI cDNA and Hindlll tailed; by the same way, a reverse 
primer specific for the 3’ end was designed and BamHl tailed. The vector was 
amplified by PCR with the primers, digested with Hindlll/BamHl and subcloned in the 
mammalian vector pEGFP-Nl (BD Biosciences, Clontech, Milan, Italy) therefore 
codifying for a chimeric protein CX3CRI-GFP.
After ligation of the foreign DNA and pEGFP-Nl with the enzyme DNA ligase, 
the resulting vector was introduced into bacterial cells (DH5a) by transformation and 
cells containing foreign DNA selected by screening for kanamycin.
A receptor-negative pancreatic tumor cell line, MiaPaCa2, known to grow in 
nude mice, was then transiently transfected with the construct and checked for transgene
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expression by FACS analysis; both GFP and CX3CRI expression were analysed, the 
latter by PE-labeled anti human CX3CRI antibody.
Viral vector construction
The generated CX3CRI-PEGF-NI vector was expanded by transformation o f bacterial 
cells and purified with Marligen Columns (Marlingen, Heidelberg, Germany), yielding 
endotoxin free DNA. Final concentration was approximately 1 jug/pl. The viral vector 
(pRRLsinPPT.CMV.GFPpre) was then kindly prepared by Maria Luisa Malosio in 
collaboration with Naldini’s group (San Raffaele Hospital, Milan). Briefly, 293T cells, 
selected as good recipients of DNA, are cotransfected with four plasmids (each carrying 
a sequence for a viral particle component: two 3rd generation core packaging plasmid, a 
Self Inactivating transfer vector plasmid, an Envelope plasmid and the plasmid 
CX3CRI-PEGF-NI). This passage allows the rescue of the recombinant HIV genome 
with the gene of interest, CX3CR1-GFP and packaging into viral particles. The 
calcium-phosphate precipitation method is used to transfect cells. After 16 hours, 
medium is replaced with a fresh one to begin virus collection; after 48 hours, 
supernatant, containing viral particles, is collected and concentrated by 
ultracentrifugation; the final pellet is resuspended in a very small volume (1/500 of the 
starting volume of medium), splitted into small aliquots and stored at -80°C. The 
subsequent passage is titration of the lentiviral vector: Hela cells are plated and ten-fold 
dilutions o f the viral stock are added. After 72 hours, cells are harvested and analyzed 
by flow cytometry to calculate the titer. The infectivity of the vector preparation is 
calculated by the ratio of transduction units (TU)/ml and should be >104. TU/ml value is 
calculated by (N° of cells analyzed) x (% of cells GFP+) x (10N), N=(-) viral dilution factor (see 
(271-274) for reference). After titration, the appropriate amount of vector (3x106 TU in 
2 ml medium) was used to infect MiaPaCa2 cells. Due to the high efficiency of
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infection procedure, no selection was required and CX3CRI-GFP MiaPaCa2 almost 
9 9% pure were obtained and used for experiments.
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Aim of the Study
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In the last two decades there has been increasing evidence for a role of 
chemokines in tumour biology. Tumours constitutively produce chemokines, which 
have been found to exert a variety of biological activities, including leukocyte 
recruitment, promotion or inhibition of angiogenesis, activation o f matrix 
metalloproteases, growth promoting activity and inhibition o f apoptosis. While the 
significance of chemokine expression in human and experimental tumours has been the 
object of intense research activity, the expression of chemokine receptors on tumour 
cells has been investigated to a lesser extent. The hypothesis that tumour cells may use 
chemokines to determine metastatic destinations has recently begun to be investigated. 
If  this hypothesis is correct, a corollary is that the expression of chemokine receptors in 
tumour cells could not be random, but selective chemokine receptors might be 
expressed, which recognize ligand chemokines present in high amounts at the site of 
metastasis
Human pancreatic adenocarcinoma is a highly aggressive, early metastatic 
disease; at the time of diagnosis, more than 80% of the patients show tumours locally 
extended beyond the pancreas and metastases in regional lymph nodes. Peculiar of this 
tumour is its dissemination to peripheral nerves. Surprisingly, in spite o f the clinical 
importance of this process, the molecular events driving the tumour cell spreading are 
only in part understood.
The principal aim of this thesis was to investigate the role of chemokines and 
their receptors in pancreatic cancer and to understand if receptors and their ligand 
chemokines are involved in tumor dissemination.
Specifically, I have extensively analyzed the expression of a number of 
chemokine receptors on tumor cell lines o f pancreatic adenocarcinoma and on freshly
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isolated tumour cells obtained from surgical specimens. Later on, I have concentrated 
my efforts on the significance and biological role of receptors/ligands in this tumor. The 
process of metastasis involves the escape of tumor cells from the primary mass via 
lymphatic and blood vessels, transport to and arrest in a target organ and growth of 
metastasis in the target organ; all o f these steps are strictly regulated by chemokines. 
Therefore, I have tried to investigate whether chemokines and their receptors could 
affect each of these processes. I have performed in vitro studies of adhesion o f tumor 
cells to endothelial cell monolayers, transendothelial migration assays and invasion 
assays through Matrigel-coated filters. Finally, I have investigated whether selected 
chemokines can increase resistance to apoptosis in injured tumor cells or regulate their 
cell cycle progression.
After a preliminary biological characterization of eleven pancreatic adenocarcinoma cell 
lines, focused on molecular properties and capability of releasing cytokines and 
chemokines, I screened a panel of chemokine receptors on these tumor cell lines and 
also on freshly isolated tumor cells from pancreatic adenocarcinoma surgical specimens.
CXCR4 emerged as the most expressed receptor in human pancreatic 
adenocarcinoma, I have focused on the role of this chemokine receptor in pancreatic 
tumor cells. mRNA expression, regulation and functional activity have been analyzed 
with available in vitro assays.
The initial screening has revealed that some pancreatic cancer cell lines and freshly 
isolated tumor cells express also the chemokine receptor CX3CR1. Given the 
peculiarity to disseminate along nerve fibers, I have tested the hypothesis that the 
chemokine Fractalkine/Neurotactin, highly expressed in neuronal tissues, and its
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receptor CX3CR1 expressed by tumor cells, are involved in the peculiar tropism of 
pancreatic adenocarcinoma cells for neural tissues. After mRNA analysis on cell lines 
and primary tissues, the functional role o f the receptor has been investigated. Moreover, 
the CX3CR1 receptor has been successfully infected into a CX3CR1-negative cell line 
and functional assays are being performed with CX3CR1- and parental cell line. 
Specifically, I’m going to use CX3CR1-transfected turnout cells in in vivo experiments 
aimed at investigating the role of CX3CR1 in the growth and metastatic potential of 
pancreatic cancer.
The obtained results reveal for a role of chemokines and their receptors in pancreatic 
cancer cells migration and growth; these finding contributes to a better understanding of 
the biology of this carcinoma and raises the possibility that the system of 
chemokines/receptors may be a valuable therapeutic target.
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Chapter 4
Preliminary characterization of 
pancreatic adenocarcinoma cell lines 
and isolation of pancreatic tumour 
cells from surgical specimens
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4.1 Collection and characterization of pancreatic 
cancer cell lines
During my project, I have based the study of cell biology of ductal 
adenocarcinoma of the pancreas on in vitro investigations, employing various stable 
pancreatic ductal carcinoma cell lines (PDCL), commonly available through cell culture 
collections. The use of cell lines is necessary to obtain information on a homogeneous 
population of pancreatic tumour cells that are common to researchers worldwide. 
However, the various cell lines can reveal a great deal of diversity, so that generalized 
interpretation of results needs to be viewed cautiously. Therefore, the characterization 
of PDCL used in in vitro experiments has been a necessary preliminary step of the 
project.
The molecular and biological analysis of 11 established cell lines is shown in 
Table 4.1. Most cell lines (9/11) were grade G2/G3 and only 3 G l.
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Cell Line Source Grade In vitro 
grade
Tumorigenic 
(nude mouse)
Transplanted 
tumor grade
Panc-1 Primary
tumor
G3 G3 Yes G3
MiaPaCa2 G3 G3 Yes G3
Paca44 G2 Nt Yes G2/3
PT45 G3 G3 Yes G3
Capan-1 Metastasis G1 G1 Yes G1
CFPAC G1 Nt Yes ?
Hs 766T G2 Nt Yes 9
T3M4 G2 G3 Yes G2/G3 j
AsPC-1 Ascites G2 G2 Yes G1/G2/G3
HPAF G1 G2 Yes G1
A8184 G2 G2 Yes G2
Table 4.1. Biological analysis of 11 human pancreatic adenocarcinoma cell lines. For each 
cell line, source, grade, in vivo tumorigenicity and grade of trasnplanted tumour are 
reported.(Adapted from (26))
All the cell lines expressed many of the typical genetic lesions which represent 
the molecular profile of pancreatic adenocarcinoma (7, 8 ), including mutation in KRAS, 
p53, p 16 SMAD4/DPC4 (Table 4.2).
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Cell Line K -ra s p53 p l 6 DPC4/smad
Panc-1 + + + -
M iaPaCa2 + + + -
Paca44 + + + -
PT45 + + + —
Capan-1 + + + +  j
CFPAC + + + +
Hs 766T 9
• + 9• +
T3M4 4- + 4-
AsPC-1 + + + +
HPAF + + + -
A8184 + + + -
Table 4.2. Molecular profile of pancreatic adenocarcinoma cell lines. All the cell 
lines express many of the typical genetic lesions representing the molecular profile of pancreatic 
adenocarcinoma (275, 276).
1 next focused my attention on the release of immunoregulatory molecules, i.e. 
cytokines, angiogenic and growth factors, chemokines. In fact, self-sufficiency of 
growth-promoting factors and release of immuno-modulatory and pro-angiogenetic 
factors are hallmarks of the pathogenesis of pancreatic cancer. Tumour cell lines 
cultured for 24h under standardized conditions have been tested for the ability to secrete 
soluble factors using ELISA. I have measured the following molecules:
- chemokines: CCL5, CCL2, CXCL8 , CXCL12, CCL22;
- cytokines: IL-6 , IL-10, TNFa, IL-1 (3;
- pro-angiogenetic and growth-promoting factors: VEGF, TGFJ3, HGF
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A summary o f the results is reported in Table 4.3 and Table 4.4.
Cell Line CCL2 CCL5 CCL22 CXCL8 CXCL12
Panc-1 2290 107 0 0 28
M iaPaca2 0 847 20 20 24
Paca44 0 91 70 0 24
PT45 2290 27 0 480 19
C apanl 970 107 60 10 17
CFPAC 0 14 20 40 27
Hs766T 580 n .t . 20 0 1326
T3M 4 0 n . t . 1200 130 28
A sP C l 0 n . t . 20 0 59
HPAF 0 0 20 0 27
A8184 n . t . 42 n . t . n . t . 28
Table 4.3. Chemokine production by human pancreatic adenocarcinoma cell lines. CCL2, 
CCL5, CCL22, CXCL8, CXCL12 were measured by ELISA. Results are expressed as pg/ml for 
tumour cell monolayers (24h culture), n.t. not tested {Adapted from (26)). Data are the median 
of three different experiments.
VEGF, CCL2, CCL5 and TGFp are the more frequent factors released by 
pancreatic cancer cell lines; less frequent is the secretion of CXCL8 , CCL22, IL- 6  and 
the secretion of CXCL12, IL-10 and HGF. TNFa and ILl(3are always undetectable. 
Some of these tumor-derived factors, including VEGF, TGFp, IL-10 and IL- 6  have 
immunomodulatory effects and have been well described as relevant in pancreatic 
cancer progression, inducing angiogenesis, metastasization and stroma reaction (40). 
Moreover, chemokines may influence the extent and phenotype of the leukocyte
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infiltrate within tumour mass but also may have multiple effects on tumor growth, 
angiogenesis and metastasis.
Cell Line VEGF HGF TGFp IL -lp IL-6 IL-10 TNFct
Panc-1 140 0 40 0 0 0 0
M iaPaca2 60 0 40 0 0 0 0
Paca44 110 310 180 0 0 0 0
PT45 1070 0 90 0 530 0 0
C apanl 190 0 30 0 40 0 0
CFPAC 90 0 260 0 600 40 0
Hs766T 0 0 0 0 0 80 0
T3M 4 90 0 0 n . t . 90 0 0
A sP C l 70 0 0 0 0 0 0
HPAF 40 0 40 0 0 0 0
A8184 n .t . n . t . n . t . n . t . n . t . n . t . n . t .
Table 4.4. Secretion of soluble factors by human pancreatic adenocarcinoma cell lines.
Inflammatory cytokines (IL-1(3, IL-6), IL-10, pro-angiogenetic factor (vascular endothelial 
growth factor (VEGF)), growth promoting factor (transforming growth factor P (TGFP)), 
hepatocyte growth factor (HGF) were measured by ELISA. Results are expressed as pg/ml for 
tumour cell monolayers (24h culture), n.t. not tested . (Adapted from (26)). Data arc the median 
of three different experiments.
4.2 Primary tumour isolation
It is known that cell lines may display different cell behaviour with respect to the 
original tumor and in order to overcome this problem, the use of freshly isolated 
pancreatic cancer cells in short-term culture (primary cultures) may represent a valid
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alternative. It may be a more representative model of in vivo conditions compared to 
long standing cell lines. Therefore, I have tried to isolate pancreatic tumor cells from 
surgical specimens of resected patients. Due to the high stromal reaction characterizing 
pancreatic adenocarcinoma tumor, surgical samples are generally enriched in 
fibroblasts, leukocytes and non-tumoral cells, which make tumor cell isolation very 
hard. Moreover, leukocyte contamination may be very confusing in the type of analysis 
I was udertaking, as they express chemokines and their receptors in very high amounts. 
To this aim, I have set up a method to isolate the minority of tumor cells from the bulk 
of stromal cells. Tumour is cut in little pieces and subjected to mechanical agitation 
with trypsin (0.125%); this way neoplastic ducts detach from the rest o f the tissue in 
groups of cells which can be separated on a density gradient (Ficoll). The obtained cells 
(usually 90% tumour cells and 10% fibroblasts) are further purified by adherence on 
tissue plastic, by taking advantage of the strong adherence of fibroblasts. They can be 
either immediately lysed for RNA extraction or stained with antibodies.
CK7 is a specific marker of epithelial cells which is not present on fibroblasts (277, 
278). To assess the purity of pancreatic tumor ducts preparations, I stained cells with an 
anti-cytokeratin 7 antibody and performed a FACS analysis. Most all the cells were 
Cytokeratin-7 positive. Two representative profiles are shown in Fig 4.1.
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Specimen 1
( 9 9 %  C y 7 + )
Specimen 2 
( 9 4 %  C y 7 + )
©
Cytokeratin-7
Fig. 4.1. Cytokeratin expression in pancreatic cancer tumor cells from surgical samples.
Two surgical specimens (PK93 and PK96, see Table 3.1 for clinico-pathological features) are 
represented of at least 8 analyzed; 94-99% of cells are Cytokeratin-7-positive.
4.3 Chemokine receptor overview
Recent evidence demonstrate that tumour cells themselves express chemokine 
receptors, which possibly supports tumour cell survival and invasion. Therefore, it 
seemed interesting to investigate the expression of a number o f chemokine receptors in 
human pancreatic adenocarcinoma cell lines
RNA was extracted by tumour cell lines grown in monolayers and subjected to 
analysis by Real-Time PCR for the expression of different chemokines receptors. A first
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experiment was designed to obtain an overview of the chemokines receptors expressed 
by tumour cell lines. To this aim, we evaluated CCR2, CCR6 , CCR7, CXCR2, CXCR4 
and CX3CRI. The chemokine receptor CXCR4 was expressed in more than half of cell 
lines (6/11), in some of which it was present in high amounts. Also CX3CR1, the 
chemokine receptor binding Fractalkine was expressed in 6/11 cell lines, although in 
lower quantity. The chemokine receptor CCR7 was expressed in 4 cell lines and CCR6  
was significantly expressed only in two cell lines. CCR2 and CXCR2 were not 
significantly expressed. Table 4.4 summarizes these results.
CCR2 C C R 6 CCR7 CXCR2 CXCR4 CX3CR1
P anC l - - - - - +
M iaPaC a2 - - - - - -
PaCa44 - - - - - -
PT45 - - - - - -
C ap an l + + + + + +
C FPA C - - - - + -
Hs766T - - + - + + +
T3M 4 - - + - + -
A sP C l - + + - + +
H PA F - - - - + +
A8184 - - - - + +
Table 4.4 Chemokine receptor analysis in eleven pancreatic tumor cell lines. mRNA 
extracted by cell lines was analysed by Real-Time PCR with specific primers. Chemokine 
receptor amount, normalized to the housekeeping gene (3-actin, was expressed as a fold increase 
over the cell line with the lowest expression; fold below 10 was considered negative (-), fold 
above 10 was considered positive (+); (++) indicates fold above 1000.
After this preliminary analysis, we decided to focus our attention on CXCR4 and
CX3CRI and their role in pancreatic cancer progression.
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I will discuss these results more in detail in the following Chapters.
Chapter 5
CXCR4 in Pancreatic 
Adenocarcinoma
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5.1 Introduction and goal
This chapter will focus on the expression and function of the chemokine receptor 
CXCR4 and its chemokine ligand CXCL12 in human pancreatic adenocarcinoma. My 
preliminary experiments clearly indicated that CXCR4 was the most frequently 
expressed among the chemokine receptors tested. Therefore, the aim o f the experiments 
I am going to present was to gain some insight into the possible role of this chemokine 
receptor in tumor spreading. Metastasis is a complex multi step process in which 
migration to a distant site is only one of the passages; indeed metastatic tumor cells may 
also have a variety of properties endowing them with tissue invasion and growth ability; 
I have therefore extensively analyzed possible functions exerted by CXCL12 in 
pancreatic cancer cell lines, trying to reproduce in vitro the main steps involved in 
metastasis.
5.2 CXCR4 mRNA analysis
CXCR4 expression in pancreatic tumor cell lines
I first evaluated the expression o f CXCR4 by RT-PCR in eleven established 
PDCL. CXCR4 mRNA expression was clearly detected in six out of eleven lines, with 
different amounts of CXCR4 transcripts; in particular, Hs766T showed a very high 
expression, quite comparable to the expression in normal PBMCs, used as positive 
control (Fig 5.1).
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Fig 5.1 CXCR4 in pancreatic cancer cell lines. RT-PCR expression of CXCR4 and (3-actin 
mRNA in human pancreatic adenocarcinoma cell lines and in the immortalized epithelial cell 
line HPDE6, derived from normal human pancreatic ducts. Human PBMCs were used as 
positive control. Reaction was stopped at 26 cycles for CXCR4 and at 20 cycles for P-actin. One 
representative analysis of three performed is reported.
I tested the expression of CXCR4 mRNA also in an immortalized epithelial cell line 
derived from normal human pancreatic ducts (HPDE6 ). This cell line has been 
previously shown to maintain the phenotypic and genotypic characteristics of normal 
human pancreatic ducts (260). HPDE6  showed no detectable expression of CXCR4 
transcripts.
To better appreciate the differences between cell lines, the expression of CXCR4 
mRNA was evaluated by semi quantitative Real Time PCR; the cell line HPDE6  was 
used as a reference. This second analysis confirmed the expression of CXCR4 in the six 
positive tumor cell lines (at least 20-fold compared with HPDE6  cells). The cell lines 
Hs766T, AsPCl and Capanl showed the highest expression (1165-, 122- and 8 6 -fold, 
respectively (Fig 5.2).
1 1 0
10000
Origin Primary Tumors Ascites Metastasis
Fig 5.2 CXCR4 in pancreatic cancer cell lines. Semi quantitative Real-Time PCR was used to 
better appreciate differences between cell lines. For each cell line, the amount of CXCR4 
mRNA, normalized to P-actin, is expressed as relative to the cell line HPDE6 . One 
representative analysis of three performed is reported.
This second analysis proved to be very important and revealed that, 
interestingly, CXCR4 is expressed at higher levels in cell lines originating from 
metastatic or ascitic lesions, compared to cell lines derived from primary tumors.
Regulation of CXCR4 expression in pancreatic tumor cell lines
Cytokines are potent modulators of chemokine receptor expression and are 
frequently present in the tumor microenvironment. Also some tumor cells, as I 
discussed in Chapter 4, are able to secrete cytokines and chemokines. I was therefore
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interested in evaluating the effect o f some inflammatory or immunomodulatory 
cytokines on CXCR4 expression in pancreatic tumor cells. RNA was analyzed after cell 
stimulation with IL-10, IL-6 , HGF, IFNy, IL -lp  and TNFa . Modulation by HGF is of 
interest as it has been demonstrated that HGF increases the expression o f chemokines 
by papillary carcinoma of the thyroid (279). In two cell lines tested (AsPCl and 
H766T), IL-10, IL-6 , HGF, and the combination o f IL -lp and TNFa did not modify 
CXCR4 expression (not shown), while IFNy consistently down regulated CXCR4 
transcript (Fig 5.3).
Xfl
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M IL-l/TNFot 
■  IFNy
Hs766T AsPCl
Fig 5.3 CXCR4 modulation. Regulation of CXCR4 mRNA by inflammatory cytokines in cell 
lines was assessed by Real-Time PCR. Cells were treated for 8 hours with a combination of 
TNFa (10 ng/ml) and IL-ip (10 ng/ml) or IFNy (500U/ml). One representative analysis of two 
performed is reported.
Regulation of CXCR4 expression by Hypoxia
Recently, our group (280) demonstrated that hypoxia, a low oxygen tension
condition frequently present in tumoral necrotic areas, regulates the expression of
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CXCR4 in monocytes as well as in ovarian cancer cells. Hypoxic conditions can be 
reproduced in vitro by colturing cells in an atmosphere-controlled culture chamber 
containing a gas mixture composed of 94% N2, 5% CO2 and 1% O2. I tested the effect 
of hypoxia in pancreatic cancer cell lines and found that, in line with the previous 
results, hypoxia up regulated CXCR4 mRNA in pancreatic cancer cell lines (Fig 5.4). 
As the use of the culture chamber implies some manipulation, an internal control is 
usually recommended; we used Desferrioxamine, an iron chelator, which mimics 
hypoxia conditions. In 4 out of 6 cell lines, the effect was similar to the one observed in 
low oxygen colture, as CXCR4 was upregulated compared to control conditions. In 
Hs766T and A8184, the upregulation was much higher than in hypoxic culture, possibly 
meaning that the effect due to the culture chamber was underestimated and further 
confirming that hypoxia upregulates CXCR4.
Fig 5.4 CXCR4 modulation by hypoxia in cell lines, as assessed by Real-Time PCR. Cells 
were cultured in low-oxygen tension (Hypoxia) or treated with Desferrioxamine as a control 
(0.4 mmol/L) for 4 hours. Hypoxia consistently up regulated CXCR4 mRNA in pancreatic 
cancer cell lines. One representative analysis of two performed is reported.
□ Control 
□ Desferrioxamine 
■ Hypoxia
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Expression of CXCR4 in freshly isolated pancreatic tumor cells
Pancreatic tumour cells from surgical specimens (see Table 3.1 for clinico- 
pathological features) of resected patients were isolated and routinely checked for purity 
from stromal components (see Fig.4.1). In 7 different tumor samples, the amount of 
CXCR4 mRNA, normalized to p-actin, was evaluated by Real Time PCR, and expressed 
as relative to the cell line HPDE6 , used as reference, as for the above experiments. 
Moreover, I also analyzed the RNA derived from a preparation of freshly isolated 
normal pancreatic ducts.
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Fig 5.5 CXCR4 mRNA expression in tumor cells from surgical samples of resected 
pancreatic cancer patients. The amount of CXCR4 mRNA, normalized to P-actin, is expressed 
as relative to the cell line HPDE6 (white bar). Human epithelial pancreatic ducts were isolated 
from the pancreatic tissue of a multiorgan donor (grey bar). For some tumor samples, numbers 
on top of bars indicate the fold increase relative to expression of CXCR4 in HPDE6. One 
representative analysis of two performed is reported.
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As shown in Fig. 5.5, freshly isolated tumor cells showed much higher levels of 
CXCR4 compared to HPDE6 cells. Freshly isolated normal pancreatic ducts expressed 
substantial amounts of CXCR4, although always at lower levels compared with tumor 
samples.
CXCR4 surface expression
To confirm that mRNA transcripts correspond to receptor expression on the 
surface of tumor cells, I evaluated CXCR4 cell-surface expression by FACS analysis. 
Five cell lines that were scored positive by RT-PCR (Hs766T, AsPCl, Capanl, A8184, 
and CFPAC) had high surface expression of CXCR4. Representative FACS profiles are 
shown in Fig 5.6.
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Fig.5.6 Surface expression of CXCR4 on pancreatic cancer cell lines detected by flow 
cytometry. Cells were removed from flasks non-enzimatically and incubated with 10 mg/ml 
FITC-CXCR4 anti-human antibody (clone 12G5). One representative analysis of four 
performed is reported.
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5.3 CXCR4 functional activity
Setting up migration assays
Chemotaxis (migration towards a chemical gradient) is the eponymous function 
of chemokines. Therefore, the first functional assay I performed was the migration of 
tumour cells in response to chemokines, in chemotaxis assays.
Here, I report chemotaxis experiments performed for the cell line Hs766T. 
Different pore filters, (8 and 13 pm), were used and three times o f migration (4, 8 and 
16 hours). As shown in Fig 5.7, an appreciable migration was achieved with 13 pm pore 
filters in 16 hours, as the CXCL12-elicited migration was significantly higher than the 
basal one, while no appreciable migration was observed with 8 pm pores and a shorter 
time was not optimal. For other cell lines (e.g. MiaPaCa2, PT45, CFPAC), in contrast, 
migration in this condition was not optimal and an aspecific migration was observed 
also in response to the control medium. For these cell lines, 8 hour/8  pm pore was the 
best combination (data not shown). Finally, A8184 cell line migration was performed in 
4 hour/8  pm pore conditions, as basal migration was too high, if  longer times were used.
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Fig. 5.7. Setting up of migration assay for Hs766T cell line. Two different pore sizes (8 and 
13 pm) and two times (8 and 16 hours) were combined and the best condition selected for future 
assays.
CXCL12 stimulates pancreatic cancer cell chemotaxis
To verify that CXCR4 is functional in pancreatic cancer, selected cell lines were 
tested in chemotaxis as well as other migration assays. The cell line Capanl was 
excluded for its characteristic to disaggregate in large clusters. Fig 5.8 shows that the 
CXCR4-positive cell lines Hs766T, A sPCl, A8184 and CFPAC did migrate in response 
to CXCL12 in a classical chemotaxis assay, with an optimal response at 300 ng/ml. In 
contrast, the CXCR4-negative cell lines PT45 and MiaPaCa2 did not migrate to 
CXCL12 (Fig. 5.8). We recently reported that none o f the 11 pancreatic tumour cell 
lines express CCR2 (25). In line with this finding, different concentrations o f CCL2 did 
not induce a chemotactic response neither in Hs766T nor in AsPCl cells.
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Fig 5.8 CXCL12 stimulates pancreatic cancer cell chemotaxis. CXCR4-positive cell lines 
(Hs766T, AsPCl, CFPAC, and A8184) migrated in classical chemotaxis assays to different 
concentrations of CXCL12 in a dose-response manner, whereas CCL2 did not induce a 
chemotactic response in the cell lines Hs766T and AsPCl. The CXCR4-negative cell lines, 
PT45 and MiaPaCa2 did not migrate to CXCL12. Shown are net numbers of migrated cells 
counted in 10 high power fields over basal migration (in the absence of chemokine). Basal 
migration was 120 cells/10 HPF for Hs766T, 23 cells/10 HPF for AsPCl, 27 cells/10 HPF for 
CFPAC, 25 cells/10 HPF for A8184, 47 cells/10 HPF for MiaPaCa2 and 27 cells/lOHPF for 
PT45 (*p<0.02 versus control; **p<0.001 versus control, calculated by Student t Test). 
Migration conditions were as follows: 16 hours and 13 pm pore filters for Hs766T; 16 hours 
and 8 pm pore filters for AsPCl; 8 hours and 8 pm pore filters for CFPAC, PT45 and 
MiaPaCa2; 4 hours and 8 pm pore filtrs for A8184. Values are the mean ±SE of eight replicates. 
One representative experiment of three performed is shown.
To confirm that the migratory activity observed in chemotaxis assays was 
specifically mediated by CXCR4 engagement, I tried to inhibit it by incubating cells
with an anti-CXCR4 monoclonal antibody. Pretreatment o f Hs766T cells with the 
blocking antibody completely blocked cell migration in response to CXCL12 (Fig. 5.9). 
A similar effect was observed by pretreating cells with a CXCR4-selective inhibitor, 
AMD3100.
AMD 3100Control
CXCR4
Fig. 5.9 CXCL12 induced migration is mediated by CXCR4. Pre-treatment of Hs766T cells 
with a blocking anti-CXCR4 mAb (10 fig/ml) or with AMD3100 (1 pg/ml) significantly 
reduced cell migration in response to 300 ng/ml of CXCL12 (**p<0.01 versus control, Student t 
Test). Values are the mean ± SE of eight replicates. One representative analysis of two 
performed is reported.
CXCL12 stimulates pancreatic cancer cell adhesion and 
transmigration
Tumor cell adhesion to endothelial cells and transendothelial migration are key steps in 
the process o f tumor invasion and metastasis. CXCL12 significantly enhanced adhesion 
to human umbilical vascular endothelial cells and transendothelial migration o f the 
CXCR4-positive cell line Hs766T (Fig 5.10).
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Fig 5.10 CXCL12 stimulates adhesion and transmigration through endothelial cells in the 
CXCR4-positive cell line Hs766T. HUVEC were grown on polycarbonate filters. 51Cr- 
labeled tumour cells were seeded in the upper compartment and trans-endothelial migration 
assessed after 16 hour incubation in the presence of CXCL12 (300 ng/ml) in the lower 
compartment. Nonhaderent cells were washed away and the radioactivity in the filter referred to 
adhered cells, while the radioactivity in the filter and in the lower compartment referred to 
transmigrated cells. Values are the mean ± SE of three different experiments performed 
(**p<0.02 versus control, Student t Test).
CXCL12 stimulates gelatinase activity
Chemokines are potent activators of matrix metalloproteases (MMPs) (49, 133, 
238, 239). Hence, it was of interest to measure the activity o f MMP2 and MMP9 in the 
supernatants of CXCL12-treated tumor cells. Freshly isolated human monocytes were 
used as positive control. The gelatinase activity of MMPs from untreated tumor cells 
was very low (Fig. 5.11). CXCL12 significantly increased MMP activity in Hs766T and 
AsPCl, with levels o f activity similar or higher than human monocytes, while CXCL12 
did not affect the MMP activity in the CXCR4-negative cell line MiaPaCa2. The 
activity of metalloproteases is of major importance in the digestion of the extracellular 
matrix and has been implicated in the metastasizing ability of tumor cells
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Fig 5.11 CXCL12 stimulates the activity of selected metalloproteases. Induction of MMP2 
and MMP9 gelatinase activity; the assay used does not discriminate between MMP2 and MMP9 
and measures the overall gelatinase activity of supematantts tested. Three pancreatic cancer cell 
lines were stimulated with 100 ng/ml CXCL12 for 24h, in synthetic medium (X-Vivo) and 
supernatants were tested for metalloprotease activity in ELISA. CXCL12 induces 
metalloprotease activity in two CXCR4-positive cell lines (AsPCl and Hs766T) but not in the 
CXCR4-negative cell line (MiaPaCa2). Human monocytes were used as positive control. 
Values are the mean ±SE of three different experiments performed (*p<0.01 versus control, 
Student t Test).
In line with the finding that CXCL12 induces MMP activity, tumor cells 
stimulated with CXCL12 showed enhanced ability to invade Matrigel-coated filters 
(Fig. 5.12).
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Fig 5.12 CXCL12 stimulates invasion. Invasion of Matrigel coated filters was assessed after 
16 hours (*p<0.01 versus control, Student t Test). Shown is one representative experiment of 
two performed.
5.4 The axis CXCR4/CXCL12 role in pancreatic 
cancer cell proliferation and survival
CXCL12 stimulates pancreatic cancer cell line proliferation
I investigated whether the expression of CXCR4 on tumor cells had an effect on 
their proliferation. Tumors frequently produce chemokines, thus I previously evaluated 
whether pancreatic cancer cells produced CXCL12 (Chapter 4). O f eleven cell lines 
tested, only Hs766T produced significant amounts of the chemokine (1326 pg/ml/106 
cells, Table 4).
The effect of CXCL12 on tumor cell proliferation was assessed on CFSE- 
labelled cells. Under optimal culture conditions (in the presence of 10% serum), 
addition of CXCL12 increased proliferation in the cell line AsPCl (CXCR4-positive, 
CXCL12-non producing), but not in Hs766T cells, which produces the chemokine.
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Treatment with AMD3100 greatly inhibited spontaneous proliferation only in Hs766T 
cells, which is in line with the presence of the endogenous chemokine (Fig. 5.13).
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Fig 5.13. CXCL12 enhances proliferation in Hs766T and AsPCl cell lines, under optimal 
conditions. Cells were labeled with CFSE and fluorescence measured after 3 days. Proliferation 
is indicated by decrease in mean fluorescence (MFI). In the presence of 10% serum, CXCL12 
enhances the proliferation of AsPCl cells (compare black bar with white bar) and addition of 
the CXCR4-antagonist AMD3100 reverts this effect (grey bar). In the CXCL12-producing cell 
line Hs766T, AMD3100 inhibits proliferation (compare dashed bar with white bar). Each 
sample was obtained by mixing a triplicate, to get a representative number of cells. One 
representative of three experiments is shown.
Under suboptimal culture conditions (absence of serum), the presence o f 
CXCL12 greatly enhanced cell proliferation in both Hs766T and AsPCl cell lines (Fig. 
5.14). This is in agreement with our finding that CXCL12 release was reduced by 90% 
in serum-free conditions (not shown). The enhancing effect of CXCL12 on cell
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proliferation was strongly inhibited by treatment with AMD3100 in AAsPCl cells and 
to a lesser extent in Hs766T cells.
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Fig 5.14. CXCL12 enhances proliferation in Hs766T and AsPCl cell lines, under sub- 
optimal conditions. Under conditions of serum deprivation (culture in medium 1% FBS), 
CXCL12 restores the proliferation of Hs766T and AsPCl cells (black and white bar); this effect 
is partially inhibited by the AMD3100 inhibitor (grey bar). Each sample was obtained by 
mixing a triplicate, to get a representative number of cells. One representative of three 
experiments is shown.
These results indicate that CXCL12 stimulates pancreatic cancer cell line 
proliferation, and, in at least one representative CXCR4-positive cell line, the 
chemokine acts as an autocrine growth factor.
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CXCL12 promotes survival of pancreatic cancer cells
An important feature of metastatic cells is the ability to regulate their survival. I 
therefore tested whether CXCL12 could rescue Hs766T and AsPCl tumor cells from 
serum deprivation-induced death. Treatment of cells cultured in serum-free medium 
with CXCL12 reduced the percentage of propidium iodide (PI) positive cells by 46% in 
Hs766T and by 50% in AsPCl (n=4, data not shown). We next performed cell cycle 
analysis. As shown in Fig.5.15, serum deprivation enhanced the proportion o f apoptotic 
cells, as indicated by the sub-Gl peak detection (from 13% to 27% in Hs766T and from 
2% to 11% in AsPCl). We used also IL -ip as an apoptotic stimulus, as we previously 
observed that this cytokine induces apoptosis in these cell lines (26). Addition of 
CXCL12 (100 ng/ml) significantly reduced spontaneous DNA degradation, as shown by 
decrease of sub-Gl peak (from 27% to 16% and from 11% to 4% for Hs766T and 
AsPCl respectively; where IL-1(3 was used, from 21% to 16% and from 6% to 2%, in 
Hs766T and in AsPCl respectively).
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Fig 5.15 CXCL12 rescues Hs766T and AsPCl cells from apoptosis induced by serum 
deprivation and IL-1 p. Cell cycle analysis of cells cultured in normal or apoptosis-inducing 
conditions, with or without 100 ng/ml CXCL12. After 72 h cell cycle analysis was performed, 
by staining cells with PI. In all the apoptosis inducing conditions, addition of CXCL12 
decreased sub-Gl peak. One representative of three experiments is shown.
To further address the question whether CXCL12 regulates survival o f pancreatic 
cancer cell lines, we evaluated the percentage of annexin-V* cells under serum-deprived 
culture conditions. In both Hs766T and AsPCl cell lines, treatment with CXCL12 
decreased the percentage of apoptotic annexin-V+ cells (from 19% to 15% in Hs766T
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and from 17% to 12% in AsPCl), while CXCL12 had no significant effect in the 
CXCR4-negative cell line MiaPaCa2 (Fig.5.16).
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Fig.5.16. CXCL12 rescues Hs766T and AspCl from apoptosis. Percentage of AnnexinV* 
positive cells in cell lines cultured in serum-free medium for 24 h with or without CXCL12. In 
Hs766T and AsPCl, CXCL12 (100 ng/ml) decreased number of apoptotic annexing cells, 
while CXCL12 had no significant effect in the CXCR4 negative cell line MiaPaCa2. Values are 
the mean ± SE of three different experiments performed (*p <0.01, Student t Test).
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5.5 Discussion
In this Chapter, I presented data on the expression and functional role o f the 
CXCR4/CXCL12 axis in human pancreatic adenocarcinoma.
From the first mRNA screening of eleven pancreatic tumor cell lines, I found 
that CXCR4 is the chemokine receptor mostly expressed. In particular, 6 o f 11 cell lines 
tested express considerable levels o f CXCR4 transcripts, that was confirmed at the 
protein level in selected cell lines.
Interestingly, I found that CXCR4 is differentially expressed in the pancreatic 
cancer cell lines depending on their origin. Only one out o f three cell lines derived from 
primary tumors expresses the transcript, in very low amounts, while all but one cell 
lines derived either from ascites or metastasis express higher amounts o f CXCR4 
mRNA. This result suggests an association between the expression of the receptor and 
the in vivo origin (either primary tumour or metastatic site) of tumor cells.
Also surgical specimens from pancreatic adenocarcinoma express CXCR4 in 
higher amounts compared with an immortalized cell line derived form human pancreatic 
ducts (HPDE6) as well as compared to freshly isolated normal pancreatic ducts. The 
finding that tumor tissues have higher expression o f CXCR4 compared to the normal 
counterpart is in agreement with previous reports (281-283).
Surprisingly, the preparation of freshly isolated pancreatic ducts that was tested 
had relatively high levels o f CXCR4. One possible explanation is that these pancreatic 
ducts were isolated from a multi-organ donor in irreversible coma. Although it is 
unknown whether this specific pathological condition affects the expression of 
chemokine receptors, it is well known, and I also confirm it in this report, that hypoxia
128
up-regulates CXCR4. It may be possible that the high CXCR4 expression is the result o f 
hypoxic conditions surely occurred before pancreas explants. High expression of 
CXCR4 in pancreatic ducts has also been recently reported by Kajali et al in NOD-IFN- 
y-transgenic mice, as well as in parental NOD mice (284). These authors also highlight 
the importance of the CXCR4-CXCL12 ligand-receptor axis in the survival 
proliferation and migration of ductal pancreatic ells.
CXCR4 is expressed on a variety o f tissues and cell types, including leukocytes, 
haematopoietic progenitor cells, endothelial cells, epithelial cells and cells o f the central 
nervous system (285). Its chemokine ligand, CXCL12, is a homeostatic chemokine; it is 
expressed constitutively in a range of tissues and does not appear to be regulated by pro- 
inflammatory cytokines (286, 287). Its ubiquitous expression may be due to the 
presence of a GC-rich sequence in the 5’-flanking region of the CXCL12 gene, a feature 
which is associated with ‘housekeeping’ genes (287).
Both CXCR4- and CXCL 12-deficient mice have been generated and have 
contributed to the comprehension of the very broad spectrum of actions o f this 
receptor/ligand pair (145, 146). Both the transgenic mice die in utero and present very 
similar phenotypes, a feature confirming that CXCL 12 only acts through CXCR4; this 
has been the general consensus till some months ago, when another receptor for 
CXCL 12 has been cloned, named CXCR7 (288).
Besides the usual functions attributed to a homeostatic chemokine/receptor pair, 
both CXCR4 and CXCL 12 play a critical role in other physiological processes, 
including foetal development and organogenesis (severe heart defects, disorganised 
cerebellum are observed in knockout mice), vascularisation, and mobilization of 
haematopoietic stem cells (285). Moreover, they also have importance in pathological
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conditions as HIVinfection, being CXCR4 a co-receptor for the virus entry, and in 
tumour metastasis, as here discussed.
Modulation of chemokine receptors has not been extensively investigated on 
tumor cells. It has been recently reported that hypoxia (low oxygen tension) up- 
regulates CXCR4 expression in endothelial and tumor cells (280). Indeed CXCR4 is an 
hypoxia inducible gene, being a target o f Hypoxia-inducible factor 1 alpha (HIF) (289). 
In line with this finding we observed that CXCR4 expression was enhanced in two cell 
lines cultured under hypoxic conditions. As low oxygen tension is likely to occur in the 
neoplastic mass; hypoxia-induced up-regulation of CXCR4 may have direct in vivo 
relevance.
To assess whether cytokines present in the tumor microenvironment could 
modulate CXCR4,1 tested IL-10, IL-6 and hepatic growth factor (HGF), (known to be 
produced by human pancreatic tumor and stromal cells) (290, 291). CXCR4 mRNA 
transcripts were never affected by the above cytokines (data not shown). The 
inflammatory cytokines, TN Fa and IL -lp  were also ineffective; in contrast, treatment 
with IFNy consistently reduced CXCR4 expression. It is well established that IFNy plays 
a crucial role in immune resistance against tumors (292). Therefore the IFNy-mediated 
down modulation o f CXCR4 may contribute to inhibition o f tumor growth and 
metastasis.
In line with other results that CXCR4 is implicated in promoting the migratory 
phenotype of a variety o f tumors (81, 281-283, 293) in this study CXCL 12 induced a 
chemotactic response in CXCR4-positive cell lines and this response was inhibited 
when CXCR4 receptors were blocked by a specific monoclonal antibody or by the
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CXCR4 antagonist AMD3100. Tumor cell adhesion to endothelium and 
transendothelial migration are key events in the process of tumor invasion and 
metastasis and are chemokine-regulated steps. Adhesion to endothelial cells and 
transendothelial migration were enhanced by CXCL 12 in CXCR4-positive pancreatic 
tumor cells.
Cancer dissemination can be viewed as a tissue remodeling process that involves 
proteolytic degradation o f ECM in the surrounding normal tissue. Metalloproteases are 
a family of enzymes activated by chemokines, involved in the degradation o f ECM and 
known to mediate cancer invasion and metastases (50-53, 55, 238). The initial interest 
in proteases was on their critical role in degrading the basement membrane, to permit 
the penetration by tumor cells of surrounding connective tissues and blood vessels; 
moreover, the ECM blocks tumor metastasis not only in the sense of being a physical 
barrier but also because it forms a self-protective, apoptosis resistant microenvironment 
(50). Later on it has been clear that proteases, and in particular matrix 
metalloproteinases, can target many non-ECM proteins, including growth factor 
receptors, cell-associated molecules, and cytokines VEGF and TGFp represent two 
examples of such factors that are stored in a latent complex within the ECM and can be 
released by MMP proteolysis (53, 70), enhancing their bioavailability. As a result, the 
activity of proteases in cancer is far more complex than initially anticipated and 
includes tumor promoting as well as tumor-suppressive effects (52). Moreover, several 
lines of evidence suggest also a supportive role for ECM components in metastasis, 
possibly due to the capability of ECM components (e.g. fibronectin, laminin-5) of 
promoting migration and MMPs have been demonstrated to have a role in exposing 
cryptic domains within ECM molecules that can promote migration and metastasis
Among the eleven types of metalloproteases, MMP-2 and MMP-9 participate in 
the degradation of type IV collagen, which is one of the major components of cellular 
basement membranes, whose elimination is essential to invade stroma and vessels; 
indeed, expression of MMP-2 and MMP-9 has been associated with venous invasion 
and hematogenous metastasis (72). Pancreatic cancer is strongly invasive, usually 
directed to large vessels, such as the portal vein, and the development of liver metastasis 
is generally dependent on venous invasion by primary tumor cells. Proteases are 
expressed in the extracellular milieu as inactive proforms that become activated through 
a variety of mechanisms that often involve a close collaboration among several families 
of proteases. Thus overexpression o f proteases as detected by antibody staining does not 
necessarily mean an increase in proteolytic activity. For this reason, the availability o f a 
functional assay measuring metalloprotease activity rather than expression, as the one I 
used in this work, acquires much importance.
In this study, I found that in the absence of chemokines, the gelatinase activity of 
MMPs from untreated tumor cells was very low. In contrast, in CXCL12-treated tumor 
cell lines, MMPs were significantly more active. In line with these findings, CXCL 12 
triggered tumor cell invasion through a Matrigel layer. Collectively, these results 
indicate that CXCR4 expression confers tumor cells with increased motility and 
invasion ability.
Although the functional significance of chemokine receptor expression by tumor 
cells has largely being investigated, in general, few biological assays have been 
performed, mainly aimed at demonstrating that chemokines enhance the migratory 
phenotype of tumor cells bearing their cognate receptor.
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It is now well established that chemokines play other important roles besides 
chemotaxis; in particular, they may have direct or indirect growth stimulating effects on 
tumor cells. There is evidence that CXCL8 and CXCL1 are implicated as endogenous 
growth stimulating factors in melanoma as well as in tumors o f different 
histologies(187, 188). A promoting effect of CXCL 12 on tumor cell proliferation was 
reported also for ovarian carcinoma (295). Our group has extensively analyzed the 
expression and production of different chemokines in pancreatic cancer; some of the 
cell lines produce CCL2, CCL5 and CXCL8, with a heterogeneous pattern (25, 26). In 
this work, I found out that CXCL12 is produced only by Hs766T, the cell line 
expressing the highest levels of CXCR4. Interestingly, the CXCR4 antagonist 
AMD3100 inhibited proliferation in Hs766T, suggesting that the endogenous CXCL 12 
may function as an autocrine or paracrine factor. In vivo, CXCL 12 can be produced by 
several cell types, including stromal and endothelial cells (283); moreover, this 
chemokine is produced in lymph nodes, where secondary localization of tumors, 
including pancreatic carcinoma, occurs. In in vitro experiments, CXCL 12 enhanced the 
proliferation of the CXCR4-bearing cell lines, especially under sub optimal culture 
conditions. When the Hs766T cell line was cultured in serum-free medium, CXCL12 
release was dramatically reduced and exogenous CXCL 12 significantly stimulated cell 
growth, both in Hs766T and in A sPC l.
AMD3100 has been originally tested in HIV patients as CXCR4 is one o f the 
major receptor for the virus, and showed to have a good safety profile (296, 297); 
moreover, it has been considered as a therapeutic tool for other pathologies in which 
CXCR4 may play a role. For instance, it has been shown to mobilize CD34+ stem cells 
from the bone marrow into the bloodstream; indeed, AMD3100 is actively pursued as a 
stem cell mobilizer for transplantation in patients with multiple myeloma and non-
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Hodgkin’s lymphoma (297). Some recent data have provided the scientific rationale for 
the clinical evaluation of AMD3100 also in cancer. In cells from adult glioblastoma and 
pediatric medulloblastoma, CXCR4-CXCL12 signalling induced chemotaxis and 
enhanced proliferation and survival (298). When tested in vitro in cell cultures, the 
selective CXCR4 antagonist (AMD3100) was shown to reverse these effects. When 
AMD3100 was used to treat mice bearing intracranial glioblastoma or medulloblastoma, 
tumor burden was significantly smaller in AMD3100-treated animals (298, 299).
An essential feature of tumour cells is the ability to regulate their survival and to 
resist to apoptosis. The chemokine CXCL12 has been shown to be involved in 
promoting survival o f CD34+ hematopoietic progenitors and T lymphocytes (132, 300) 
and of several types of cancer, including glioma, melanoma, NSCLC, renal and thyroid 
(91,282,299).
In this study, CXCL 12 has been shown to protect CXCR4+ pancreatic tumor 
cells from serum starvation-induced death or IL-1-induced damage, by decreasing the 
rate of apoptosis.
Collectively, these results show that expression o f CXCR4 by pancreatic tumour 
cells mediates migration and invasion in the surrounding tissues and also promotes 
survival and proliferation of cancer cells.
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5.6 Summary of results in Chapter 5
The results presented here demonstrate that metastatic pancreatic carcinoma cells 
express CXCR4 and that autocrine or paracrine loops centered on this chemokine 
receptor promote tumor cell migration, matrix degradation and invasion, proliferation 
and survival.
Specifically, the following results have been presented:
- pancreatic cancer cell lines express CXCR4 mRNA; the expression is higher in cell 
lines derived form metastatic lesions compared with those derived from primary tumors;
- different inflammatory cytokines do not modify the expression, whereas IFNy down 
regulates and hypoxia up regulates CXCR4 transcripts;
- transcript expression is associated to surface expression in pancreatic carcinoma cell 
lines;
- CXCR4 is expressed also in pancreatic cancer cells from primary tumors; all surgical 
(N=7) carcinoma samples tested express higher levels o f CXCR4 than normal pancreatic 
duct cells
- CXCR4 on pancreatic cancer cells is functional and mediates their migration to 
CXCL 12; migration is selectively inhibited by anti-CXCR4 monoclonal antibody and by 
the antagonist AMD3100;
- CXCL 12 also mediates transendothelial migration, Matrigel invasion and activation of 
metalloproteases;
- in CXCR4-positive cell lines CXCL 12 stimulates cell proliferation and protects from 
apoptosis induced by serum starvation.
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Chapter 6
CX3CR1 and Pancreatic 
Adenocarcinoma
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6.1 Introduction and goal
This chapter will focus on the expression and function of the chemokine receptor 
CX3CR1 and its chemokine ligand CX3CL1/Fractalkine in human pancreatic 
adenocarcinoma. In the preliminary screening of chemokine receptors in pancreatic 
adenocarcinoma cell lines, I found that some cell lines express the receptor CX3CR1; 
its chemokine ligand, CX3CL1, also called Neurotactin, is found expressed in neurons 
and nerve fibers (301-304). Besides local and lymph node metastasis, hallmark of 
pancreatic cancer is a peculiar propensity to disseminate and grow along nerves. 
Therefore, the presence o f CX3CR1 can assume a particular relevance in the context of 
pancreatic cancer tropism for neural structures. Hence, I wanted to test the hypothesis 
that CX3CR1 and its ligand CX3CL 1/Neurotactin could have a role in pancreatic 
adenocarcinoma dissemination to nerves.
6.2 CX3CR1 mRNA analysis
CX3CR1 expression in pancreatic tumor cell lines
In a first series of experiments, I evaluated the expression of CX3CR1 in eleven 
pancreatic adenocarcinoma cell lines by semi quantitative Real Time PCR. The 
immortalized epithelial cell line (HPDE6) derived from normal human pancreatic ducts 
was used as a reference o f normal tissue. This analysis revealed that 6 pancreatic tumor 
cell lines express CX3CR1, with three cell lines (Capan-1, A8184, A sPCl) showing the 
highest expression (Fig. 6.1). Moreover, in each cell line, the expression o f CX3CRJ is 
higher than in the normal ductal epithelium, in which CX3CR1 expression is not 
detected.
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I reported in the previous chapter that human pancreatic tumor cells express 
functional CXCR4, it was of interest to verify whether CX3CR1 is co-expressed with 
CXGR4 on the same cell lines; two cell lines with the highest amount o f CX3CR1 
(Capan-1 and AsPCl) are also high CACR4-expressing, while A8184 expresses only 
CX3CR1 at high levels. I also confirm in this analysis what was observed for CXCR4, 
i.d. the cell lines expressing the chemokine receptors are more frequently derived from 
metastatic lesions or ascites, while the negative cell lines derive from a primary tumor. 
This evidence, although based on a low casistic, seems to confirm our hypothesis that 
an association exists between chemokine receptor expression and the malignant 
potential of tumor cells (Fig.6.1).
Origin Primary Tumors Ascites Metastasis
Fig 6.1 CX3CR1 in pancreatic cancer cell lines. Semiquantitative Real-Time PCR of 
pancreatic cancer cell lines. For each cell line, the amount of CX3CR1 mRNA, normalized to f3- 
actin, is expressed as relative to the cell line HPDE6. One representative analysis of two 
performed is reported.
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As no data are available in the literature regarding the expression of CX3CR1 by 
tumour cells, we asked whether the results described above were specific to pancreatic 
cancer. Therefore, I screened a panel of cell lines derived from other adenocarcinoma, 
including ovarian cancer cells, breast cancer and two colon carcinoma cell lines and 
found out that the expression is much lower compared to pancreatic cancer cells (Fig 
6.2).
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Fig 6.2 CX3CR1 in pancreatic and other tumour type derived cell linesc. Semiquantitative 
Real-Time PCR. For each cell line, the amount of CX3CR1 mRNA, normalized to fi-actin, is 
expressed as relative to the cell line HPDE6. One representative analysis of two performed is 
reported.
Expression of CX3CR1 in freshly isolated pancreatic tumor cells
I next examined tumor cells from surgical samples o f resected patients (see 
Table 3.1 for clinico-pathological features). Tumor cells isolated by density gradients 
from the stromal component and checked for purity by staining with cytokeratin-7 were 
analyzed. In 7 different tumor samples, the amount of CX3CR1 mRNA, normalized to
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/3-actin, was evaluated by Real Time PCR, and expressed as relative to the cell line 
HPDE6, used as reference, as for the above experiments. As shown in Fig.6.3, freshly 
isolated tumor cells showed much higher levels of CX3CR1 compared to HPDE6. In 
addition, a cell preparation o f freshly isolated pancreatic ducts was tested, in which 
CX3CR1 expression is much lower than in primary tumors, although higher than the 
HPDE6 cell line.
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Fig 6.3 CX3CR1 mRNA expression in tumor cells from surgical samples of resected 
pancreatic cancer patients. The amount of CX3CR1 mRNA, normalized to /3-actin, is 
expressed as relative to the cell line HPDE6 (white bar). Human epithelial pancreatic ducts were 
isolated from the pancreatic tissue of a multiorgan donor (grey bar). Shown is one representative 
analysis of two performed.
CX3CR1 surface expression
As for CXCR4, before starting to investigate the functional activity o f CX3CR1 
expressed by tumor cells, it was necessary to verify the expression o f the receptor on the
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surface of tumor cells. I evaluated CX3CR1 cell-surface expression by flow cytometry. 
Representative profiles of the cell lines A8184, AsPCI, Panel, found to express the 
CX3CR1 are presented in Fig. 6.4, showing that CX3CR1 is expressed on the 
membrane of pancreatic tumour cell lines.
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Fig 6.4 CX3CR1 is expressed at the surface of pancreatic cancer cell lines. Flow cytomety 
analysis of cell lines was performed with a PE-labeled anti-CX3CRl antibody (3 pg/ml, clone 
2A9-1). A PE-labeled mouse anti human isotype control (3 pg/ml) was used as control. 
Representative profiles are shown.
CX3CR1 in vivo expression
We also investigated, by immunohistochemistry, CX3CR1 protein expression in three 
surgical sections of pancreatic cancer patients (PK 93, PK96 and PK97, see Table 3.1 
for clinico-pathological features) and verified that CX3CR1 is expressed in vivo in 
pancreatic adenocarcinoma (Fig 6.5, Panel B-D). Most importantly, the expression of 
the receptor was detected in normal pancreatic ducts obtained from a multi-organ donor 
(Fig 6.5, Panel A).
141
'■ . ■ ■ ■-
. .* ■ ‘ rfg %i
-
* 2 - \ !
142
cD
Fig 6.5 CX3CR1 expression by pancreatic cancer cells in vivo. Immunohistocheinical 
analysis of three surgical sections of human pancreatic adenocarcinoma (PK 93, PK96, PK97, 
Panel B-D) and of a section of normal pancreatic ducts (Panel A) with an anti-CX3CRl specific 
antibody.
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6.3 CX3CR2 functional activity
CX3CL1 stimulates pancreatic cancer cell chemotaxis
To confirm that CX3CR1 expressed in tumor cells is functional, I selected the 
cell lines with the highest receptor expression, A8184 and AsPC-1 (Capan 1, as said 
previously, was excluded for its characteristic to disaggregate in clusters) and tested in 
classical chemotaxis assays. Fig. 6.6 shows that CX3CL1 elicited migration of tumor 
cells in a dose-response manner in both cell lines.
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Fig 6.6 CX3CL1 stimulates pancreatic cancer cell chemotaxis. Selected CX3CR1-positive 
cell lines, A8184 and AsPCl migrated in classical chemotaxis assays to different concentrations 
of Fractalkine in a dose-response manner. 8 pm pore filters were used and time of migration 
was 8 hours. Shown are net numbers of migrated cells over basal migration (in the absence of 
chemokine). Basal migration was 15 cells/10 HPF for A8184 and 7 cells/10 HPF for AsPCl, 
(*p<0.02 versus control; **p<0.001 versus control, Student t Test). Values are the mean ±SE of 
eight replicates. One representative experiment of three performed is shown
Moreover, cell migration was drastically inhibited by a blocking anti-CX3CRl 
monoclonal antibody while was not affected by an irrelevant antibody (Fig.6.7).
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Fig. 6.7 CX3CL1 induced migration is mediated by CX3CR1. Pre-treatment of A8184 cells 
with a blocking anti-CX3CRl mAb (10 jig/ml) drastically reduced cell migration in response to 
300 ng/ml of CX3CL1 (**p<0.01 versus control; Student t Test); an irrelevant antibody did not 
block CX3 CL 1-induced migration.
CXC3CL1 stimulates pancreatic cancer cell adhesion to endothelial 
cells
CX3CL1 is an unusual chemokine which can also function as an adhesion 
molecule. It was first described as produced by endothelial cells upon stimulation with 
inflammatory cytokines, the most potent stimulus being the combination o f TN Fa and 
IFNy (266). CX3CL1 on endothelium mediates initial capture, firm adhesion and 
activation of circulating leukocytes. Therefore it was of interest to test a CX3CR1- 
expressing pancreatic cell line in adhesion assays to endothelial cell monolayers
Firstly, I verified by Northern Blot analysis that TNFa and IFNy treatment of 
HUVECs (Human Umbilical Endothelial Cells), isolated following well established 
methods set up in our laboratory, (262) induced Fractalkine expression, and this was the 
case (Fig. 6 .8).
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Fig. 6.8 TNFa/IFNy induce CX3CL1 expression in endothelial cells. HUVEC cells were 
stimulated with TNFa (10 ng/ml) and IFNy (1000 U/ml); RNA extracted after 24 hours was run 
in Northern Blot analysis. CX3CL 1 -specific mRNA was detected with cDNA 32P-labeled probe.
Pancreatic tumor cell adhesion to the endothelial cell monolayer was enhanced 
upon stimulation of HUVECs with a combination of TNFa and IFNy; this increase 
(nearly 70%) was partially reverted by pre-treatment of pancreatic cells with a CX3CR1 
blocking antibody, thus demonstrating a specific role for CX3CL1 in adhesion to 
endothelial cells (Fig 6.9). In the same assay, adhesion of the cell line PaCa44, not 
expressing CX3CR1, to TNFa and IFNy stimulated endothelial cells was not enhanced, 
thus supporting that the CX3CR1/CX3CL1 pair mediates pancreatic cancer cell 
adhesion to endothelial cells.
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Fig 6.9 CX3CL1 mediates pancreatic cancer cell line adhesion to endothelium. Monolayers 
of HUVEC cells were stimulated with TNFa (10 ng/ml) and IFNy (1000 U/ml) overnight and 
pancreatic cancer cell adhesion to the endothelial cell monolayer was assessed, at 37°C, for 1 
hour. A8184 adhesion to the endothelial cell monolayer was enhanced upon stimulation of 
HUVECs with TNFa/IFNy and this increase (nearly 70%) was partially reverted by pre­
treatment of pancreatic cells with a CX3CR1 blocking antibody. Adhesion o f the cell line 
PaCa44, not expressing CX3CR1, to TNFa and IFNy stimulated endothelial cells was not 
enhanced. (*p<0.02 versus control **p<0.001 versus control, Student t Test). Mean values of 
two different experiments are reported.
6.4 in vitro pancreatic cancer cell nerve tropism
Human neuronal cells express and release CX3CL1
Our hypothesis of an involvement of CX3 CL 1 /Neurotactin and its receptor in 
pancreatic cancer tropism for neuronal tissues arises from the observation that CX3CL1 
is expressed in neurons (301-304). To better characterize the molecular mechanisms 
responsible for affinity of pancreatic tumor cells for neural structures, we tried to
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generate an in vitro a model of nerve tropism. To do this, I screened a panel of 4 
different cell lines of neuronal origin for the production of CX3CL 1/Neurotactin, two 
neuroblastoma (SKN-BE, SY5Y), one glioma (H4) and one astrocytoma (TGSG). I 
measured CX3CL1 production both in basal conditions and after stimulation with 
inflammatory cytokines like TNFa, IFNy, IL-ip.
A first Northern Blot analysis evidenced a neuroblastoma cell line (SKN-BE) 
producing CX3CL1 upon stimulation with TNFa/IFNy (Fig. 6.10), while IL -ip  did not 
exert this effect. Microglia is known not to produce CX3CL1, so it was not expected in 
the cell line H4.
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Fig. 6.10 TNFa/IFNy induce CX3CL1 expression in SKN-BE cell line. Different neuron- 
derived cell lines were stimulated with TNFa (10 ng/ml) and IFNy (1000 U/ml); RNA extracted 
after 24 hours was run in Northern Blot analysis. CX3CL1-specific mRNA was detected with 
cDNA 32P-labeled probe.
The results were confirmed at the protein level, by analyzing chemokine 
production both in its membrane-bound and soluble form. CX3CL1 surface expression 
was upregulated by the concomitant treatment with TNFa and IFNy in the 
neuroblastoma cell line SKN-BE (Fig. 6.11).
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Fig 6.11 TNFa/IFNy upregulate the surface expression of Fractalkine/Neurotactin in 
neuroblastoma cells. SKN-BE cells were stimulated for 24 hours and phenotype analysis 
performed with a CX3CL1 specific antibody, by FACS analysis. Percentage of positive cells 
(%age gated cells) and mean fluorescence intensity (MFI) are reported. One representative of 
three experiments is shown.
Moreover, CX3CL1 measurement in conditioned media of stimulated SKN-BE 
cells revealed that these cells are also able to release the chemokine in its soluble form. 
In line with the result obtained with Northern analysis, other neuronal cell lines did not 
produce the chemokine (Fig.6.12).
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Fig 6.12 Fractalkine is released in the supernatant of neuroblastoma cells after 
TNFa/IFNy stimulation. Only the cell line SKN-BE secreted CX3CLl/Neurotactin in the 
supernatant. The chemokine amount was measured by ELISA. Bars represent mean numbers of 
three different experiments.
CX3CL1 expression in human nerves and nerve metastasis
After I had verified in vitro that human neural cells express the chemokine 
Fractalkine, we thought it could be important to examine the expression o f CX3CL1 in 
vivo. In particular, we focused our attention on surgical sections o f pancreatic 
adenocarcinoma nerve metastasis and examined CX3CL1 protein expression by 
immunohistochemistry. Figure 6.13 depicts CX3CL1 staining o f sections 
corresponding to pancreatic cancer cells infiltrating nerve fibers.
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Fig 6.13. CX3CL1 is localized in vivo in pancreatic cancer nerve metastasis.
Himmunoistochemical staining with a CX3CL1 specific antibody of a surgical section (PK93, 
see Table.3.1 for clinico-pathological features) of pancreatic cancer tumour cells infiltrating 
nerve fibers. Picture on the right is the negative control (without primary antibody).
More specifically, Schwann cells inside the nerve are negative, while the staining is 
localized in intra axonal vesicles (Fig 6.13, close-up). Surprisingly, CX3CL1 seemed
Fig 6.13, close-up.
CX3CL1 staining is 
localized in intra axonal 
vesicles (black arrow); 
Schwann cells inside the 
nerve (red arrow) are 
negative, while staining 
is localized also in 
carcinoma cells (green 
arrow).
localized also in carcinoma cells (green arrow).
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In the same analysis, we stained sections for the marker of proliferation Ki67; notably, 
cancer cells closed to nerves were highly stained, differently from other cells (Fig. 
6.14).
Fig 6.14 Ki67 staining on a surgical 
section of pancreatic cancer cells 
infiltrating nerves. Cancer cells close to 
nerves were highly stained, differently 
from other cells, indicating a higher 
proliferation rate.
This result suggests that the interaction between cancer cells and neural structures may 
positively affect pancreatic cancer cell proliferation.
M igration of Human Pancreatic tum or Cells to Neuronal Cell 
conditioned medium
As I had assessed that CX3CRI positive pancreatic tumor cell lines migrate to 
recombinant CX3CL1, and that neuroblastoma cells are able to secrete 
CX3CLl/Neurotactin in vitro, it was of interest to verify if the natural, neuron-derived 
chemokine was functionally active and able to exert pancreatic cancer cell migration. 
Fractalkine concentration was measured in SKN-BE cell line supernatant, both in basal 
condition and after stimulation with TNFa/IFNy (Fig 6.12); appropriately diluted (1:5) 
supernatants were tested as chemoattractants for A8184 cell line.
Nerve
152
A8184
O 35 □  SKN-BE C trl 
■  SKN-BE TNFa/IFNy
C trl anti-CX 3CRl
Fig 6.16 Neuroblastoma-derived supernatant containing CX3CLl/Neurotactin stimulates 
pancreatic cancer cell chemotaxis. A8184 cells migrated in classical chemotaxis assays to 
SKN-BE conditioned supernatant, diluted 1:5; migration was higher in the presence of 
TNFa/IFNy stimulated supernatants. A8184 cell incubation with an anti CX3CR1-antibody 
partially blocked migration. Shown are net numbers of migrated cells over basal migration (in 
the absence of supernatant). Basal migration was 15 cells/10 HPF (*p<0.02 versus control, 
Student t Test). Values are the mean ±SE of eight replicates. One representative experiment of 
three performed is shown
TNFa/IFNy stimulated SKN-BE conditioned supernatant elicited a chemotactic 
response in A8184 cells; migration was higher than the one observed in response to 
basal supernatant. Moreover, in the presence of a monoclonal anti CX3CL1 antibody 
migration in response to TNFa/IFNy stimulated supernatant was decreased, 
demonstrating that A8184 migration was mostly Fractalkine mediated (Fig.6.16).
Human Pancreatic Tumor Cells adhere to Neuronal Cells expressing
One peculiarity often clinically observed in pancreatic adenocarcinoma is their 
perineural invasion. Strikingly, cancer cells appear confined within the nerves, all along 
their route, even following their branching and without invading the surrounding tissue.
CX3CL1
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To investigate whether this interaction with nerves was CX3CL1, dependent I tested 
A8184 adhesion to neuroblastoma conditioned supernatant.
Pancreatic tumor cell adhesion to the neuroblastoma monolayer was enhanced 
upon stimulation of neuroblatoma with a combination of TNFa and IFNy; this increase 
(nearly 100%) was partially reverted by pre-treatment of pancreatic cells with a 
CX3CR1 blocking antibody, thus demonstrating a specific role for 
CX3CLl/Neurotactin in the adhesion to neuroblastoma cells (Fig.6.17). In the same 
assay, SY5Y cells, the neuronal cell line not expressing the chemokine was tested and 
did not elicit pancreatic cancer adhesion after TNFa and IFNy stimulation.
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Fig 6.17 CX3CLl/Neurotactin mediates pancreatic cancer cell line adhesion to 
neuroblastoma cells. Pancreatic tumor cell line A8184 adhesion to a monolayer of the CX3CL1 
producing cell line SKN-BE was enhanced upon stimulation of SKN-BE with a combination of 
TNFa and IFNy, known to upregulate its CX3CL1 expression (see Fig 6.11); this increase 
(nearly 100%) was partially reverted by pre-treatment of pancreatic cells with a CX3CRI 
blocking antibody. Adhesion was assessed after 1 hour of coincubation at 37°C. Adhesion of 
A8184 to the cell line SY5Y, not producing CX3CL1, was not enhanced by TNFa/IFNy
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stimulus. Values are the mean ± SE of two different experiments (*p<0.02 versus control 
**p<0.001 versus control, Student t Test).
6.5 Generation of a pancreatic cancer cell line 
stably expressing CX3CR1
To study the in vivo role of CX3CR1 in pancreatic tumor cells, we decided to 
generate a pancreatic cell line expressing exogenously the receptor CX3CR1.1 prepared 
a viral construct carrying the sequence coding for human CX3CR1 fused to the 
sequence for the reporter gene GFP. This device would facilitate the recognition of 
tumor cells during the experiments, thanks to the fluorescence emitted by the green 
fluorescence protein. A similar GFP vector, lacking the CX3CR1 gene, was used as 
control (mock); the resulting parental MiaPaCa2 mock-infected cell line will be used in 
functional assays as control population.
For this experiment, I selected a receptor-negative pancreatic tumor cell line, 
MiaPaCa2, known to grow in nude mice and screened for the absence o f chemokine 
receptors (e.g. CX3CR1, CXCR4, CCR2, CCR6) and stably infected it with the 
construct. After infection, cells were collected, expanded and tested for transgene 
expression.
To our purposes, the Fractalkine receptor should be expressed on the cell 
membrane, thus I selected FACS analysis to test the result of MiaPaCa2 infection; both 
GFP fluorescence and CX3CR1 presence on the surface membrane were checked 
(CX3CR1 by PE-conjugated anti-CX3CRl antibody).
Figure 6.18 reports profiles of MiaPaCa2 not infected (left), infected with GFP 
(middle) and CX3CR1-GFP (right) vector respectively. Both the latter cell populations 
were 99% positive for the transgene.
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Fig 6.18 Transgene expression analysis of MiaPaCa2 stably infected. FACS profiles of 
MiaPaCa2 not infected (left), infected with GFP (middle) and CX3CR1-GFP (right) vector 
respectively. Both the latter cell populations were 99% positive for the transgene
MiaPaCa2 CX3CR1-GFP migration to CX3CL1
CX3CR1-GFP Miapaca2 and GFP-MiapPaCa2 were tested in vitro in chemotaxis 
assays for their capability to migrate to CX3CL1 gradients. CX3CL1 elicited migration 
only in the CX3CR1 positive cell line; notably, CX3CL1 was active at much lower 
doses (30 ng/ml and 100 ng/ml) than on A8184 and A sPCl, naturally expressing 
CX3CR1 (Fig. 6.19).
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Fig 6.19 CX3CL1 elicits dose-response migration of MiaPaCa2 stably expressing 
CX3CR1. Shown are net numbers of migrated cells over basal migration (in the absence of 
chemokine). Basal migration was 27 cells/10 HPF for MiaPaCa2-CX3CRl-GFP and 40 cells/10 
HPF for MiaPaCa2-GFP, Values are the mean ±SE of eight replicates (**p<0.001 versus 
control, Student t Test). One representative experiment of two performed is shown.
MiaPaCa2 CX3CR1-GFP sub-lines selection
We decided to select CX3CR1-GFP MiaPaCa2 growing sub-lines on the basis of 
surface expression of CX3CR1; this tool will help us in future experiments to better 
understand the relative importance o f CX3CR1 expression in pancreatic cancer cells 
and the role in nerve tropism; in fact, at least two CX3CR1-transfected sub-lines and the 
parental cell line will be characterized both in vitro and in in vivo models of pancreatic 
cancer.
Instead o f cloning the whole cell population to select sub-lines, we started from 
the subpopulation migrated to a CX3CL1 gradient in a Transwell migration assay. This 
strategy represents a cloning on functional basis. Cells passed through the filter during 
migration assay were collected and cloned to limiting dilution. Fig. 6.20 reports FACS
157
profiles of two clones with similar in vitro growth kinetics (data not shown) and 
different levels of transgene expression.
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Fig. 6.20 Different CX3CR1 surface expression of two MiaPaCa2 CX3CR1-GFP clones.
MiaPaCa2 CX3CR1-GFP cloned by limiting dilution and two sub-clones selected for having 
different surface expression of the receptor. Mean fluorescence intensity was 10 x 103 for Clone 
D6 and 25 x 103 for Clone A7.
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6.6 Discussion
In this Chapter I presented data on the expression and functional role o f the 
chemokine receptor CX3CR1 in pancreatic adenocarcinoma and its possible 
involvement in the tropism of this cancer type for neuronal tissues.
The screening of pancreatic cell lines revealed that 6 o f 11 cell lines tested 
express heterogeneous levels of CX3CR1, with three cell lines (Capan-1, A8184, 
AsPCl) showing the highest expression transcripts, that was confirmed at the protein 
level in selected cell lines. The expression of this particular receptor in pancreatic 
cancer had never been reported up to now; recently, CX3CR1 expression in prostate 
cancer has been documented and associated to prostate metastasis to bone marrow 
(305).
As observed for CXCR4, also CX3CR1 seemed most frequently expressed in 
those pancreatic cancer cell lines derived either from ascites or metastasis, supporting 
the hypothesis that CX3CR1 may be involved in tumour dissemination.
Also surgical specimens from pancreatic adenocarcinoma express CX3CR1 in 
higher amounts compared with the immortalized cell line derived from human 
pancreatic ducts (HPDE6) as well as compared to freshly isolated normal pancreatic 
ducts.
In the world of chemokines, C and CX3C chemokines have been long regarded 
as two minor components, but the interest in these two classes has recently gained a 
new impetus, resulting from the identification o f their receptors and the accumulation o f 
data about their expression in several human diseases. Differently from the other
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chemokines, XC and CX3C chemokines show less redundancy (303); 
CX3CLl/Fractalkine/Neurotactin binds only the receptor CX3CR1.
CX3CL1 is encoded as a transmembrane molecule, consisting o f a chemokine 
domain linked to a mucin-rich stalk domain (299, 304); the cleavage of the full-length 
molecule results in the soluble form. As expected, the two different forms correspond 
two distinct biological functions: soluble CX3CLlacts as a chemoattractant, while the 
membrane-bound molecule, found expressed predominantly by epithelial cells (306), 
mediates adhesion of CX3CR1-bearing cells to cells expressing the ligand (304, 307, 
308). We wanted to confirm that CX3CR1 expressed in tumor cells is functional, by 
testing both the biological activities mediated by the chemokine. Thus, we firstly 
verified that CX3CL1 elicits migration of pancreatic tumor cell lines in a dose-response 
manner (Fig 6 .6 ) and this response was prevented by a CX3CR1 antibody (Fig 6.7).
Fractalkine was first described on endothelial cells upon stimulation with 
inflammatory cytokines (304, 309), the most potent stimulus being the combination of 
TNFa/IFNy (266). CX3CL1 on endothelium mediates initial capture, firm adhesion and 
activation of circulating leukocytes. In our studies, CX3CL1 expressed on endothelial 
cells promoted CX3CR1 positive pancreatic tumor cell adhesion; the effect was 
CX3CL 1 -dependent, as blocked by a specific antibody and not observed in a CX3CR1- 
negative cell line (Fig 6.9). This result is particularly important as tumor cell adhesion 
to endothelium is a key event in the process of tumor invasion and metastasis; 
moreover, and most important, pancreatic cancer is particularly invasive through the 
hematogenous route, often giving metastasis to large vessels (72) and the involvement 
of CX3CL1 in tumor cell adhesion to endothelial cells might represent a possible 
mechanism o f venous invasion.
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Other cell types have been reported to produce the chemokine CX3CL1. In 
particular, the relatively high levels of Fractalkine in the brain and nerve terminations 
(310) has raised questions related to the function o f this chemokine in the central nervous 
system; it has been proposed that CX3CL1 regulates cellular communication between 
neurons, producing the ligand and microglia, expressing the receptor (302, 311).
The expression of CX3CLl/Neurotactin in cells of the nervous system triggered 
our interest in the perspective of pancreatic cancer nerve tropism. Indeed, detailed 
pathohistologic studies of large series of resected pancreatic ductal adenocarcinoma 
have shown that one o f the most persistent characteristics is perineural invasion (72). In 
studies conducted in a large series of patients with pancreatic cancer, the incidence of 
perineural invasion resulted to be 100%, most o f which extended also to extrapancreatic 
nerves. Some other studies indicate that all pancreatic cancers show perineural invasion 
if  several sections are histologically considered (74, 79), and this pattern o f tumor 
spreading seems to be an early event, occurring in 75% of cases of stage I disease (77, 
78). Collectively, many different observations support the idea that a tropism of 
pancreatic cancer cells to neural tissues really exists, observation confirmed also in a 
hamster model (74). The aggressive and unchecked spread through haematogenous and 
perineural routes accounts for the rapid and fatal progression o f the disease; invasion of 
vessels and nerves is associated with poor prognosis in this disease and tumor growth 
along nerve fibers is the cause of severe pain in tumor patients. Moreover, growth of 
tumor foci around root ganglia in the spinal cord, is the first cause of tumor recurrence 
after surgery.
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The peculiar tropism of pancreatic tumors for vessels and nerves prompted us to 
investigate whether Fractalkine and its receptor on tumor cells confer the ability to 
invade and disseminate along nerve fibers expressing the ligand CX3CL1.
To better characterize the molecular mechanisms responsible for affinity of 
pancreatic tumor cells for neural structures, we tried to reproduce in vitro a model of 
nerve tropism. We analyzed the biological interaction between a neuronal cell line 
expressing the chemokine and CX3CR1-positive pancreatic cancer cells and found out 
that neuronal-derived CX3CL1 is chemotactic for pancreatic cancer cells (Fig 6.16) and 
mediates their adhesion to neurons (Fig 6.17). Moreover, by immunohistochemistry we 
had evidence of the in vivo role of CX3CL1 in pancreatic cancer cell crosstalk with 
nerves; in surgical sections of intrapancreatic nerves infiltrated by pancreatic cancer 
metastasis, neural cells contain CX3CL1. Up to now, the chemokine has been reported 
in central neurons as well as in peripheral nerves (302, 310), but has never been 
analyzed in intra-pancreatic nerves.
Other molecules have been involved in the neural tropism of pancreatic cancer 
cells. In particular, the neurotrophin family of growth factors and their receptors, which 
have been found to be implicated in the paracrine growth and regulation of a number of 
neuronal as well as non-neuronal tumor types, including pancreatic adenocarcinoma. 
The expression of various neurotrophins (BDNF (brain-derived nerve growth factor), 
NT-3, NT-4, NT-5) and their receptors (Trk A, B, C) in pancreatic cancer cells have 
been demonstrated to play a role in their invasiveness (312). By the same way, Zhu and 
coll. have found that the expression of nerve growth factor and its receptor TrkA 
correlates with perineural invasion and pain in pancreatic cancer (313).
162
Part of the results in this Chapter is focused on the generation of a pancreatic 
tumour cell line stably expressing exogenous CX3CR1. This tool would be 
indispensable to define the involvement of the chemokine receptor CX3CR1 in the 
pattern of migration, adhesion and growth of tumor cells. The preliminary in vitro 
characterization of the CX3CR1 expressing cell line has confirmed what previously 
observed that CX3CR1 mediates pancreatic cancer cell chemotaxis to CX3CL1 
gradient, as well as the parental mock cell line did not migrate to the chemokine (Fig 
6.19). This cell line will be used in future in vivo models of nerve tropism.
To investigate whether receptor expression confers tumor cells with enhanced ability to 
spread and grow along nerve structures in vivo, we are planning to set up a model of 
nerve injury. Right sciatic nerves of immunodeficient mice will be crushed at the mid 
height and after 24 hours tumor cells (CX3CRI-GFP MiaPaCa2 and mock GFP 
MiaPaCa2 tumor cells) will be injected in the tail vein. After 24-48 hours, sections of 
the injured (and control-lateral) nerves closed to the crush site will be taken and 
analyzed for the presence of GFP transgene by Real-Time PCR.
The crush model should maximize the expression of the chemokine ligand by 
nerves; as reported in the literature (310, 311, 314), in fact, a transient crush o f sciatic 
nerve induces CX3CL1 expression. If the axis Neurotactin/CX3CRl is indeed involved 
in the adhesion and dissemination o f pancreatic tumor cells along nerve fibers, 
CX3CR1-transfected cells should localize preferentially to the site o f nerve injury, 
where Neurotactin is upregulated.
We are also planning other in vivo experiments, in which CX3CR1-GFP MiaPaCa2 sub­
clones expressing the surface receptor in different amounts will be transplanted
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orthotopically in nude mice and the growth characteristics, pattern o f tumor 
metastatization and overall survival will be evaluated.
The observation that perineural invasion occurs earlier than lymph node has recently 
lead to the suggestion that considering neural invasion as an independent factor would 
better correlate with survival (74). Targeting nerve invasion would therefore represent a 
valuable therapeutical tool; indeed, given the lack o f success of conventional surgical 
intervention, less aggressive procedures targeting the tumor cells within the nerve could 
be a valid alternative strategy. Our results pointing out a role of CX3CR1 and its ligand 
CX3CL1 in pancreatic cancer nerve invasion suggest that this chemokine/ receptor pair 
could be considered as good candidates.
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6.7 Summary of results in Chapter 6
In this Chapter, I have presented data suggesting a role of CX3CR1/ CX3CL1 
axis in human pancreatic cancer neural tropism.
Specifically, the following results have been presented:
- pancreatic cancer cell lines express CX3CR1 mRNA; the expression is higher in lines 
derived form metastatic lesions compared with those derived from primary tumors;
- transcript expression is associated to surface expression in pancreatic carcinoma cell 
lines;
- CX3CR1 is expressed also in pancreatic cancer cells from primary tumors; all surgical 
carcinoma samples tested express higher levels o f CX3CR1 than normal pancreatic duct 
cells; moreover, CX3CR1 is expressed in vivo in pancreatic cancer cells, as assessed by 
immunohistochemical analysis;
- CX3CR1 on pancreatic cancer cells is functional and mediates their migration to 
CX3CL 1/Fractalkine; migration is selectively inhibited by anti-CX3CRl monoclonal 
antibody
- CX3CR1-positive tumor cells adhere to endothelial cells stimulated with TNFa/IFNy, 
stimuli known to induce CX3CL1 expression; adhesion was prevented by pre incubation 
with an anti-CX3CRl specific antibody
- in an in vitro model o f nerve tropism, neuronal derived Fractalkine elicits CX3CR1- 
positive pancreatic tumor cell adhesion and migration
- in surgical sections of pancreatic metastasis to nerves, CX3CL1 is found localized in 
neuronal cells, suggesting a role in tumour cell and nerve crosstalk.
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Chapter 7 
Conclusions and future directions
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7.1 Summary and overall conclusions
In the last decade, the role o f chemokines in tumor biology has dramatically 
developed and has expanded from the regulation o f leukocyte attraction within the 
tumor mass to the promotion of tumor cell survival, proliferation and dissemination (82, 
83, 181). Experimental evidence have supported the concept that chemokines could 
direct tumor cell migration in vivo: malignant cells bearing chemokine receptors on the 
cell surface would be endowed with the capability to respond to chemokine gradient and 
selectively migrate to specific organs where the chemokine is present.
The data presented here demonstrate that a selected set of chemokine receptors 
are expressed in carcinoma of the pancreas and are involved in tumour cell migration 
and invasion. We found that the chemokine receptors CXCR4 and CX3CRI are 
functional in pancreatic adenocarcinoma. In particular, the CXCR4/CXCL12 axis 
promotes pancreatic tumor cell migration, matrix degradation and invasion, 
proliferation and survival. For CX3CR1, a role in perineural tropism is suggested as 
CX3CR1/Fractalkine axis seems to be involved in the dissemination o f pancreatic 
tumour cells via nerve structures.
An increased understanding of the mode of action of chemokines on tumor cells 
and their microenvironment would be important to achieve significant therapeutic 
results in the management of cancer patients. If chemokine and receptor expression is an 
advantage for tumor cells, it is possible that these molecules will become target o f 
therapeutic interventions. Indeed, chemokine and receptor antagonists are being 
developed and actively investigated. In the case of pancreatic adenocarcinoma, if  
CX3CR1 and CXCR4 receptors are really involved in invasion and metastasis, their
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inhibition could potentially result in a controlling the metastatic behaviour of this 
aggressive cancer.
7.2 Targeting the chemokine system
Beside the results presented in this thesis, concerning the role of chemokine 
receptors in human pancreatic adenocarcinoma, an increasing number of studies have 
clearly shown that several types of cancers express various chemokine receptors, and 
that these receptors may be implicated in the process of distant metastasis and even 
organ specific metastasis. In addition, chemokines have been demonstrated to deliver 
growth signals to tumor cells and therefore may be directly involved in their survival 
and progression. As a consequence, chemokines and their receptors are now regarded a 
valuable molecular target for the treatment of malignant tumors. Indeed, disrupting the 
interaction between the receptor and its ligand chemokine may prove to be a useful 
approach for treating cancers.
Several drugs targeting the chemokine system are being developed and actively 
investigated in inflammatory and autoimmune diseases and could be useful to treat 
cancer patients. In several pre-clinical studies, these molecules have shown activity both 
as inhibitors of leukocyte recruitment, as well as inhibitors o f metastatic spreading. 
These studies provide a scientific rationale for the use of anti-chemokine or anti­
receptor agents in human cancer (81, 83, 91, 315, 316).
Some of these drugs are chemokine antagonists and prevent the binding and/or 
the signalling of the right ligand through its specific receptor. Recent pre-clinical studies 
have reported anti-cancer activity of chemokine receptor specific antibodies, in several 
murine cancer models. For instance, an anti-CXCR4 monoclonal antibody significantly
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inhibits the metastasis of human breast carcinoma cells to the lymph node of SCID mice 
(81). Pretreatment of non-Hodgkin lymphoma cells with anti-CXCR4 antibody also 
inhibits subsequent growth of the cells in immunodeficient mice (317). In a model of 
non-small-cell lung cancer, immunodeficient mice inoculated with CXCR4-positive 
human NSCLC had lower organ metastasis if  mice were injected with antibodies to 
CXCL12 (318). However, whether the inhibitory effects observed with these antibodies 
are caused only by the inhibition o f chemotaxis remains unclear, because antibody- 
bound tumor cells are likely to be subject to Fc-mediated trapping by the liver and/or 
lung and to Fc-mediated killing by macrophages.
Other studies have focused on selective inhibitors, including the CXCR4 
antagonist AMD3100, originally tested in HIV patients and shown to have a good safety 
profile (296, 297); these studies have provided the scientific rationale for the clinical 
evaluation of AMD3100 in malignant brain tumors (298, 299). We interestingly found 
that AMD3100 inhibits the CXCL12-stimulated proliferation o f CXCR4-positive 
pancreatic tumour cell lines. Consistently with our results, recently, Saur et al found out 
that AMD3100 effectively blocks in vivo the enhanced metastatic potential o f CXCR4- 
expressing pancreatic cancer cells (319). Another CXCR4 inhibitor, the synthetic 
polypeptide TN I4003, was recently demonstrated to block breast cancer metastasis in 
an animal model (320),- as well as the CXCR4 inhibitor TCI 14012 strongly 
counteracted lymphoma development in SCID mice with lymphomas (321, 322).
Murine breast cancer cells express also the chemokine CCL5 and the leukocyte 
infiltrate bears the corresponding receptors CCR1 and CCR5 (212). In a recent work, 
treatment of mice with Met-CCL5, a CCR1/CCR5 receptor antagonist, significantly 
reduced the volume and weight of tumors. Furthermore, this treatment strongly
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decreased the total number of tumor-infiltrating macrophages, supporting the hypothesis 
that macrophages contribute to tumor development (2 1 2 ).
An original strategy to inhibit chemokine and receptor binding is to prevent their 
cell surface expression. Cells transfected with a modified CXCL12 bearing an 
endoplasmic reticulum (ER) sequence (KDEL), retained both ligand and receptor 
(CXCR4) in the ER, thus preventing CXCR4 from reaching the cell surface (323). 
When a T cell hybridoma was transfected, the CXCR4-negative cells failed to 
disseminate to multiple organs upon intravenous injection, indicating a decisive role for 
CXCR4 in the dissemination of haematopoietic malignancies (323). Another example 
comes from colon carcinoma cells transfected with the ER-retention sequence. As a 
matter of fact, CXCR4-deficient cells did colonize the lungs to the same extent as 
control cells, however, they proliferated significantly less and did not expand (324). 
Once more, these results underline the important role o f CXCL12 in the survival and 
proliferation of cancer cells in vivo.
Recently, RNA interference technology has also been used to prevent 
tumorigenesis in different mouse models. In mice injected with breast cancer cells 
expressing CXCR4, a reduction in lung metastases was observed, by silencing CXCR4, 
either by transfecting breast cancer cells with interfering RNA molecules or weekly 
injecting them in the animals (325). In other works, RNAi reduced expression of 
CXCR4 in a murine highly metastatic mammary cancer cell line, thus limiting the 
growth of orthotopically transplanted breast cancer cells (326) and in nasopharyngeal 
human carcinoma cell lines injected in mice, limiting metastasis to the lungs (327).
Finally, viral proteins could represent promising molecules for the chemokine
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system targeting. Such proteins, used as immune escape mechanism by the virus, in 
some instances can bind and inhibit chemokine activity. Among others, the protein M3 
has been described to bind several human and murine CC chemokines (including CCL2, 
CCL13, CCL5, and CCL21), some CXC chemokines, such as CXCL1 and CXCL10 
and also Fractalkine. Binding of chemokines is associated with inhibition of their 
activity (328-330) Finally, more recently, the vaccinia virus soluble protein 35K, which 
binds to and inactivates a broad spectrum of CC-chemokines, has been shown to inhibit 
macrophage recruitment and atherosclerosis in ApoE-/- mice (161, 162).
These and other strategies based on emerging mechanistic data represent some 
o f the promising new directions in the therapy of metastatic disease. However, some 
problems need to be faced: although CXCR4 has been found to be the most expressed 
chemokine receptor in cancer cells from different histological types, tumors display 
heterogeneity in respect to chemokine receptor expression and selective inhibitors might 
be required to treat different cancers. In this perspective, gene-array analyses are 
revealing important tools in defining tumour subsets based on specific marker 
heterogeneity (331).
Another important consequence of the use o f chemokine inhibitors to treat 
cancer arises from the complexity of the chemokine system and their role in normal 
physiology; disrupting this system could bear important clinical side effects. However, a 
peculiarity of the complex system of chemokines and their receptors is their 
redundancy, which guarantees the chemokine system performance, even if  alterations 
affecting individual components occur.
It is more probable that chemokine-receptor-based agents could contribute 
significantly to the control of tumor cell invasion and metastasis, making cancer 
clinically manageable, when used in conjunction with other therapeutic regimens. In
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fact, in many tumor types, including pancreatic cancer, classical surgical intervention is 
often impossible or not successful, due to the persistence of micrometastatic lesions and 
chemokines, used as adjuvant therapy, might be useful to limit tumor dissemination.
This could be even more important in the case of pancreatic adenocarcinoma 
nerve invasion, which is a source of severe pain in tumour patients; indeed, if  the 
CX3CR1 receptor is involved, as supported here, blocking it could represent an 
alternative, less aggressive procedure, targeting the interaction of tumour cells with 
nerves.
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7.3 Future plans
A number of questions arose from this thesis and we are now planning further 
experiments necessary to investigate in detail the role of chemokine and receptors in 
human pancreatic adenocarcinoma.
Specifically, some tasks we would like to achieve in the future:
- localisation of CXCR4 in vivo, by immunohistochemistry on surgical sections. It 
would be interesting to analyze different pancreatic cancer stages and investigating if  a 
correlation exists between the progression of the disease and CXCR4 tumor expression 
This would give us a confirmation o f the role of CXCR4 in human pancreatic 
adenocarcinoma dissemination in vivo.
- assess the therapeutic benefits o f CXCR4 antagonists; we have already used 
AMD3100 in vitro and to assess its effect in in vivo models could be an interesting task. 
We have several pancreatic adenocarcinoma cell lines that will grow as a xenograft in 
nude mice. The effect of AMD3100 or other CXCR4 antagonists on tumour growth 
could be assessed.
- functional in vitro characterization of CX3CR1-GFP MiaPaCa2, to verify if  the 
CX3CR1 receptor confers pancreatic tumor cells with an enhanced capability to spread 
to nerves. To this aim, adhesion assays and other functional activities will be tested.
- investigate if proliferation and survival of CX3CR1 positive pancreatic cancer cell 
lines are affected by the receptor expression. To this aim, the proliferation rate o f the 
infected cell line, upon stimulation with the ligand CX3CL1, compared to the 
uninfected cell line will be assessed, to test whether a possible autocrine loop exists.
- optimize the model of sciatic nerve crush and perform in vivo experiments with the 
CX3CR1-GFP MiaPACa2 cell line
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- perform other in vivo experiments; CX3CR1-transfected tumor cells will be inoculated 
orthotopically in nude mice and their growth and metastatic potential will be 
characterized and compared to parental cells.
- assess the therapeutic benefits of CX3CR1 antagonists. As up to now there are no 
selective CX3CR1 inhibitors; we could plan to silence the receptor with the available 
tool o f RNA interference.
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List of Abbreviations
(m)Ab (monoclonal) antibody
bp base pair
BSA bovine serum albumin
CAM cell-cell adhesion molecules
CCL, CXCL, XCL, CX3CL ligands
CCR, CXCR, XCR, CX3CR receptors
DNA deoxyribonucleic acid
cDNA complementary DNA
CK7 cytokeratin 7 .
DC dendritic cell
ECM extracellular matrix
EDTA ethylenediaminetetraacetic acid
EG F epidermal growth factor
ELISA enzyme-linked immunosorbent assay
ELR tripeptide motif glutamic acid-leucine-arginine
FACS fluorescence activated cell sorter
FBS foetal bovine serum
FGF fibroblast growth factor
HGF hepatocyte growth factor
HHV8 human herpes virus 8
H IF hypoxia inducible factor
HPC haematopoietic progenitor cell
HPF high power field
HUVEC human umbilical vascular endothelial cells
ICAM intercellular adhesion molecule
IG F insulin-like growth factor
IFN interferon
Ig immunoglobulin
IL interleukin
Kb kilobase
kDa kilodalton
LPS lipopolysaccharide
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M APK mitogen activated protein kinase
M FI mean fluorescence intensity
M HC major histocompatibility complex
M M P matrix metalloproteinase
M M PI matrix metalloproteinase inhibitor
MS multiple sclerosis
NF-kB nuclear factor kappa B
NK natural killer
NSCLC non small cell lung cancer
PanIN  pancreatic intraepithelial neoplasia
PBMC peripheral blood mononuclear cells
PBS phosphate buffered saline
PDCL pancreatic ductal carcinoma cell lines
PKB/C protein kinase B/C
PLC phospholypase C
PM A phorbol myristyl acetate
RNA ribonucleic acid
mRNA messenger RNA
RT-PCR reverse transcription polymerase chain reaction
SE standard error
SSC sodium chloride, sodium citrate buffer
SD standard deviation
SDS sodium dodecyl sulphate
TAM tumour associated macrophage
TGF transforming growth factor
TIM P tissue inhibitor of matrix metalloproteinases
TNF tumour necrosis factor
tPA  tissue plasminogen activator
uPA urokinase-type plasminogen activator
uPAR urokinase-type plasminogen activator receptor
VCAM vascular cell adhesion molecule-1
VEGF vascular endothelial growth factor
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